triazoles has been researched along with maraviroc in 564 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 134 (23.76) | 29.6817 |
| 2010's | 427 (75.71) | 24.3611 |
| 2020's | 3 (0.53) | 2.80 |
| Authors | Studies |
|---|---|
| Abel, S; Comby, P; Muirhead, GJ; Nedderman, AN; Smith, DA; Walker, DK | 1 |
| Armour, D; Wood, A | 1 |
| Abel, S; Dezube, BJ; Fätkenheuer, G; Goebel, FD; Hoepelman, AI; James, IT; Jenkins, TM; Johnson, MA; Medhurst, C; Plettenberg, A; Pozniak, AL; Ridgway, C; Rockstroh, JK; Saag, MS; Staszewski, S; Sullivan, JF; van der Ryst, E; Youle, M | 1 |
| Armour, D; Dobbs, S; Dorr, P; Griffin, P; Irvine, B; Macartney, M; Mori, J; Napier, C; Perros, M; Price, D; Rickett, G; Smith-Burchnell, C; Stammen, B; Webster, R; Westby, M; Wood, A | 1 |
| Dorr, P; Holbrook, M; Mansfield, R; Mosley, M; Napier, C; Rickett, G; Sale, H | 1 |
| Dorr, P; Hitchcock, C; Jacqmin, P; Rosario, MC; van der Ryst, E | 1 |
| Clausen, RP | 1 |
| Poland, B; Rosario, MC; Sullivan, J; van der Ryst, E; Westby, M | 1 |
| James, IT; Jenkins, TM; Lewis, M; Perros, M; Pozniak, AL; van der Ryst, E; Westby, M; Whitcomb, J; Youle, M | 1 |
| Goebel, FD; Horster, S | 1 |
| Boffito, M; Mallon, PW; Winston, A | 1 |
| Franti, M; Maddon, PJ; Murga, JD; Olson, WC; Pevear, DC | 1 |
| Temesgen, Z | 1 |
| Ciaramella, G; Dorr, P; Lewis, M; Mori, J; Mosley, M; Perros, M; Smith-Burchnell, C; Stockdale, M; Westby, M | 1 |
| Cohen, J | 1 |
| Stephenson, J | 1 |
| Ahuja, SK; He, W; Ketas, TJ; Klasse, PJ; Kuhmann, SE; Moore, JP; Palmer, A; Zurita, J | 1 |
| Opar, A | 1 |
| Egger, M; Telenti, A | 1 |
| Jackson, V; McHale, M; Penny, M; Wheeler, J | 1 |
| Laurence, J | 1 |
| Boyle, BA; Cohen, CJ; Elion, R; Frank, I; Moyle, GJ; Sax, P | 1 |
| Valenti, WM | 1 |
| Kadow, JF; Meanwell, NA | 1 |
| Kuritzkes, DR | 1 |
| Groeschen, HM | 1 |
| Kondo, M; Saita, Y; Shimizu, Y | 1 |
| Carter, NJ; Keating, GM | 1 |
| Mosier, DE | 1 |
| Emmelkamp, JM; Rockstroh, JK | 2 |
| Lorenzen, T; Plettenberg, A; Stoehr, A; Walther, I | 1 |
| Bredeek, UF; Harbour, MJ | 1 |
| van Lunzen, J | 2 |
| Bogner, JR; Mueller, MC | 1 |
| Lou, S; Moquist, PN; Schaus, SE | 1 |
| Delfraissy, JF; Ghosn, J; Méchai, F; Quertainmont, Y; Sahali, S | 1 |
| Dioszegi, M; Ji, C; Kondru, R; Mirzadegan, T; Rotstein, D; Sankuratri, S; Zhang, J | 1 |
| Fadel, H; Temesgen, Z | 1 |
| Abel, S; Boffito, M | 1 |
| Abel, S; Medhurst, CG; Muirhead, GJ; Ridgway, CE; Rosario, MC; Taylor-Worth, RJ; van der Ryst, E | 1 |
| Abel, S; Muirhead, GJ; Ridgway, CE; Russell, D; Whitlock, LA | 2 |
| Abel, S; Muirhead, GJ; Ridgway, CE; Russell, D; Taylor-Worth, RJ | 1 |
| Abel, S; Jenkins, TM; Muirhead, GJ; Ridgway, CE; Whitlock, LA | 1 |
| Boffito, M; Muirhead, GJ; Pozniak, AL; Ridgway, CE; Russell, D | 1 |
| Abel, S; Nedderman, AN; Ridgway, CE; Russell, D; Walker, DK; Whitlock, LA | 1 |
| Davis, JD; Hackman, F; Higgins, T; Layton, G; Sudworth, D; Weissgerber, G | 1 |
| Chan, PL; McFadyen, L; Weatherley, B | 1 |
| Abel, S; Dorr, P; Jacqmin, P; James, I; Jenkins, TM; Rosario, MC; van der Ryst, E | 1 |
| Jacqmin, P; McFadyen, L; Wade, JR | 1 |
| Sax, PE | 3 |
| Vandekerckhove, L; Verhofstede, C; Vogelaers, D | 2 |
| Taéron, C | 1 |
| de la Tribonnière, X; Reynes, J; Yazdanpanah, Y | 1 |
| Peytavin, G | 1 |
| Chidiac, C; Katlama, C; Yeni, P | 1 |
| MacArthur, RD; Novak, RM | 1 |
| Barber, T; Hughes, A; Nelson, M | 1 |
| Hussar, DA | 1 |
| Collins, C; Dickins, M; Hyland, R; Jones, B; Jones, H | 1 |
| Bandres, JC; Fung, HB; Lieberman-Blum, SS | 1 |
| Armour, D; de Groot, M; Leishman, D; Napier, C; Perros, M; Price, DA; Stammen, BL; Wood, A | 1 |
| Edmunds-Ogbuokiri, T | 1 |
| Jiang, H; Li, J; Liu, Y; Xie, X; Yu, K; Zhang, Y; Zhou, E; Zhu, J | 1 |
| Clotet, B; Clumeck, N; DeJesus, E; Dunne, MW; Felstead, S; Goodrich, J; Gulick, RM; Horban, A; Karlsson, A; Lalezari, J; Mayer, H; McHale, M; Montana, JB; Nadler, J; Ridgway, C; Sullivan, J; van der Ryst, E; Wohlfeiler, M | 1 |
| Bellos, N; Cooper, DA; Dunne, MW; Fätkenheuer, G; Felstead, S; Hirschel, B; Hoepelman, AI; Konourina, I; Lampiris, H; Lazzarin, A; Mayer, H; Nelson, M; Raffi, F; Ridgway, C; Saag, M; Sullivan, JF; Tawadrous, M; Tebas, P; Trottier, B; van der Ryst, E; Westby, M | 1 |
| Dolin, R | 1 |
| Calvez, V; Katlama, C; Lambert-Niclot, S; Malet, I; Marcelin, AG; Murphy, R; Simon, A; Soulié, C; Thévenin, M; Tubiana, R | 1 |
| Bowers, SJ; Mitchell, RJ; Potchoiba, MJ; Schroeder, CM; Small, HF; Walker, DK | 1 |
| Alcamí, J; Calvez, V; Fätkenheuer, G; Geretti, AM; Perno, CF; Pillay, D; Reynes, J; Rockstroh, J; Soriano, V; Tambussi, G | 1 |
| Barros Aguado, C; Morales Conejo, M; Moreno Cuerda, VJ; Rubio García, R | 1 |
| Caldwell, DJ; Evans, JD | 1 |
| Melby, T; Westby, M | 1 |
| Boyle, B; Cohen, C; DeJesus, E; Elion, R; Frank, I; Moyle, G; Sax, P | 1 |
| Alcamí, J | 2 |
| Arenzana-Seisdedos, F | 1 |
| Poveda, E; Soriano, V | 1 |
| Delsol, E; Gutiérrez, C; Hernández, B; Moreno, S | 1 |
| Arribas López, JR | 1 |
| Delgado, R | 1 |
| Camacho, A; Genebat, M; Leal, M; Rivero, A | 1 |
| Kroon, FP; Roukens, AH; Visser, LG | 1 |
| Hunt, JS; Romanelli, F | 1 |
| Ascenzi, P; Bellagamba, R; Narciso, P; Nicastri, E; Notari, S; Pucillo, LP; Tempestilli, M; Tommasi, C | 1 |
| Pasquale, TR; Sahloff, EG; Yost, R | 1 |
| Kuritzkes, DR; Moore, JP | 1 |
| Lanzafame, M; Lattuada, E; Vento, S | 1 |
| Archer, J; Braverman, MS; Desany, B; Harrigan, PR; James, I; Lewis, M; Robertson, DL; Taillon, BE | 1 |
| Clotet, B; Clumeck, N; Fätkenheuer, G; Goodrich, J; Mayer, H; Saag, M; Sullivan, J; van der Ryst, E; Westby, M | 1 |
| Able, S; Dorr, P; Griffin, P; Irvine, B; James, I; Macartney, M; Mansfield, R; Miller, K; Mills, J; Napier, C; Navratilova, I; Perros, M; Rickett, G; Root, H; van der Ryst, E; Westby, M | 1 |
| Pett, SL | 1 |
| Andrews, E; Damle, B; Dumond, JB; Kashuba, AD; Patterson, KB; Pecha, AL; Tressler, R; Werner, RE; Worsley, J | 1 |
| Arribas, JR | 1 |
| Chiang, TS; Dever, LL; Eng, RH; Paez, SL; Perez, G; Smith, SM; Stepanyuk, O | 1 |
| Khanlou, H; Sayana, S | 1 |
| Goodrich, J; Mayer, H; Moyle, G; Rajicic, N; Valdez, H | 1 |
| Ferrando-Martínez, S; Genebat, M; González-Serna, A; Leal, M; León, JA; Muñoz-Fernández, MA; Pulido, I; Rivas, I; Ruiz-Mateos, E; Sánchez, B | 1 |
| Doms, RW; Tilton, JC | 1 |
| Agrawal-Gamse, C; Collman, RG; Doms, RW; Haggarty, B; Hoxie, JA; Jordan, AP; Laakso, MM; Lee, B; Lee, FH; Yi, Y | 1 |
| Abel, S; Back, DJ; Vourvahis, M | 1 |
| Edmunds-Ogbuokiri, J | 1 |
| McFadyen, L; Weatherley, B | 1 |
| Fätkenheuer, G; Kümmerle, T; Lehmann, C; Meuer, K | 1 |
| Abel, S; Davis, JD; Hamlin, JC; Ridgway, CE; Vourvahis, M | 1 |
| Calvez, V; di Perri, G; Gatell, JM; Geretti, AM; Kaiser, R; Perno, CF; Pillay, D; Rockstroh, J; Soriano, V | 1 |
| Reynes, J | 1 |
| Aiuti, F; Esposito, A; Fantauzzi, A; Isgro, A; Leti, W; Mezzaroma, I; Pastori, D | 1 |
| Abel, S; Hui, J; Kearney, BP; Ramanathan, S; Tweedy, S; West, S | 1 |
| Else, L; Gisslèn, M; Watson, V; Yilmaz, A | 1 |
| Alvarez, M; Cuvinciuc, V; Cuzin, L; Delobel, P; Dumas, H; Marchou, B; Martin-Blondel, G; Massip, P | 1 |
| Cohen, AF; Dubois, EA | 1 |
| Louie, M; Marfatia, S; Mear, I; Meunier, J; Regnault, A; Viala-Danten, M | 1 |
| Asmuth, DM; Cooper, DA; Goodrich, J; Haubrich, R; Hirschel, B; Mayer, H; Rajicic, N; Valdez, H | 1 |
| Baietto, L; Bonora, S; D'Avolio, A; Di Perri, G; Patanella, S; Sciandra, M; Siccardi, M; Simiele, M | 1 |
| McKinnell, JA; Saag, MS | 1 |
| Armand-Ugón, M; Ballana, E; Clotet, B; Esté, JA; Gonzalez, E; Mena, M; Moncunill, G | 1 |
| Andrews, E; Crownover, P; Damle, B; Fang, J; Glue, P; Tressler, R | 1 |
| Baldinger, T; deRosier, A; Heilek, G; Jekle, A; Ji, C; Lemoine, RC; Petersen, AC; Rotstein, DM; Setti, L; Wanner, J | 1 |
| Clumeck, N; Coakley, E; Cooper, DA; Dejesus, E; Goodrich, J; Hackman, F; Heera, J; Horban, A; Ive, P; Mayer, H; Mingrone, H; Mohapi, L; Reeves, JD; Reyes-Teran, G; Saag, M; Sullivan, J; Tawadrous, M; Ting, N; Van Der Ryst, E; Walmsley, S; Westby, M | 1 |
| Bigoloni, A; Canducci, F; Castagna, A; Galli, L; Gianotti, N; Lazzarin, A; Nozza, S; Salpietro, S; Soria, A; Tambussi, G; Torre, LD; Visco, F | 1 |
| Rotstein, DM; Yang, H | 1 |
| Armstrong-James, D; Ferns, B; Nelson, M; Pillay, D; Scourfield, A; Smit, E; Stebbing, J | 1 |
| Alex, A; Nyaruwata, T; Parsons, T; Pullen, F; Wright, P | 1 |
| Altamura, M; Angarano, G; Brindicci, G; Lagioia, A; Monno, L; Punzi, G; Saracino, A; Trillo, G | 1 |
| Baroncelli, S; Cicalini, S; Cusato, M; Floridia, M; Francisci, D; Galluzzo, C; Ladisa, N; Preziosi, R; Regazzi, M; Tommasi, C; Villani, P; Vullo, V; Weimer, LE | 1 |
| Huitema, AD; Kromdijk, W; Mulder, JW | 1 |
| Chung, HK; Galmin, L; Pal, R; Rose, N; Suschak, J | 1 |
| Back, D; Else, L; Hughes, A; Khoo, S; Siccardi, M; Tjia, J; Watson, V | 1 |
| Poizot-Martin, I | 1 |
| Ghosh, AK; Kamata, W; Kruhlak, M; Li, J; Maeda, K; Mitsuya, H; Nakata, H; Ogata-Aoki, H | 1 |
| Perry, CM | 1 |
| Charpentier, C; Cottalorda, J; Desbois, D; Descamps, D; Ferré, V; Flandre, P; Izopet, J; Lazrek, M; Macé, M; Marcelin, AG; Masquelier, B; Montes, B; Morand-Joubert, L; Pallier, C; Raymond, S; Recordon-Pinson, P; Reynes, J; Ruffault, A; Schneider, V; Soulié, C; Tamalet, C; Trabaud, MA; Vabret, A | 1 |
| Alvarez, M; Cazabat, M; Delobel, P; Izopet, J; Marchou, B; Massip, P; Mavigner, M; Raymond, S | 1 |
| Churchill, MJ; Cowley, D; Cunningham, AL; Ellett, A; Farrugia, W; Gorry, PR; Gray, LR; Lee, B; Poumbourios, P; Ramsland, PA; Roche, M; Sterjovski, J; Wesselingh, SL | 1 |
| Fang, J; Heera, J; Huyghe, I; Vourvahis, M | 1 |
| Bouvier-Alias, M; Calvez, V; Canestri, A; Clavel, C; Katlama, C; Lascaux, AS; Lelievre, JD; Levy, Y; Melica, G; Peytavin, G | 1 |
| Dufour, J; Green, LC; Ketas, TJ; Klasse, PJ; Moore, JP; Moroney-Rasmussen, T; Veazey, RS | 1 |
| Ferrando-Martínez, S; García-Pergañeda, A; Genebat, M; González-Serna, A; Leal, M; Méndez, G; Pulido, I; Romero-Sánchez, MC; Ruiz-Mateos, E | 1 |
| Lichtner, M; Marocco, R; Massetti, AP; Mastroianni, CM; Mengoni, F; Rossi, R; Sauzullo, I; Vullo, V | 1 |
| Balduin, M; Braken, P; Häussinger, D; Jensen, B; Kaiser, R; Oette, M; Reuter, S; Sierra-Aragon, S | 1 |
| Holodniy, M; Kashuba, AD; Shulman, NS; Van Rompay, KK; Winters, MA | 1 |
| Agrawal-Gamse, C; Bushman, FD; Deeks, SG; Didigu, CA; Doms, RW; Harrison, JE; Henning, EA; Martin, JN; Sinha, R; Tilton, JC; Wilen, CB | 1 |
| Fätkenheuer, G; Goodrich, J; Gulick, RM; Hardy, WD; Heera, J; Mayer, H; Nelson, M; Rajicic, N | 1 |
| Curto, J; Niubo, J; Podzamczer, D; Tiraboschi, JM | 2 |
| Abbate, I; Bartolini, B; Bruselles, A; Capobianchi, MR; Chillemi, G; Ippolito, G; Narciso, P; Nicastri, E; Rozera, G; Tommasi, C | 1 |
| Chapman, D; Dong, W; Harrigan, PR; Heera, J; James, I; Lewis, M; McGovern, RA; Mo, T; Thielen, A; Valdez, H; Woods, CK | 1 |
| Hu, Q; Huang, X; Shattock, RJ | 1 |
| Hirano, A; Kaneda, T; Kinoshita, E; Nomura, T; Okubo, N; Takahashi, M | 1 |
| D'Avolio, A; Fuchs, D; Gisslén, M; Hagberg, L; Svennerholm, B; Verhofstede, C; Watson, V; Yilmaz, A | 1 |
| Henrich, TJ; Konstantinidis, I; Kuritzkes, DR; Leopold, KE; Lewine, NR; Sagar, M; Tsibris, AM | 1 |
| Alston, S; Ayoub, A; Goodrich, J; Heera, J; Hoepelman, AI; Lalezari, J; Mayer, H; Mchale, M; Nelson, M; van der Ryst, E | 1 |
| Aguilera, A; de Mendoza, C; del Romero, J; González, Mdel M; Lapaz, M; Poveda, E; Rodríguez, C; Seclén, E; Soriano, V | 1 |
| Abad, MA; Ferrando-Martinez, S; Garcia-Perganeda, A; Genebat, M; Gonzalez-Serna, A; Leal, M; Ruiz-Mateos, E | 1 |
| Eason, J; Funderburg, N; Goodrich, J; Heera, J; Kalinowska, M; Lederman, MM; Mayer, H; Rajicic, N; Valdez, H | 1 |
| Assoumou, L; Autran, B; Canestri, A; Carcelain, G; Guihot, A; Katlama, C; Krivine, A; Le Corre, M; Marcelin, AG; Rozenberg, F; Samri, A; Schneider, L | 1 |
| Alencar, CS; Diaz, RS; Ferreira, S; Giret, MT; Nishiya, AS; Sabino, EC | 1 |
| Kast, RE | 1 |
| Brewer, E; Clarke, P; Edgington, A; Felix, T; Muirhead, D | 1 |
| Chan, PL; Jacqmin, P; Lavielle, M; McFadyen, L; Weatherley, B | 1 |
| Becker, D; Chancellor, J; Contreras-Hernandez, I; Kühne, F; Marfatia, S; Mould-Quevedo, J; Vega, G | 1 |
| Alcami, J; Arenzana-Seisdedos, F; Garcia-Perez, J; Kellenberger, E; Lagane, B; Rueda, P; Staropoli, I | 1 |
| Batchelor, DV; Corless, M; Dorr, PK; Ellis, D; Fenwick, DR; Galan, SR; Jones, RM; Mason, HJ; Middleton, DS; Perros, M; Perruccio, F; Platts, MY; Pryde, DC; Rodrigues, D; Smith, NN; Stephenson, PT; Stupple, PA; Webster, R; Westby, M; Wood, A | 1 |
| Ferrando-Martínez, S; Genebat, M; González-Serna, A; Leal, M; Muñoz-Fernández, MÁ; Pulido, I; Ruiz-Mateos, E | 1 |
| Hizue, M | 1 |
| Banerjee, S; Grunbeck, A; Huber, T; Knepp, AM; Sakmar, TP | 1 |
| Archer, J; Harrigan, PR; Lewis, M; Rambaut, A; Robertson, DL; Taillon, BE | 1 |
| De Wit, S; Demecheleer, E; Florence, E; Fransen, K; Geretti, AM; Kabeya, K; Mackie, N; Mostmans, W; Moutschen, M; Plum, J; Stuyver, LJ; Vaira, D; Van Baelen, K; Van Eygen, V; Van Marck, H; Vandekerckhove, L; Vandenbroucke, I; Verhofstede, C; Vogelaers, D | 1 |
| Akkina, R; Habu, Y; Ndolo, T; Neff, CP; Tandon, A | 1 |
| Hosoya, N; Iwamoto, A; Kawana-Tachikawa, A | 1 |
| Back, D; Baietto, L; Bonora, S; Calcagno, A; Castagna, A; D'Avolio, A; Di Perri, G; Kwan, WS; Lazzarin, A; Moss, D; Nozza, S; Owen, A; Siccardi, M; Simiele, M; Stefani, FR | 1 |
| Fätkenheuer, G; Foulke, JS; Heredia, A; Latinovic, O; Le, NM; Lehmann, C; Redfield, RR; Reitz, M | 1 |
| Collman, RG; Kienzle, M; Loftin, LM; Yi, Y | 1 |
| Gilliam, BL; Redfield, RR; Riedel, DJ | 1 |
| Chapman, D; Dong, WW; Harrigan, PR; Heera, J; James, I; Jensen, MA; Lewis, M; Mo, T; Swenson, LC; Thielen, A; Valdez, H; Woods, CK; Zhong, X | 1 |
| Chen, G; Chen, W; Li, J; Stepkowski, SM; Wang, S; Xia, J; Ye, P; Zhang, K; Zhong, S | 1 |
| Casado, MA; González, J; Lekander, I; Martí, B; Moreno, S; Oyagüez, I; Sánchez-de la Rosa, R | 1 |
| Kaptur, PE; Mertenskoetter, T | 1 |
| Churchill, MJ; Ellett, A; Gorry, PR; Jakobsen, MR; Jubb, B; Lee, B; Lewin, SR; Posta, F; Ramsland, PA; Roche, M; Sterjovski, J; Westby, M | 1 |
| Chen, CH; Huang, L; Lai, WH | 1 |
| Aerssens, J; Andreoni, M; Aquaro, S; Balestra, E; Buonomini, AR; Ceccherini-Silberstein, F; Cento, V; D'Arrigo, R; Dori, L; Mostmans, W; Perno, CF; Saccomandi, P; Sarmati, L; Stuyver, LJ; Surdo, M; Svicher, V; Van Marck, H; Vandenbroucke, I | 1 |
| Bigoloni, A; Castagna, A; Cossarini, F; Della Torre, L; Galli, A; Galli, L; Lazzarin, A; Nicola, G; Nozza, S; Pogliaghi, M; Salpietro, S; Tambussi, G | 1 |
| Zhang, XQ | 1 |
| Abel, S; Davis, J; Hamlin, J; Hoetelmans, RM; Kakuda, TN; Mack, R; Ndongo, N; Petit, W; Ridgway, C; Schöller-Gyüre, M; Sekar, V; Tweedy, S | 1 |
| Bernard, J; Ferain, T; Fraser, G; Hoveyda, H; Ooms, F; Schols, D | 1 |
| de Jong, D; Hoepelman, AI; Nijhuis, M; Symons, J; van Ham, PM; van Lelyveld, SF; Wensing, AM | 1 |
| Büchel, G; Haefeli, WE; Herzog, M; Jödicke, L; Weiss, J; Zembruski, NC | 1 |
| Harada, S; Maeda, Y; Monde, K; Terasawa, H; Yuan, Y; Yusa, K | 1 |
| Brown, KC; Cohen, MS; Dumond, JB; Heidt, PE; Kashuba, AD; Malone, SA; Patterson, KB; Prince, HM; Shaheen, NJ; Spacek, MB | 1 |
| DeVico, A; Foulke, JS; Heredia, A; Latinovic, O; Le, N; Pal, R; Redfield, RR; Reitz, M | 1 |
| Dong, WW; Harrigan, PR; Heera, J; James, I; Lengauer, T; Lewis, M; McGovern, RA; Swenson, LC; Thielen, A; Valdez, H | 1 |
| Boucher, CA; Chapman, D; Delogne, C; Kuritzkes, DR; Lewis, M; Llibre, JM; McFadyen, L; Perros, M; Schapiro, JM; Simpson, P; Valdez, H; van de Vijver, DA; van der Ryst, E; Westby, M | 1 |
| Bargalló, E; Espiau, M; Figueras, C; Martín-Nalda, A; Paredes, R; Soler-Palacín, P | 1 |
| Alonso-Villaverde, C; Berenguer, J; Blanco, JL; Domingo, P; Dronda, F; Galera, C; Gutiérrez, F; Kindelán, JM; Knobel, H; Leal, M; López-Aldeguer, J; Mariño, A; Miralles, C; Moltó, J; Ortega, E; Oteo, JA; Parra, J; Portilla, J; Pulido, F; Sánchez-de la Rosa, R | 1 |
| Zorn, F | 1 |
| Bonora, S; Calcagno, A; Castagna, A; D'Avolio, A; Di Perri, G; Gonzalez de Requena, D; Lazzarin, A; Nozza, S | 1 |
| Dixit, NM; Mulampaka, SN | 1 |
| Akkina, R; Fox, K; Kurisu, T; Ndolo, T; Neff, CP | 1 |
| Berro, R; Flegler, A; Hope, TJ; Klasse, PJ; Lascano, D; Moore, JP; Nagashima, KA; Sakmar, TP; Sanders, RW | 1 |
| Coetzer, M; Hartley, O; Lederman, MM; Mosier, DE; Nedellec, R; Offord, RE | 1 |
| Alcami, J; Arenzana-Seisdedos, F; Garcia-Perez, J; Kellenberger, E; Lagane, B; Rognan, D; Rueda, P | 1 |
| Férir, G; Palmer, KE; Schols, D | 1 |
| Ferrando-Martinez, S; Genebat, M; González-Serna, A; Leal, M; Machmach, K; Muñoz-Fernández, A; Ruiz-Mateos, E; Vidal, F | 1 |
| Anton, ED; Archary, M; Bobat, R; Coovadia, H; Gordon, ML; Green, TN; Grobler, A; Lie, Y; Ndung'u, T; Padayachi, N; Reeves, JD | 1 |
| Doyle, LA; Forbes, CJ; Geer, L; Goldman, L; Klasse, PJ; Lowry, D; Malcolm, RK; Mitchnick, M; Moore, JP; Muldoon, BC; Shattock, RJ; Veazey, RS; Woolfson, AD | 1 |
| Chapman, D; Dong, WW; Harrigan, PR; Heera, J; James, I; Jensen, MA; Knapp, DJ; Lewis, M; Mo, T; Portsmouth, S; Swenson, LC; Thielen, A; Valdez, H; Woods, CK; Zhong, X | 1 |
| Azevedo-Pereira, JM; Calado, M; Dorr, P; Espirito-Santo, M; Santos-Costa, Q | 1 |
| De Rosa, A; Lichtner, M; Massetti, AP; Mastroianni, CM; Mengoni, F; Rossi, R; Sauzullo, I; Vullo, V | 1 |
| Allsop, JM; Back, D; Erlwein, OW; Garvey, L; Kaye, S; Latch, N; Mitchell, A; Nelson, M; Taylor-Robinson, SD; Watson, V; Winston, A | 1 |
| De Luca, A; Dello Russo, C; Lisi, L; Navarra, P; Tramutola, A | 1 |
| Arendt, V; Baatz, F; De Landtsheer, S; Lemaire, M; Perez Bercoff, D; Schmit, JC; Servais, JY; Struck, D | 1 |
| Machala, L; Perlík, F; Slanar, O; Stanková, M; Vondracková, H | 1 |
| Gulick, RM; Wilkin, TJ | 1 |
| Churchill, MJ; Ellett, A; Gorry, PR; Jakobsen, MR; Jubb, B; Lee, B; Lewin, SR; Roche, M; Salimiseyedabad, H; Westby, M | 1 |
| Antoine, R; Brun-Vézinet, F; Charpentier, C; Damond, F; Descamps, D; Hurtado-Nedelec, M; Matheron, S; Peytavin, G; Storto, A; Visseaux, B | 1 |
| Hardy, WD; Rockstroh, JK; Wasmuth, JC | 1 |
| Banerjee, S; Davis, J; Labadie, RR; Langdon, G; Layton, G; Ndongo, MN; Vourvahis, M | 1 |
| Abad, MA; Ferrando-Martinez, S; Genebat, M; Gonzalez-Serna, A; Harrigan, PR; Leal, M; McGovern, RA; Poon, AF; Ruiz-Mateos, E; Vidal, F | 1 |
| Back, DJ; Else, LJ; Khoo, SH; Taylor, S | 1 |
| Henrich, TJ; Klasse, PJ; Kunstman, KJ; Kuritzkes, DR; Moore, JP; Pal, U; Schure, AL; Tsibris, AM; Veazey, RS; Wolinsky, SM | 1 |
| Ainsworth, J; Cook, R; Dufty, N; Gandhi, K; Hickinbottom, G; Khonyongwa, K; Okoli, C; Owen, A; Siccardi, M; Taylor, S; Thomas-William, S; Watson, J | 1 |
| Abad, M; Casado, JL; Dahl, V; Díaz, L; Dronda, F; Gutiérrez, C; Hernández-Novoa, B; Madrid, N; Moreno, AM; Moreno, S; Muñoz, E; Muñoz-Fernández, MÁ; Navas, E; Palmer, S; Pérez-Elías, MJ; Rubio, R; Vallejo, A; Zamora, J | 1 |
| Belvisi, V; Branà, MT; Di Bari, G; Gramegna, P; Latronico, T; Lichtner, M; Liuzzi, GM; Mascellino, MT; Mastroianni, CM; Mengoni, F; Vullo, V | 1 |
| Genebat, M; Leal, M; Machmach, K; Mendez-Lagares, G; Pulido, I; Romero-Sánchez, MC; Ruiz-Mateos, E | 1 |
| Arrowsmith, J; Drummond, KS; Feltner, DE; Morgan, P; Street, SD; Van Der Graaf, PH; Wegner, CD | 1 |
| Fleishaker, DL; Garcia Meijide, JA; Goodrich, JM; Kohen, MD; Mayer, HB; Mebus, CA; Menon, S; Petrov, A; Stock, TC; Wang, X; Zeiher, BG | 1 |
| Berro, R; Gulick, RM; Henrich, TJ; Kuritzkes, DR; Lee, SH; Lewine, NR; Moore, JP; Rao, SS; Tsibris, AM | 1 |
| Camacho, A; de los Santos, I; Di Lello, F; Gómez-Mateos, J; Macías, J; Márquez, M; Mata, R; Ojeda, G; Pineda, JA; Portilla, J; Rivero, A; Sanz-Sanz, J; Viloria, MM | 1 |
| Brudney, D; Garcia, A; Geretti, AM; Johnson, M; MacCartney, M; Marshall, N; Smith, C; Vitiello, P | 1 |
| Antunes, F; Barroso, H; Bártolo, I; Borrego, P; Caixas, U; Calado, R; Cavaco-Silva, P; Doroana, M; Maltez, F; Marcelino, JM; Rocha, C; Taveira, N | 1 |
| Bujan, L; Daudin, M; Izopet, J; Massip, P; Moinard, N; Pasquier, C; Sauné, K; Trancart, S | 1 |
| Peterson, K; Rowland-Jones, S | 1 |
| García, F; Gutiérrez, F; Poveda, E; Rodríguez, JC | 1 |
| Best, BM; Clifford, DB; Collier, AC; Croteau, D; Ellis, RJ; Gelman, BB; Grant, I; Letendre, S; McArthur, JC; McCutchan, JA; Morgello, S; Rossi, SS | 1 |
| Boyd, P; Doyle, LA; Fetherston, SM; Geer, L; Goldman, L; Ketas, TJ; Klasse, PJ; Lowry, D; Major, I; Malcolm, RK; Moore, JP; Murphy, DJ; Rasmussen, KK; Shattock, RJ; Veazey, RS | 1 |
| Baroncelli, S; Bucciardini, R; Cavalli, A; Degli Antoni, A; Floridia, M; Fragola, V; Francisci, D; Galluzzo, CM; Ladisa, N; Mercuri, A; Monno, L; Pirillo, MF; Volpe, A; Weimer, LE | 1 |
| Boyd, SD; McLaughlin, M; Morse, CG; Pau, AK; Penzak, SR | 1 |
| Berro, R; Gorry, PR; Jakobsen, MR; Klasse, PJ; Moore, JP; Sanders, RW | 1 |
| Chen, L; Chen, Z; Cheung, AK; Kang, Y; Lau, TC; Li, B; Li, S; Liang, J; Liu, L; Lu, X; Ng, J; Tan, Z; Wang, H; Wu, Z; Zheng, B | 1 |
| Abrol, R; Goddard, WA; Grunbeck, A; Huber, T; Sakmar, TP; Trzaskowski, B | 1 |
| Katanaga, H | 1 |
| Cho, SJ; Gadhe, CG; Kothandan, G | 1 |
| Das, D; Maeda, K; Mitsuya, H; Nakata, H | 1 |
| Abad, MA; Ferrando-Martinez, S; Genebat, M; Gonzalez-Serna, A; Leal, M; Muñoz-Fernández, MÁ; Romero-Sánchez, MC; Ruiz-Mateos, E; Vidal, F | 1 |
| Barouch, DH; Dufour, J; Klasse, PJ; Moore, JP; Veazey, RS | 1 |
| Colby-Germinario, SP; Donahue, DA; Kramer, VG; Oliveira, M; Schader, SM; Singhroy, DN; Sloan, RD; Tressler, R; Wainberg, MA | 1 |
| De La Fuente, M; Ertel, A; Jiao, X; Lisanti, MP; Pestell, RG; Pestell, TG; Velasco-Velázquez, M | 1 |
| Bigoloni, A; Castagna, A; Cossarini, F; Della Torre, L; Galli, A; Galli, L; Gianotti, N; Lazzarin, A; Nozza, S; Salpietro, S; Spagnuolo, V; Vinci, C | 1 |
| Chiappetta, S; Faioni, EM; Fontana, G; Nozza, S; Pogliaghi, M; Razzari, C; Spagnuolo, V; Tambussi, G | 1 |
| Caixas, U; Faustino, I; Ferreira, J; Germano, I; Grilo, NM; Lampreia, F; Marinho, AT; Monteiro, EC; Pereira, SA | 1 |
| Fang, J; Jadhav, PR | 1 |
| Acosta, EP; Barreca, ML; Chirullo, B; Collins, M; Della Corte, A; Greenhouse, J; Iraci, N; Lewis, MG; Norelli, S; Savarino, A; Shytaj, IL; Yalley-Ogunro, J | 1 |
| Bigoloni, A; Carini, E; Castagna, A; Cossarini, F; Galli, L; Gianotti, N; Lazzarin, A; Nozza, S; Piatti, P; Salpietro, S; Spagnuolo, V; Vinci, C | 1 |
| Currier, JS; Fox, L; Gandhi, RT; Gulick, R; Lalama, CM; Landay, A; Lin, N; McKinnon, J; Mellors, JW; Ribaudo, H; Tenorio, AR; Wilkin, TJ | 1 |
| Ferrando-Martínez, S; Genebat, M; González-Serna, A; Leal, M; Machmach, K; Muñoz-Fernández, MÁ; Pacheco, YM; Pulido, I; Romero-Sánchez, MC; Ruiz-Mateos, E | 1 |
| Dhiver, C; Durant, J; Gagnieu, MC; Garraffo, R; Katlama, C; Lê, MP; Muret, P; Peytavin, G; Poizot-Martin, I; Solas, C; Yeni, P | 1 |
| Bailey, S; Emerson, SG; Frey, NV; Goldstein, SC; Heitjan, DF; Hexner, EO; Hoxie, JA; Loren, AW; Luger, SM; Mick, R; Nasta, SD; Porter, DL; Reshef, R; Smith, J; Stadtmauer, EA; Vonderheide, RH | 1 |
| Briz, V; de José, MI; de Mulder, M; García, D; González-Tomé, MI; Leal, M; León-Leal, JA; Mellado, MJ; Méndez-Lagares, G; Moreno-Pérez, D; Muñoz-Fernández, MA; Navarro, ML; Ramos, JT; Ruiz-Mateos, E | 1 |
| Anders, M; Bozek, K; Eckhardt, M; Kaiser, R; Kräusslich, HG; Lengauer, T; Müller, B; Sierra, S | 1 |
| Boesecke, C; Pett, SL | 1 |
| Murray, JM; Savkovic, B; Symonds, G | 1 |
| Imami, N; Jackson, A; Mandalia, S; Moyle, G; Nelson, M; Westrop, SJ | 1 |
| Mugavero, MJ; Napolitano, LA; Nevin, CR; Raper, JL; Saag, MS; Tamhane, A; Wilkins, SA; Willig, JH | 1 |
| Bumpus, NN; Hendrix, CW; Lu, Y | 1 |
| Alvarez-Ríos, AI; Ferrando-Martinez, S; García-García, M; Genebat, M; Gonzalez-Serna, A; Leal, M; Machmach, K; Pulido, I; Romero-Sánchez, MC; Ruiz-Mateos, E | 1 |
| Allavena, C; Barbuat, C; Corbeau, P; Cuzin, L; Delobel, P; Flandre, P; Ghosn, J; Lascoux-Combe, C; Peytavin, G; Psomas, C; Reynes, J; Trabelsi, S | 1 |
| Brower, V | 1 |
| Biswas, P; Chapman, DS; Johnson, EP; Kagan, RM; Pesano, RL; Platt, JL; Siaw, M; Su, Z | 1 |
| Abad Fernández, M; Díaz, L; Dronda, F; Gutiérrez, C; Hernández-Novoa, B; Madrid, N; Moreno, S; Muñoz-Fernández, MÁ; Serrano-Villar, S; Vallejo, A; Zamora, J | 1 |
| Cardoso, SW; Grinsztejn, B; Guimarães, ML; Morgado, MG; Passaes, CP; Pilotto, JH; Veloso, V | 1 |
| Brumme, CJ; Chapman, D; Dong, W; Harrigan, PR; Heera, J; James, I; Lewis, M; McGovern, RA; Mo, T; Portsmouth, S; Thielen, A; Valdez, H; Woods, CK; Zhong, X | 1 |
| Forbes, CJ; Geer, L; Goldman, L; Klasse, PJ; Malcolm, RK; Moore, JP; Veazey, RS | 1 |
| Hoepelman, AI; van Lelyveld, SF; Wensing, AM | 1 |
| Arts, EJ; Ratcliff, AN; Shi, W | 1 |
| Arberas, H; Bargalló, ME; Blanco, JL; Calvo, M; García, F; Gatell, JM; Guardo, AC; Maleno, MJ; Plana, M | 1 |
| Craig, C; Fätkenheuer, G; Heera, J; Leal, M; McFadyen, L; Mildvan, D; Mills, A; Podzamczer, D; Portsmouth, S; Rinehart, AR; Than, S; Valdez, H; Valluri, SR; Vourvahis, M | 1 |
| Bellecave, P; Calvez, V; Descamps, D; Fleury, H; Harrigan, PR; Izopet, J; Marcelin, AG; Masquelier, B; Raymond, S; Recordon-Pinson, P; Soulie, C | 1 |
| Dufty, NE; Else, LJ; Gilleran, G; Hawkins, D; Taylor, S | 1 |
| Ampofo, S; Boyd, P; Edwards, KL; Fetherston, SM; Malcolm, RK; McBride, MC; McCoy, CF | 1 |
| Berro, R; Chikere, KC; Didigu, CA; Doms, RW; Hahn, BH; Iyer, SS; Klasse, PJ; Lee, B; Lee, FH; Moore, JP; Parker, ZF; Parrish, NF; Shaw, GM; Wilen, CB | 1 |
| Boonchawalit, S; Harada, S; Matsushita, S; Yamaguchi, A; Yoshimura, K; Yusa, K | 1 |
| Henrich, TJ; Kuritzkes, DR | 1 |
| Courbon, E; Declèves, X; Duro, D; Gavard, L; Giraud, C; Manceau, S; Mandelbrot, L; Peytavin, G; Scherrmann, JM; Tréluyer, JM; Vinot, C | 1 |
| Ferrando-Martínez, S; Genebat, M; Leal, M; Méndez-Lagares, G; Muñoz-Fernández, MÁ; Pacheco, YM; Romero-Sánchez, MC; Ruiz-Mateos, E | 1 |
| Blanco, JR; Martínez, A; Ochoa-Callejero, L; Oteo, JA; Pérez-Martínez, L; Rubio-Mediavilla, S | 1 |
| Antoniou, T; Brunetta, J; Halpenny, R; Hasan, S; Kovacs, C; La Porte, C; Loutfy, MR; Smith, G | 1 |
| Baraki, B; Benko, E; Brumme, ZL; Danroth, R; Huibner, S; Kaul, R; Kovacs, C; Le, AQ; Mazzulli, T; Osborne, BJ; Porte, Cl; Sheth, PM; Yi, TJ | 1 |
| Bellido, R; Bonjoch, A; Casadellà, M; Clotet, B; Negredo, E; Noguera-Julian, M; Paredes, R; Pérez-Álvarez, N; Pou, C; Puig, J | 1 |
| Díaz-Delfín, J; Domingo, P; Giralt, M; Villarroya, F | 1 |
| Back, D; Croucher, A; Else, LJ; Khoo, S; Mora-Peris, B; Scullard, G; Vera, JH; Winston, A | 1 |
| Bennett, LJ; Grooms-Williams, TW; Hamorsky, KT; Husk, AS; Matoba, N; Palmer, KE | 1 |
| Chapman, D; Demarest, J; Dong, WW; Ellery, S; Harrigan, PR; Heera, J; Mo, T; Poon, AF; Swenson, LC; Valdez, H | 1 |
| Abi-Habib, S; Abrol, R; Berro, R; Goddard, WA; Grunbeck, A; Klasse, PJ; Lascano, D; Moore, JP; Sakmar, TP; Trzaskowski, B; Yasmeen, A | 1 |
| Archer, J; Arts, EJ; Gibson, RM; Henry, K; King, K; Olivo, PD; Poveda, E; Quiñones-Mateu, ME; Rhea, AM; Robertson, DL; Rose, JD; Soriano, V; Vazquez, AC; Weber, J; Winner, D; Wright, A; Wylie, D | 1 |
| Bonora, S; Calcagno, A; Chiappetta, S; D'Avolio, A; Di Perri, G; Galli, A; Gonzalez de Requena, D; Lazzarin, A; Nozza, S; Simiele, M | 1 |
| Lacombe, K; Surgers, L | 1 |
| Arts, EJ; Dudley, DM; Lobritz, MA; Marozsan, AJ; Ratcliff, AN; Tilton, JC | 1 |
| Bonora, S; Calcagno, A; D'Avolio, A; Di Perri, G; Ghisetti, V; Marinaro, L; Montrucchio, C; Trentini, L | 1 |
| Adeyemi, O; Clagett, B; Dahl, V; Deeks, SG; Funderburg, NT; Gilman, LE; Hayes, TL; Hunt, PW; Landay, AL; Lederman, MM; Martin, JN; McLaughlin, B; Palmer, S; Rodriguez, B; Schacker, TW; Shacklett, BL; Shulman, NS; Somsouk, M | 1 |
| Emery, S; Harrigan, R; Kaiser, R; Kaye, S; Kelleher, AD; Land, S; Marks, K; Pett, S; Schuelter, E; Swenson, LC; Tu, E | 1 |
| Bon, I; Borderi, M; Calza, L; Clò, A; Colangeli, V; Cricca, M; Gibellini, D; Miserocchi, A; Morini, S; Re, MC | 1 |
| Churchill, MJ; Duncan, R; Ellett, A; Flynn, JK; Gorry, PR; Gray, LR; Jubb, B; Lee, B; Lewin, SR; Moore, MS; Paukovics, G; Purcell, DF; Roche, M; Salimi, H; Westby, M | 1 |
| Chikere, K; Churchill, MJ; Duncan, R; Ellett, A; Flynn, JK; Gorry, PR; Gray, LR; Jubb, B; Lee, B; Lewin, SR; Moore, MS; Payne, RJ; Ramsland, PA; Roche, M; Salimi, H; Sterjovski, J; Webb, NE; Westby, M; Wilkinson, BL; Zappi, H | 1 |
| Arnáiz, E; Córdoba, EV; De La Mata, FJ; Gómez, R; Leal, M; Muñoz-Fernández, MA; Pion, M | 1 |
| Khamadi, SA; Muigai, AW; Ng'ang'a, Z; Nyamache, AK | 1 |
| Baldelli, F; Cipriani, S; D'Amore, C; Fiorucci, S; Francisci, D; Mencarelli, A; Renga, B; Schiaroli, E | 1 |
| Aoki, R; Blauvelt, A; Gatanaga, H; Kawamura, T; Koyanagi, Y; Matsuzawa, T; Moriishi, K; Ogawa, Y; Shimada, S; Takahashi, M | 1 |
| Bercoff, DP; da Silva, ES; Lemaire, M; Lie, Y; Mulinge, M; Rybicki, A; Schmit, JC; Seguin-Devaux, C; Servais, JY; Struck, D; Verhofstede, C | 1 |
| Dong, W; Harrigan, PR; Hoepelman, AI; McGovern, RA; Nijhuis, M; Poon, AF; Symons, J; van Ham, PM; van Lelyveld, SF; Wensing, AM | 1 |
| Bicudo, EL; Cassoli, LM; da Eira, M; de Andrade Neto, JL; Furtado, J; Leite, OH; Lewi, DS; Lima, MP; Lopes, MI; Machado, AA; Madruga, JV; Miranda, AF; Netto, EM; Pedro, Rde J; Portsmouth, S; Santini-Oliveira, M; Santos, BR; Tupinambas, U; Wajsbrot, DB | 1 |
| Aubert, R; Aung, W; Bachman, S; García-Lerma, JG; Heneine, W; Kersh, E; Martin, A; Massud, I; Mitchell, J; Pau, CP; Solomon Tsegaye, T | 1 |
| Arnatt, CK; Dever, SM; El-Hage, N; Hauser, KF; Podhaizer, EM; Zhang, Y | 1 |
| Cai, YD; Chen, L; Huang, T; Jiang, M; Kong, XY; Li, BQ; Lu, J; Niu, B; Wei, ZJ; Zheng, MY | 1 |
| Hanna, GJ; Krystal, M; Lataillade, M; Li, Z; Ray, N; Sun, Y; Zhou, N | 1 |
| McNeil, C | 1 |
| Cazabat, M; Coassin, L; Delobel, P; Izopet, J; Loiseau, C; Marchou, B; Massip, P; Raymond, S; Requena, M; Saliou, A | 1 |
| Acosta, EP; Adeyemi, O; Berzins, B; Castro, J; Eron, JJ; Kuritzkes, DR; Lalezari, J; Lu, D; Ryscavage, P; Swindells, S; Taiwo, B; Tsibris, A | 1 |
| Guo, H; Kong, X; Liu, B; Liu, C; Wood, C | 1 |
| Chilukuri, M; Hussainreddy, K; Narayanareddy, P; Venkataramana, M | 1 |
| Harada, S; Maeda, Y; Sato, H; Terasawa, H; Yokoyama, M; Yuan, Y; Yusa, K | 1 |
| Drechsler, M; Grommes, J; Soehnlein, O | 1 |
| Feucht, N; Hadeler, J; Lanzl, I; Loos, D; Schmid, RM; Schwerdtfeger, C; Spinner, CD | 1 |
| Bumpus, NN; Hendrix, CW; To, EE | 1 |
| Bellazzi, LI; Bianco, C; Bruzzone, B; Colao, G; Corsi, P; De Luca, A; Monno, L; Pagano, G; Paolucci, S; Punzi, G; Rossetti, B; Setti, M; Zazzi, M | 1 |
| Binet, L; Djerada, Z; Feliu, C; Gozalo, C; Lamiable, D; Marty, H; Millart, H; Robinet, A; Tournois, C; Vautier, D | 1 |
| Degli Antoni, A; Ferrari, C; Fragola, V; Manfredi, R; Weimer, LE | 1 |
| Chen, Z; Cherezov, V; Fenalti, G; Han, GW; Jiang, H; Kufareva, I; Li, J; Li, T; Liu, H; Ma, L; Stevens, RC; Tan, Q; Wu, B; Xie, X; Yang, H; Zhang, W; Zhao, Q; Zhu, Y | 1 |
| Klasse, PJ | 1 |
| Garcia-Perez, J; Kellenberger, E; Lagane, B | 1 |
| Adams, RJ; Avery, LB; Beck, SE; Dorsey, JL; Hubbard, W; Kelly, KM; Mankowski, JL; Metcalf Pate, KA; Queen, SE; Tarwater, PM | 1 |
| Brumme, CJ; Chan, D; Chapman, D; Chui, CK; Demarest, JF; Dong, W; Goodrich, J; Harrigan, PR; Heera, J; James, I; Lewis, M; Mo, T; Portsmouth, S; Swenson, LC; Valdez, H; Woods, CK | 1 |
| Fang, A; Heera, J; Mendes da Costa, L; Plotka, A; Vourvahis, M | 1 |
| Gianella, S; Jordan, PS; Karris, MY; Little, SJ; Massanella, M; Patel, D; Pérez-Santiago, J; Richman, DD; Smith, DM; Spina, CA; Var, SR; Young, JA | 1 |
| Ballestero, M; Blanco, J; Boix, J; Buzon, MJ; Clotet, B; Esteve, A; Gatell, JM; Llibre, JM; Manzardo, C; Martinez-Picado, J; Massanella, M; Miró, JM; Ouchi, D; Puertas, MC | 1 |
| Banerjea, AC; Gupta, S; Neogi, U; Shet, A; Srinivasa, H | 1 |
| Alcami, J; Pérez-Olmeda, M | 1 |
| Liu, FC; Tsai, YF; Yu, HP | 1 |
| Piguet, V | 1 |
| Abeli, C; Adorni, F; Bai, F; Bonora, S; Buonomini, AR; Butini, L; Capetti, A; Colafigli, M; Colella, E; D'Annunzio, M; d'Ettorre, G; Di Biagio, A; Di Nardo Stuppino, S; Di Pietro, M; Focà, E; Francisci, D; Marchetti, G; Meraviglia, P; Merlini, E; Montano, M; Morosi, M; Mosti, S; Orofino, G; Parruti, G; Rusconi, S; Soria, A; Tau, P; Tommasi, C; Vitiello, P | 1 |
| Chalmet, K; Dauwe, K; Mortier, V; Staelens, D; Van Wanzeele, F; Vancoillie, L; Vandekerckhove, L; Verhofstede, C; Vogelaers, D | 1 |
| Chai, J; Chen, D; Cheng, X; Jia, S; Li, T; Liang, L; Shen, Z; Sun, M; Yang, X | 1 |
| Fang, A; Heera, J; Kantaridis, C; Plotka, A; Vourvahis, M | 1 |
| Abad-Fernández, M; Díaz, L; Dronda, F; Gutiérrez, C; Hernández-Novoa, B; Madrid, N; Moreno, A; Moreno, S; Muñoz-Fernández, MA; Serrano-Villar, S; Vallejo, A; Zamora, J | 1 |
| Burnside, R; Fatkenheuer, G; Goodrich, J; Gulick, RM; Hardy, WD; Heera, JR; Mukwaya, G; Nelson, MR; Portsmouth, S | 1 |
| Kravchenko, AV | 1 |
| Caskey, M; Evering, TH; Garmon, D; La Mar, M; Markowitz, M; Mohri, H; Palmer, S; Prada, N; Rodriguez, K; Sahi, V | 1 |
| Bigoloni, A; Bonora, S; Calcagno, A; Carbone, A; Castagna, A; D'Avolio, A; Galli, L; Lazzarin, A; Nozza, S; Pignataro, AR; Ripa, M | 1 |
| Blanco, J; Brander, C; Bravo, I; Clotet, B; Escrig, R; Gatell, JM; Iwamoto, A; Kawana-Tachikawa, A; Llibre, JM; Manzardo, C; Martinez-Picado, J; Miro, JM; Mothe, B; Pozniak, AL; Puertas, MC; Puig, J | 1 |
| Araujo, D; Arbour, N; Bar-Or, A; Giacomini, PS; Metz, I; Rozenberg, A | 1 |
| Bozzano, F; Cenderello, G; De Maria, A; Dentone, C; Di Biagio, A; Fenoglio, D; Filaci, G; Fraccaro, P; Mantia, E; Orofino, G; Parodi, A; Signori, A | 1 |
| Assoumou, L; Chablais, L; Costagliola, D; Duvivier, C; Katlama, C; Kolta, S; Marcelin, AG; Mercié, P; Peytavin, G; Pialoux, G; Simon, A; Soulié, C; Valantin, MA | 1 |
| Audino, A; Baietto, L; Bonora, S; D'Avolio, A; Di Perri, G; Sciandra, M; Simiele, M | 1 |
| Emory, JF; Marzinke, MA; Seserko, LA | 1 |
| Bancalero, P; Chueca, N; García, C; Jiménez, P; Macías, J; Márquez, M; Merino, D; Muñoz, L; Ojeda, G; Pasquau, J; Pineda, JA; Recio, E | 1 |
| Evans, A; Forbes, CJ; Malcolm, RK; McCoy, CF; Moore, JP; Murphy, DJ; Shattock, RJ; Woolfson, AD | 1 |
| Casado, JL; Dronda, F; Estébanez, M; González, J; Hernández-Novoa, B; Madrid-Elena, N; Moreno, A; Moreno, S; Pérez-Elias, MJ; Pérez-Molina, JA; Zamora, J | 1 |
| Beavis, P; Chuang, KT; Deval, J; Dioszegi, M; Gee, P; Kondru, R; Lee, I; Ravendran, P; Rotstein, DM; Sankuratri, S; Swinney, DC; Vauquelin, G; Zhang, J; Zheng, Y | 1 |
| McGowan, I | 1 |
| Panos, G; Watson, DC | 1 |
| Aguilera-Lizarraga, J; Blanco, JR; Narro, J; Ochoa-Callejero, L; Oteo, JA; Pérez-Martínez, L; Pérez-Matute, P; Recio, E; Rubio-Mediavilla, S | 1 |
| Leal, M; Martínez-Bonet, M; Méndez-Lagares, G; Muñoz-Fernández, MA; Pacheco, YM; Pozo-Balado, MM; Rodríguez-Méndez, MM; Rosado, I; Ruiz-Mateos, E; Vidal, F | 1 |
| Siegel, MO | 1 |
| Adams, RJ; Beck, SE; Bedja, D; Graham, DR; Kelly, KM; Lyashkov, A; Mankowski, JL; Metcalf Pate, KA; Paolocci, N; Queen, SE; Tarwater, PM; Tocchetti, CG | 1 |
| Baldelli, F; Baroncelli, S; Cecchini, E; Falcinelli, E; Floridia, M; Francisci, D; Gresele, P; Petito, E; Weimer, LE | 1 |
| Dash, RC; Moonsamy, S; Soliman, ME | 1 |
| Floudas, CA; Tamamis, P | 1 |
| Beliakova-Bethell, N; Dubé, MP; Goicoechea, M; Haubrich, R; Jain, S; Lada, SM; Rought, SE; Spina, CA; Sun, X; Witt, MD; Woelk, CH | 1 |
| Caballero, E; Cabezas, T; De Mendoza, C; Eiros, JM; Lopez, M; Parra, P; Poveda, E; Roc, L; Rodríguez, C; Soriano, V; Treviño, A | 1 |
| Boonchawalit, S; Harada, S; Kawanami, Y; Matsushita, S; Yoshimura, K | 1 |
| Bonora, S; Calcagno, A; Chiappetta, S; D'Avolio, A; Di Perri, G; Ghisetti, V; Lazzarin, A; Milia, MG; Nozza, S; Simiele, M | 1 |
| Bigoloni, A; Carbone, A; Castagna, A; Chiappetta, S; Galli, L; Gianotti, N; Lazzarin, A; Nozza, S; Ripa, M; Spagnuolo, V; Tambussi, G | 1 |
| Ajassa, C; Ermocida, A; Lichtner, M; Mastroianni, CM; Mengoni, F; Rossi, R; Sauzullo, I; Vullo, V | 1 |
| Colby-Germinario, SP; Kramer, VG; Mesplède, T; Oliviera, M; Varsaneux, O; Wainberg, MA | 1 |
| Ball, C; Woodrow, KA | 1 |
| Back, D; Boffito, M; Else, L; Gazzard, B; Jackson, A; Nelson, M; Newell, S; Rockwood, N; Waters, L | 1 |
| Achhra, AC; Boyd, MA; Cooper, DA; Kelleher, AD; Law, MG; Matthews, GV | 1 |
| Botes, M; Burnside, R; Clumeck, N; Cooper, DA; Dejesus, E; Heera, J; Ive, P; Lazzarin, A; Mukwaya, G; Saag, M; van Der Ryst, E; Walmsley, S | 1 |
| Abid, S; Adnot, S; Amsellem, V; Bobe, R; Combadière, C; Delcroix, M; Dubois-Randé, JL; Gary-Bobo, G; Gladwin, MT; Houssaini, A; Lipskaia, L; Marcos, E; Mouraret, N; Norris, KA; Parpaleix, A; Poupel, L; Quarck, R; Saker, M | 1 |
| Aung, WS; Emory, JF; Marzinke, MA; Parsons, TL; Seserko, LA | 1 |
| Chen, XQ; Gu, WG | 1 |
| Akkina, R; Kashuba, ADM; LeCureux, J; Remling-Mulder, L; Sykes, C; Veselinovic, M; Yang, KH | 1 |
| Bumpus, NN; Fuchs, EJ; Hendrix, CW; Lu, Y | 1 |
| Booth, C; Conibear, T; Garcia-Diaz, A; Herman, OM; Irish, D; Johnson, MA; Macartney, M; McCormick, A; Smith, C; Webster, DP; Wyatt, H | 1 |
| Abrol, R; Goddard, WA; Irons, C; Nesterov, A; Olave, I; Trzaskowski, B | 1 |
| Gilchrist, A; Karash, A; Mazzoni, MR | 1 |
| Guo, J; Wu, Y; Xu, GG | 1 |
| Abad-Carrillo, MA; Alvarez-Ríos, AI; Benhnia, MR; Bernal-Morell, E; Bravo-Urbieta, J; de Pablo-Bernal, RS; Galera-Peñaranda, C; Genebat, M; Leal, M; Romero-Sánchez, MC; Ruiz-Mateos, E; Vera, F | 1 |
| Fertig, EJ; Jin, K; Lee, E; Pandey, NB; Popel, AS; Sukumar, S | 1 |
| Agsalda, M; Chew, GM; Chow, DC; Hanks, N; Ho, E; Kallianpur, KJ; Nakamoto, B; Ndhlovu, LC; Paul, R; Shikuma, CM; Shiramizu, BT; Umaki, T; Zhang, G | 1 |
| Back, D; Davies, G; Khoo, S; Owen, A; Schipani, A; Siccardi, M | 1 |
| Brun-Vézinet, F; Charpentier, C; Damond, F; Descamps, D; Fagard, C; Glohi, D; Matheron, S; Rouard, C; Tubiana, R; Visseaux, B | 1 |
| Asin-Milan, O; Belanger-Jasmin, G; Blackburn, J; Chamberland, A; El-Far, M; Haidara, A; Sylla, M; Tremblay, CL | 1 |
| Bigoloni, A; Boeri, E; Castagna, A; Cavarelli, M; Galli, A; Mainetti, L; Nozza, S; Pignataro, AR; Sampaolo, M; Scarlatti, G; Tolazzi, M | 1 |
| Bai, Q; Chen, W; Li, X; Liu, H; Yao, X; Zhang, Y | 1 |
| Adams, DH; Bicknell, R; Curbishley, SM; Eksteen, B; Hejmadi, RK; Hepburn, E; Ismail, T; Li, KK; Reynolds, GM; Rot, A; Ward, ST; Weston, CJ | 1 |
| Calvez, V; Charpentier, C; Descamps, D; Katlama, C; Lambert-Niclot, S; Marcelin, AG; Peytavin, G; Sayon, S; Simon, A; Soulie, C; Visseaux, B; Yazdanpanah, Y | 1 |
| Heredia, A; Lakowicz, JR; Latinovic, O; Redfield, RR; Schneider, K; Szmacinski, H | 1 |
| Cohen, MS; Emerson, CW; Fedoriw, Y; Geller, EJ; Kashuba, AD; Nelson, JA; Nicol, MR; Patterson, KB; Prince, HM; Sykes, C | 1 |
| Huber, T; Naganathan, S; Park, M; Ray-Saha, S; Sakmar, TP; Tian, H | 1 |
| Liu, W; Ren, HY; Shi, YJ; Yuan, J | 1 |
| Averseng-Peaureaux, D; Bauer, J; Biotti, D; Bonneville, F; Brassat, D; Dumas, H; Fabre, N; Lassmann, H; Liblau, RS; Marchou, B; Martin-Blondel, G; Uro-Coste, E | 1 |
| Bar-Or, A; Brück, W; Metz, I; Stork, L | 1 |
| Baccarani, U; Bassetti, M; Bonora, S; Dal Zoppo, S; Della Siega, P; Delle Foglie, P; Giglio, O; Londero, A; Nasta, P; Pea, F; Righi, E; Villa, G | 1 |
| Alcaro, S; Alteri, C; Aquaro, S; Artese, A; Balestra, E; Ceccherini-Silberstein, F; Chapman, D; Clotet, B; Costa, G; Harrigan, R; Lewis, M; Martinez-Picado, J; Parrotta, L; Perno, CF; Puertas, MC; Saccomandi, P; Surdo, M; Svicher, V; Swenson, L; Valdez, H | 1 |
| Antinori, A; Bonora, S; Chiappetta, S; De Battista, D; Di Pietro, M; Galli, L; Lazzarin, A; Malnati, M; Mazzotta, F; Nozza, S; Ottou, S; Pogliaghi, M; Ripa, M; Zaccarelli, M | 1 |
| Amiel, C; Bellecave, P; Delaugerre, C; Desbois, D; Descamps, D; Izopet, J; Maillard, A; Marcelin, AG; Peytavin, G; Raymond, S; Soulie, C; Trabaud, MA | 1 |
| Cashin, K; Churchill, MJ; Demarest, JF; Drummond, F; Gorry, PR; Gray, LR; Harrigan, PR; Harvey, KL; Lee, GQ; Perez-Bercoff, D; Roche, M; Sterjovski, J | 1 |
| Assoumou, L; Autran, B; Campillo-Gimenez, L; Capeau, J; Costagliola, D; Guihot, A; Katlama, C; Marcelin, AG; Pajanirassa, P; Soulié, C; Valantin, MA; Villemonteix, J | 1 |
| Acharya, P; Bewley, CA; Kwong, PD; Lusvarghi, S | 1 |
| Angelini, A; Burg, JS; Dror, RO; Dukkipati, A; Feinberg, EN; Garcia, KC; Ingram, JR; Jude, KM; Ploegh, HL; Venkatakrishnan, AJ; Waghray, D | 1 |
| Appolloni, L; Calza, L; Cascavilla, A; Colangeli, V; Manfredi, R; Marinacci, G; Martelli, G; Puggioli, C; Salvadori, C; Viale, P | 1 |
| Adwan, H; Ansari, S; Berger, MR; Pervaiz, A | 1 |
| De La Mata, FJ; Gómez, R; Jiménez, JL; Muñoz-Fernández, MÁ; Sánchez-Rodríguez, J; Sepúlveda-Crespo, D; Serramía, MJ | 1 |
| Ganetsky, A; Hughes, ME; Miano, TA; Porter, DL; Reshef, R; Vonderheide, RH | 1 |
| Biswas, P; Cozzi, P; García-Sastre, A; Ghezzi, S; Guzzo, C; Jabes, D; Lusso, P; Malnati, M; Martínez-Romero, C; Mongelli, N; Sironi, F | 1 |
| Back, KR; Docherty, R; Doherty, CL; Feeder, N; Meenan, P; Pidcock, E; Reilly, AM; Sadiq, G | 1 |
| Assoumou, L; Calvez, V; Chas, J; Duvivier, C; Katlama, C; Lê, MP; Marcelin, AG; Peytavin, G; Ponscarme, D; Soulié, C; Valantin, MA | 1 |
| Glisic, S; Radi, M; Tassini, S; Veljkovic, N; Veljkovic, V; Vucicevic, J | 1 |
| Demarest, J; Heera, J; Knirsch, C; van der Ryst, E | 1 |
| Ahmed, N; Ainsworth, J; Okoli, C | 1 |
| Dybowski, JN; Esser, S; Fätkenheuer, G; Güney, L; Heider, D; Hoffmann, D; Jensen, B; Kaiser, R; Lengauer, T; Pfister, H; Pironti, A; Reuter, S; Sierra, S; Thielen, A | 1 |
| Arroyo, D; Blanco, JR; Crespo, M; Garcia Del Toro, M; Herrero, C; Llibre, JM; Masiá, M; Moreno, S; Pasquau, J; Pineda, JA; Rivero, A; Rojas, JF | 1 |
| Cavarelli, M; Chiappetta, S; Cossarizza, A; De Battista, D; De Biasi, S; Galli, L; Lazzarin, A; Malnati, M; Nozza, S; Pensieroso, S; Pogliaghi, M; Ripa, M; Scarlatti, G; Tambussi, G | 1 |
| Bosmann, M; Moore, BB; Roewe, J; Ruemmler, R; Russkamp, NF; Ward, PA | 1 |
| Chen, BA; Dezzutti, CS; Hendrix, CW; Hoesley, CJ; Husnik, MJ; Johnson, S; Marzinke, MA; Nel, A; Panther, L; Rabe, LK; Richardson-Harman, N; Soto-Torres, L; van der Straten, A | 1 |
| Arends, JE; Frijns, CJ; Hoepelman, AI; Middel, A; Otto, S; Schuurman, R; Tesselaar, K; van Lelyveld, SF | 1 |
| Arroyo-Manzano, D; Blanco, JR; Bravo, I; Crespo, M; Garcia Del Toro, M; Herrero, C; Llibre, JM; Moreno, S; Pasquau, J; Rivero, A; Rojas-Liévano, JF | 1 |
| Berzins, B; Brown, T; Chan, ES; Eron, JJ; Fichtenbaum, CJ; Klingman, KL; Landay, A; Ofotokun, I; Ribaudo, H; Robertson, K; Taiwo, BO; Tsibris, A | 1 |
| Shah, M; Shahani, L; Tavakoli-Tabasi, S | 1 |
| Bellecave, P; Calvez, V; Charpentier, C; Descamps, D; Flandre, P; Marcelin, AG; Masquelier, B; Pawlotsky, JM; Recordon-Pinson, P; Rodriguez, C; Soulié, C | 1 |
| Anderson, PL; Bushman, LR; Chuong, D; Dobard, CW; Garcia-Lerma, JG; Hanson, D; Heneine, W; McGowan, I; Pau, CP; Rohan, L; Sharma, S; Taylor, A; Wang, L | 1 |
| Brown, ER; Devlin, B; Dezzutti, CS; Moncla, B; Nuttall, J; Rohan, LC; Teeple, EA; Wang, L; Yandura, S | 1 |
| Alcami, J; Arenzana-Seisdedos, F; Azoulay, S; Cascajero, A; Colin, P; Garcia-Perez, J; Heinrich, JT; Kellenberger, E; Lagane, B; Lortat-Jacob, H; Staropoli, I | 1 |
| Abad, MA; de Pablo-Bernal, RS; Genebat, M; Jiménez-Mejías, ME; Leal, M; Martínez, O; Pacheco, YM; Pulido, I; Raffi-El-Idrissi Benhia, M; Ruiz-Mateos, E | 1 |
| Boonchawalit, S; Gatanaga, H; Harada, S; Matsushita, S; Oka, S; Shirai, N; Yoshimura, K | 1 |
| Basta-Kaim, A; Jurga, A; Kwiatkowski, K; Makuch, W; Mika, J; Piotrowska, A; Rojewska, E; Slusarczyk, J; Trojan, E | 1 |
| Aguilera-Lizarraga, J; Blanco, JR; Oteo, JA; Pérez-Martínez, L; Pérez-Matute, P | 1 |
| Best, B; Burchett, S; Burger, D; Capparelli, E; Colbers, A; Haberl, A; Hawkins, D; Hidalgo Tenorio, C; Kabeya, K; Kreitchmann, R; Mirochnick, M; Schalkwijk, S; Smith, E; Stek, A; Taylor, G; van Kasteren, M; Wang, J | 1 |
| Borghans, JA; Brinkman, K; Drylewicz, J; Hoepelman, AI; Krikke, M; Kroon, F; Middel, A; Mulder, JW; Nijhuis, M; Otto, SA; Prins, JM; Richter, C; Soetekouw, R; Symons, J; Tesselaar, K; van Lelyveld, SF; Veel, EM; Wensing, AM | 1 |
| Bainer, R; Becker, L; Chada, K; Frankenberger, C; Gilad, Y; Krausz, T; Rabe, D; Rosner, MR; Sankarasharma, D | 1 |
| Bertine, M; Brun-Vézinet, F; Charpentier, C; Collin, G; Damond, F; Descamps, D; Lefebvre, E; Matheron, S; Peytavin, G; Visseaux, B | 1 |
| Durdagi, S; Salmas, RE; Yurtsever, M | 1 |
| Craig, C; Feyertag, F; Jiang, X; Lewis, M; McCormack, GP; Meehan, CJ; Robertson, DL; Travers, SA; Westby, M | 1 |
| DeVico, AL; Fouts, TR; Heredia, A; Lakowicz, JR; Latinovic, OS; Redfield, RR; Schneider, K; Tagaya, Y; Zhang, J | 1 |
| Barnett, C; Cuffe, R; Granier, C; Machida, M; Roger, J; Wang, C | 1 |
| Council, OD; Garcia, JV; Spagnuolo, RA; Swanson, MD; Wahl, A | 1 |
| Assoumou, L; Caby, F; Calvez, V; Canestri, A; Costagliola, D; Darty, M; Donati, F; Katlama, C; Marcelin, AG; Peytavin, G; Rodriguez, C; Sayon, S; Schneider, L; Soulié, C; Valantin, MA | 1 |
| Chen, J; Li, L; Qin, C; Ren, Y; Wan, Y; Wang, J; Wang, W; Wei, Q; Xu, J; Zhang, X | 1 |
| Álvarez, S; Clemente, MI; Díaz, L; García-Alonso, D; Martínez-Bonet, M; Moreno, S; Muñoz, E; Muñoz-Fernández, MÁ | 1 |
| Kanmogne, GD; Woollard, SM | 1 |
| Ålenius, M; Antonsson, L; Cederfjäll, E; Esbjörnsson, J; Gisslen, M; Jansson, M; Karlsson, U; Ljungberg, B; Repits, J; Sabirsh, A | 1 |
| Garvey, L; Rojas, JH; Taylor-Robinson, S; Vigneswaran, S; Winston, A | 1 |
| Blanco, JR; Ochoa-Callejero, L | 1 |
| Cillo, AR; Coombs, RW; Currier, JS; Fox, L; Gandhi, RT; Gulick, RM; Hilldorfer, BB; Lalama, CM; McKinnon, JE; Mellors, JW; Ribaudo, H; Tenorio, AR; Wilkin, TJ | 1 |
| Back, D; Boix, J; Cabrera, C; Carrillo, A; Clotet, B; Coll, J; Else, L; Escrig, R; García, E; Gómez-Mora, E; Moltó, J; Ouchi, D; Paredes, R | 1 |
| Briz, V; De Ory, SJ; Espiau, M; Gómez, ML; González-Tomé, MI; Guasch, CF; Guillén, SM; Guruceta, IP; Hoyos, SP; León-Leal, JA; Méndez, M; Moreno-Pérez, D; Palladino, C; Sierra, AM; Soler-Palacín, P | 1 |
| Ding, L; Li, N; Shu, R; Wang, G; Wang, H; Wang, Z; Yu, Y; Zhang, L | 1 |
| Connell, BJ; Hoepelman, AI; Nijhuis, M; Symons, J; van Ham, P; van Lelyveld, SF; Wensing, AM | 1 |
| Carcenac, R; Cazabat, M; Delobel, P; Dubois, M; Izopet, J; Jeanne, N; Lefebvre, C; Loiseau, C; Nicot, F; Raymond, S; Saliou, A | 1 |
| Azzoni, L; Fair, MG; Joseph, J; Montaner, LJ; Patro, SC; Rassool, MS; Sanne, I; Sierra-Madero, JG | 1 |
| Battinelli, EM; El-Husayni, SH; Forward, JA; Italiano, JE; Johnson, KE; Kulenthirarajan, R; Machlus, KR; Soussou, TS; Tippy, MD; Wang, S; Watnick, RS; Wu, SK | 1 |
| Ball, C; Hamlyn, E; Jarosz, J; Post, FA; Sudhanva, M | 1 |
| Armanasco, N; Fletcher, P; Herrera, C; Nuttall, J; Shattock, RJ | 1 |
| Aubin, C; Costagliola, D; Ferry, T; Finkielsztejn, L; Potard, V; Reynes, J; Yazdanpanah, Y | 1 |
| Carcenac, R; Cazabat, M; Cuzin, L; Delobel, P; Izopet, J; Jeanne, N; Nicot, F; Raymond, S; Requena, M | 1 |
| Baker, DP; Branch, DR; Fish, EN; Hoenen, T; Kobinger, GP; Kozlowski, HN; Majchrzak-Kita, B; McCarthy, SD; Racine, T | 1 |
| Albanese, A; Asmuth, DM; Chun, TW; Deeks, SG; Kashuba, AD; Landay, A; Ma, ZM; Mann, S; Miller, CJ; Moreno, S; Pollard, RB; Sainz, T; Serrano-Villar, S; Siewe, B; Sinclair, E; Somasunderam, A; Troia-Cancio, P; Utay, NS; Wook-Chun, T; Yotter, T | 1 |
| Benhnia, MR; Leal, M; Méndez-Lagares, G; Muñoz-Fernández, MA; Pacheco, YM; Pozo-Balado, MM; Rodríguez-Méndez, MM; Rosado-Sánchez, I; Ruiz-Mateos, E | 1 |
| Brew, BJ; Chaganti, J; Cysique, LA; Gates, TM; Moffat, KJ; Siefried, KJ | 1 |
| Chen, BA; Cheng, H; Hoesley, CJ; Horn, S; Husnik, MJ; Laborde, N; Nel, A; Panther, L; Soto-Torres, L; van der Straten, A | 1 |
| Alcamí, J; Armanasco, N; García-Pérez, J; Herrera, C; Nuttall, J; Olejniczak, N; Shattock, RJ; Ziprin, P | 1 |
| Golan-Paz, S; Jiang, Y; Ramanathan, R; Read, B; Woodrow, KA | 1 |
| Garvey, LJ; Mora-Peris, B; Scott, J; Underwood, J; Winston, A | 1 |
| Woodland, DL | 1 |
| Fukutake, K | 1 |
| Allmon, A; Cottrell, ML; Dellon, ES; Hudgens, MG; Kashuba, AD; Madanick, RD; Malone, S; Mollan, KR; Patterson, KB; Prince, HM; Shaheen, NJ; Sykes, C; White, N | 1 |
| Garg, H; Joshi, A; Lee, RT; Maurer-Stroh, S | 1 |
| Dirks, M; Dittmer, U; Esser, S; Joedicke, JJ; Verheyen, J | 1 |
| Ball, C; Chou, SF; Jiang, Y; Woodrow, KA | 1 |
| Amin, J; Andrade-Villanueva, J; Arnaiz, JA; Belloso, W; Clark, A; Clarke, A; Cooper, D; Emery, S; Fisher, M; Gatell, J; Gill, J; Harrigan, R; Horban, A; Kaiser, R; Kelleher, A; Losso, M; Mallon, P; Pett, SL; Porteiro, N; Prazuck, T; Rockstroh, JK; Ruxrungtham, K; Sierra Madero, J; Silk, D; Sugiura, W; Tu, E; Wolff, M; Woolley, I | 1 |
| Baum, MM; Butkyavichene, I; Churchman, SA; Easley, JT; Fanter, R; Gunawardana, M; Hendrix, CW; Marzinke, MA; Miller, CS; Moss, JA; Smith, TJ; Yang, F | 1 |
| Benner, A; Berthel, A; Brand, K; Buechler, MW; Falk, CS; Grabe, N; Halama, N; Herrmann, T; Jaeger, D; Kahlert, C; Klupp, F; Koch, M; Krauss, J; Kunz, C; Lasitschka, F; Lerchl, T; Luckner-Minden, C; Luecke, S; Schneider, M; Springfeld, C; Suarez-Carmona, M; Suetterlin, T; Ulrich, A; Weitz, J; Zitvogel, L; Zoernig, I | 1 |
| Kwiatkowski, K; Makuch, W; Mika, J; Piotrowska, A; Rojewska, E | 1 |
| Choo, HW; Fang, J; Heera, J; Vourvahis, M | 1 |
| Ajana, F; Alidjinou, EK; Bocket, L; Calvez, V; Charpentier, C; Choisy, P; Descamps, D; Katlama, C; Lê, M; Marcelin, AG; Peytavin, G; Simon, A; Soulie, C; Yazdanpanah, Y | 1 |
| Blakney, AK; Jiang, Y; Whittington, D; Woodrow, KA | 1 |
| Brown, TT; Chan, ES; Eron, JJ; Fichtenbaum, CJ; Klingman, KL; Landay, AL; Martinson, J; Mirmonsef, P; Ofotokun, I; Plants, J; Ribaudo, HJ; Taiwo, BO; Weitzmann, MN | 1 |
| Berzins, B; Brown, TT; Chan, ES; Eron, JJ; Lee, A; Miyahara, S; Robertson, KR; Rusin, D; Taiwo, BO | 1 |
| Baba, T; Mukaida, N; Sasaki, S; Tanabe, Y | 1 |
| Clerici, M; Cossu, M; Masetti, M; Piconi, S; Pocaterra, D; Rainone, V; Rizzardini, G; Trabattoni, D | 1 |
| Dong, Y; Liu, H; Liu, W; Miao, S; Ren, H; Shi, Y; Tang, B; Yin, Y | 1 |
| Chen, BA; Dezzutti, CS; Hoesley, CJ; Johnson, S; Marzinke, MA; Nel, A; Nuttall, JP; Panther, L; Richardson-Harman, N; Rohan, LC | 1 |
| Brochier, C; Cottalorda-Dufayard, J; Cotte, L; Dellamonica, P; Durant, J; Gagnieu, MC; Gatey, C; Izopet, J; Jacomet, C; Lucht, F; Pradat, P; Raffi, F; Trabaud, MA; Vassallo, M | 1 |
| Achhra, AC; Amin, J; Boyd, MA; Mwasakifwa, G | 1 |
| De Luna-Romero, M; Dominguez-Molina, B; Genebat, M; Gonzalez-Serna, A; Leal, M; Muñoz-Fernández, MA; Pacheco, YM; Ruiz-Mateos, E; Tarancon-Diez, L | 1 |
| Baldelli, F; Cipriani, S; Distrutti, E; Fiorucci, S; Francisci, D; Mencarelli, A; Santucci, L | 1 |
| Davies, SM; Fukuda, T; Kashuba, ADM; Khandelwal, P; Marsh, RA; Mehta, PA; Mizuno, K; Teusink-Cross, A; Vinks, AA | 1 |
| Liu, FC; Yu, HP; Zheng, CW | 1 |
| Marzinke, MA; Parsons, TL | 1 |
| Alteri, C; Boeri, E; Castagna, A; Clementi, M; Galli, L; Lazzarin, A; Nozza, S; Perno, CF; Pignataro, AR; Ripa, M; Sampaolo, M; Svicher, V | 1 |
| Arnatt, CK; El-Hage, N; Falls, BA; Hauser, KF; Knapp, PE; Masvekar, RR; Nicola, AV; Raborg, TJ; Selley, DE; Yuan, Y; Zhang, Y | 1 |
| Blanco, JR; Iñiguez, M; Oteo, JA; Pérez-Martínez, L; Pérez-Matute, P; Pichel, JG; Recio-Fernández, E; Torrens, R | 1 |
| Back, D; Boffito, M; Dickinson, L; Egan, D; Else, L; Fox, J; Herrera, C; Jackson, A; Khoo, S; Olejniczak, N; Shattock, R; Tiraboschi, JM | 1 |
| Kaku, Y; Minami, R; Takahama, S; Yamamoto, M | 1 |
| Giesler, KE; Kim, MB; Liotta, DC; Tahirovic, YA; Truax, VM; Wilson, LJ | 1 |
| Borm, K; Cashin, K; Churchill, MJ; Ellenberg, P; Flynn, JK; Gorry, PR; Jakobsen, MR; Lee, B; Ostergaard, L; Roche, M | 1 |
| Amico, KR; Andrade, A; Andrew, P; Chege, W; Chen, YQ; Cottle, LM; Eshleman, SH; Farley, JE; Frank, I; Gulick, RM; Hendrix, CW; Ho, K; Klingman, KL; Landovitz, RJ; Liu, A; Magnus, M; Marcus, C; Marzinke, MA; Mayer, KH; McCauley, M; McGowan, I; Richardson, P; Rinehart, AR; Rooney, JF; Salata, RA; Santana, J; Stekler, JD; Wilkin, TJ; Young, AM | 1 |
| Karris, MY; Little, S; Richman, D; Smith, D; Umlauf, A; Vaida, F | 1 |
| Athota, VR; Day, CJ; Elsworth, B; Freeman, R; Gasch, C; Mellick, AS; Mittal, V; Nikolic, I; Pouliot, N; Rasighaemi, P; Rogers, K; Sax, MJ; Swarbrick, A; Wei, M; Westcott, DE | 1 |
| Chiappetta, S; Coppalini, G; Nozza, S; Pogliaghi, M; Ripa, M; Rovelli, C; Soria, A; Tambussi, G | 1 |
| Cason, J; Davies, O; Fidler, S; Fox, J; Frater, J; Hopkins, E; Kaye, S; Klenerman, P; Mant, C; Meyerowitz, J; Pace, M; Patel, K; Phalora, P; Ray, S; Robinson, N; Sanderson, J; Tiraboschi, J; Wang, Y | 1 |
| Asmuth, DM; Bansal, M; Fätkenheuer, G; Heera, J; Pialoux, G; Pineda, JA; Plonski, F; Rockstroh, JK; Small, CB; Wang, R; Zhang-Roper, R | 1 |
| Foster, C; Fraser-Taliente, T; Kaye, S; Mackie, NE; Nyirenda, M | 1 |
| Aiestaran, A; Artero, A; Bernal, E; Blanco, F; Flores, J; García, F; García-Deltoro, M; Gutiérrez, F; Hernández-Quero, J; Imaz, A; Martínez-Madrid, OJ; Mínguez-Gallego, C; Navarro, J; Ocampo, A; Paredes, R; Pasquau, J; Pérez, N; Pérez-Elías, MJ; Poveda, E; Ribas, MA | 1 |
| Angarano, G; Bruno, G; Ladisa, N; Maggi, P; Perilli, F; Santoro, C; Saracino, A; Volpe, A | 1 |
| Capetti, AF; Carenzi, L; Dedivitiis, G; Landonio, S; Micale, M; Niero, F; Rizzardini, G; Vimercati, S | 1 |
| Blakney, AK; Jiang, Y; Little, AB; Woodrow, KA | 1 |
| Kong, X; Liu, X; Ma, J; Ou, C; Wang, Q; Yu, Y; Zhang, Y | 1 |
| Bieniasz, P | 1 |
| Arenas-Pinto, A; Benn, P; Brima, N; Clarke, A; Copas, A; Fisher, M; Gilson, R; Hawkins, D; Milinkovic, A; Schembri, G; Williams, A | 1 |
| Benko, E; Huibner, S; Kandel, G; Kaul, R; Kim, CJ; Kovacs, C; Ostrowski, M; Rousseau, R; Shahabi, K | 1 |
| Capobianco, M; Capra, R; De Rossi, N; Gerevini, S; Imberti, L; Lugaresi, A; Mancinelli, CR; Moiola, L; Naldi, P; Prosperini, L; Scarpazza, C | 1 |
| Abagyan, R; Cherezov, V; Han, GW; Handel, TM; Kufareva, I; Stevens, RC; Wu, B; Zheng, Y | 1 |
| Alberto Arnaiz, J; Amin, J; Andrade-Villanueva, J; Belloso, W; Clark, A; Clarke, A; Cooper, D; Emery, S; Gatell, J; Gill, J; Harrigan, R; Horban, A; Kaiser, R; Kelleher, A; Losso, M; Madero, JS; Mallon, P; Pett, SL; Porteiro, N; Prazuck, T; Rockstroh, JK; Ruxrungtham, K; Silk, D; Sugiura, W; Tu, E; Wolff, M; Woolley, I | 1 |
| Borm, K; Cashin, K; Churchill, M; Duncan, R; Ellenberg, P; Ellett, A; Flynn, JK; Gorry, PR; Gray, LR; Jubb, B; Lee, B; Lewin, SR; Lewis, M; Roche, M; Sterjovski, J; Westby, M; Zhou, J | 1 |
| Amico, KR; Andrade, A; Andrew, P; Chege, W; Chen, YQ; Cottle, LM; Eshleman, SH; Frank, I; Gulick, RM; Hendrix, CW; Ho, K; Hodder, S; Klingman, KL; Landovitz, RJ; Manabe, YC; Marcus, C; Marzinke, MA; Mayer, KH; McCauley, M; McGowan, I; Richardson, P; Rinehart, AR; Rooney, JF; Salata, RA; Santana, J; Siegel, M; Stekler, JD; Swaminathan, S; Wilkin, TJ; Young, AM | 1 |
| Emanuel, K; Fox, HS; Lamberty, BG; Morsey, B; Stauch, KL | 1 |
| Belarbi, L; Chaix, ML; Dulioust, E; Duvivier, C; Ghosn, J; Launay, O; Lê, MP; Mahjoub, N; Peytavin, G; Salmon, D; Viard, JP | 1 |
| Asmuth, DM; Chun, TW; Garcia, JC; Kashuba, AD; Landay, A; Ma, ZM; Mann, S; Miller, CJ; Pollard, RB; Sainz, T; Serrano-Villar, S; Thompson, CG; Troia-Cancio, P; Utay, NS | 1 |
| Cox, EK; Garg, H; Joshi, A; Kaur, P; Lee, RT; Maurer-Stroh, S; Ng, OT; Punke, EB; Sedano, MJ | 1 |
| Antinori, A; Canovari, B; Colafigli, M; Colangeli, V; D'Arminio Monforte, A; D'Avino, A; De Luca, A; Di Biagio, A; Di Giambenedetto, S; Fantauzzi, A; Francisci, D; Gagliardini, R; Ghisetti, V; Grima, P; Lamonica, S; Latini, A; Lisi, L; Mastroianni, C; Meini, G; Micheli, V; Navarra, P; Orofino, G; Re, MC; Rossetti, B; Rusconi, S; Sterrantino, G; Trezzi, M; Vignale, F; Vullo, V; Zazzi, M | 1 |
| Bernardo, I; Blanco, JR; Narro, J; Ochoa-Callejero, L; Oteo, JA; Pérez-Martínez, L; Rubio-Mediavilla, S | 1 |
| Aralaguppe, SG; Ashokkumar, M; Hanna, LE; Neogi, U; Tripathy, SP | 1 |
| Appiah-Kubi, P; Iwuchukwu, EA; Soliman, MES | 1 |
| Chen, H; Chen, L; Li, J; Liu, H; Luo, RH; Ma, D; Peng, P; Wang, J; Xie, X; Yang, LM; Zhang, S; Zheng, CB; Zheng, YG; Zheng, YT | 1 |
| Bolzenius, J; Chow, D; Clements, DM; De Gruttola, V; Kallianpur, K; Matos, M; Ndhlovu, LC; Paul, R; Premeaux, TA; Rodriguez-Benitez, RJ; Shikuma, CM; Shiramizu, B; Siriwardhana, C; Souza, SA; Turner, EH; Wojna, V | 1 |
78 review(s) available for triazoles and maraviroc
| Article | Year |
|---|---|
The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS.
Topics: Animals; Anti-HIV Agents; CCR5 Receptor Antagonists; Chemokine CCL4; Cyclohexanes; Humans; Macrophage Inflammatory Proteins; Maraviroc; Protein Binding; Radioligand Assay; Receptors, CCR5; Receptors, HIV; Triazoles | 2005 |
Serious doubts on safety and efficacy of CCR5 antagonists : CCR5 antagonists teeter on a knife-edge.
Topics: Benzoates; CCR5 Receptor Antagonists; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Cyclohexanes; Diketopiperazines; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Piperazines; Pyrimidines; Spiro Compounds; Treatment Outcome; Triazoles | 2006 |
The clinical pharmacology of antiretrovirals in development.
Topics: Animals; Anti-Retroviral Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Darunavir; Drug Evaluation, Preclinical; Drug Interactions; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Maraviroc; Nitriles; Organic Chemicals; Protease Inhibitors; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Receptors, CCR5; Reverse Transcriptase Inhibitors; Sulfonamides; Triazoles | 2006 |
Assessing theoretical risk and benefit suggested by genetic association studies of CCR5: experience in a drug development programme for maraviroc.
Topics: Adult; Arthritis, Rheumatoid; CCR5 Receptor Antagonists; Cyclohexanes; Drug Design; Female; Genotype; Hepatitis C; HIV Fusion Inhibitors; HIV Infections; Humans; Male; Maraviroc; Multiple Sclerosis; Mutation; Pharmacogenetics; Receptors, CCR5; Risk Assessment; Risk Factors; Triazoles | 2007 |
Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Animals; Anti-HIV Agents; Anti-Inflammatory Agents; Arthritis, Rheumatoid; CCR5 Receptor Antagonists; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclohexanes; HIV Infections; Humans; Maraviroc; Receptors, CCR5; Structure-Activity Relationship; Triazoles | 2007 |
Maraviroc.
Topics: Animals; Anti-HIV Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclohexanes; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Maraviroc; Triazoles | 2007 |
CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.
Topics: Anti-HIV Agents; Benzoates; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Diketopiperazines; Drug Interactions; Humans; Maraviroc; Piperazines; Pyrimidines; Spiro Compounds; Triazoles | 2007 |
CCR5 antagonists in the treatment of treatment-experienced patients infected with CCR5 tropic HIV-1.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; HIV Infections; HIV-1; Humans; Maraviroc; Piperazines; Pyrimidines; Triazoles | 2007 |
CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1.
Topics: Adolescent; Adult; Anti-HIV Agents; Benzoates; CCR5 Receptor Antagonists; Cyclohexanes; Diketopiperazines; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Piperazines; Pyrimidines; Randomized Controlled Trials as Topic; Spiro Compounds; Triazoles | 2007 |
How will CCR5 antagonists influence the recommendations for the antiretroviral treatment of HIV-1 infection.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Patient Selection; Practice Guidelines as Topic; Triazoles | 2007 |
Treatment with CCR5 antagonists: which patient may have a benefit?
Topics: Anti-Retroviral Agents; CCR5 Receptor Antagonists; Cyclohexanes; HIV Infections; HIV-1; Humans; Maraviroc; Patient Selection; Treatment Outcome; Triazoles | 2007 |
Maraviroc.
Topics: Animals; Controlled Clinical Trials as Topic; Cyclohexanes; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Female; Food-Drug Interactions; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Triazoles | 2007 |
A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects.
Topics: Adolescent; Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; Computer Simulation; Cyclohexanes; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Models, Biological; Models, Statistical; Randomized Controlled Trials as Topic; Triazoles | 2008 |
Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Computer Simulation; Cyclohexanes; HIV Infections; Humans; Maraviroc; Models, Biological; Models, Statistical; Randomized Controlled Trials as Topic; Triazoles; Viral Load | 2008 |
Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents.
Topics: Anti-HIV Agents; Biological Assay; CCR5 Receptor Antagonists; CD4-Positive T-Lymphocytes; Clinical Trials as Topic; Cyclohexanes; Cytochrome P-450 CYP3A; Drug Interactions; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Maraviroc; Receptors, CCR5; Triazoles; Tropism; Virus Internalization | 2008 |
New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Darunavir; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Maraviroc; Nitriles; Pyridazines; Pyridines; Pyrimidines; Pyrones; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Salvage Therapy; Sulfonamides; Treatment Outcome; Triazoles | 2008 |
Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Interactions; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Maraviroc; Triazoles | 2008 |
Maraviroc, risks and benefits: a review of the clinical literature.
Topics: CCR5 Receptor Antagonists; Clinical Trials, Phase III as Topic; Cyclohexanes; Drug Resistance, Multiple, Viral; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Triazoles | 2008 |
Optimal use of maraviroc in clinical practice.
Topics: Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Drug Interactions; Drug Resistance, Viral; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Receptors, CCR5; Triazoles; Tropism; Viral Load | 2008 |
[New CCR5 inhibitor antiretroviral drugs and integrase inhibitors].
Topics: CCR5 Receptor Antagonists; Cyclohexanes; HIV Fusion Inhibitors; Humans; Integrase Inhibitors; Maraviroc; Pyrrolidinones; Raltegravir Potassium; Triazoles | 2008 |
Developing clinical role of a CCR5 co-receptor antagonist in HIV-1 infection.
Topics: Anti-Retroviral Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Therapy, Combination; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles; Virus Replication | 2008 |
Inhibitors of viral entry.
Topics: Animals; Chemokines; Cyclohexanes; Drug Resistance, Viral; Enfuvirtide; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Peptide Fragments; Triazoles; Virus Attachment; Virus Internalization | 2009 |
[Viral entry as therapeutic target. Current situation of entry inhibitors].
Topics: Adult; Amides; Benzoates; CCR5 Receptor Antagonists; CD4 Antigens; Chemokines, CC; Chemokines, CXC; Clinical Trials as Topic; Cyclohexanes; Diketopiperazines; Drug Design; env Gene Products, Human Immunodeficiency Virus; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Membrane Fusion; Models, Molecular; Piperazines; Pyrimidines; Quaternary Ammonium Compounds; Receptors, CCR5; Receptors, CXCR4; Spiro Compounds; Structure-Activity Relationship; Triazoles; Virus Attachment; Virus Internalization | 2008 |
[Pharmacokinetics, interactions and mechanism of action of maraviroc].
Topics: Adolescent; Adult; Aged; Biological Availability; Biotransformation; CCR5 Receptor Antagonists; Chemokines, CC; Clinical Trials as Topic; Cyclohexanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Design; Drug Interactions; env Gene Products, Human Immunodeficiency Virus; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Kidney Diseases; Liver Diseases; Maraviroc; Membrane Fusion; Receptors, CCR5; Triazoles; Virus Attachment; Virus Internalization; Virus Replication | 2008 |
[Maraviroc efficacy in clinical studies on the development of the molecule].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Cyclohexanes; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Design; Drug Resistance, Multiple, Viral; env Gene Products, Human Immunodeficiency Virus; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Multicenter Studies as Topic; Salvage Therapy; Treatment Outcome; Triazoles | 2008 |
[Secondary effects of treatment with maraviroc and other CCR5 antagonists. Potential impact of the CCR5 blocker].
Topics: Adult; Benzoates; CCR5 Receptor Antagonists; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Comorbidity; Cyclohexanes; Diketopiperazines; Disease Susceptibility; Drug Design; env Gene Products, Human Immunodeficiency Virus; HIV Fusion Inhibitors; HIV Infections; Homozygote; Humans; Hyperlipidemias; Incidence; Infections; Maraviroc; Membrane Fusion; Neoplasms; Piperazines; Receptors, CCR5; Sequence Deletion; Spiro Compounds; Triazoles; Virus Attachment; Virus Internalization | 2008 |
[Mechanisms of resistance and failure of treatment with maraviroc].
Topics: Amino Acid Sequence; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Viral; env Gene Products, Human Immunodeficiency Virus; Genes, env; HIV; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Membrane Fusion; Molecular Sequence Data; Multicenter Studies as Topic; Peptide Fragments; Receptors, CXCR4; Selection, Genetic; Treatment Failure; Triazoles; Virus Attachment; Virus Internalization | 2008 |
[At what time and with which combinations should maraviroc be indicated in the new antiretroviral treatment scenario?].
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Anti-Infective Agents; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; HIV; HIV Infections; Humans; Maraviroc; Membrane Fusion; Receptors, CXCR4; Salvage Therapy; Triazoles; Viral Load; Virus Attachment | 2008 |
[Conclusions and perspectives. Maraviroc].
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Drug Design; Drug Resistance, Viral; Drug Therapy, Combination; Gene Products, env; HIV; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Membrane Fusion; Peptide Fragments; Receptors, CXCR4; Salvage Therapy; Selection, Genetic; Triazoles; Virus Attachment; Virus Internalization | 2008 |
Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; HIV Infections; HIV-1; Humans; Maraviroc; Receptors, CCR5; Receptors, CXCR4; Triazoles; Virus Internalization | 2009 |
Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection.
Topics: Animals; CCR5 Receptor Antagonists; Cyclohexanes; Disease Management; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Receptors, CCR5; Triazoles | 2009 |
A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Resistance, Viral; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV-1; Humans; Maraviroc; Mutation, Missense; Piperazines; Pyrimidines; Triazoles | 2009 |
Immunotherapies in HIV-1 infection.
Topics: Cyclohexanes; HIV Infections; HIV-1; Humans; Immunologic Factors; Immunotherapy; Interleukin-2; Maraviroc; Treatment Outcome; Triazoles | 2009 |
[Role of the new molecules in antiretroviral therapy. Position of raltegravir].
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Enfuvirtide; Forecasting; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; Humans; Maraviroc; Nitriles; Peptide Fragments; Pyridazines; Pyridines; Pyrimidines; Pyrones; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Sulfonamides; Triazoles | 2008 |
Maraviroc: a new CCR5 antagonist.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Child; Clinical Trials as Topic; Cyclohexanes; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Pregnancy; Treatment Outcome; Triazoles | 2009 |
Entry inhibitors in the treatment of HIV-1 infection.
Topics: Cyclohexanes; Drug Resistance, Viral; Enfuvirtide; History, 20th Century; History, 21st Century; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Peptide Fragments; Triazoles | 2010 |
Maraviroc: pharmacokinetics and drug interactions.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Anti-Infective Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Reverse Transcriptase Inhibitors; Triazoles; Young Adult | 2009 |
When and how to use maraviroc in HIV-infected patients.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Drug Resistance, Viral; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Triazoles; Viral Tropism | 2009 |
[Maraviroc: update on recent clinical data].
Topics: CD4 Lymphocyte Count; Cyclohexanes; Follow-Up Studies; HIV Fusion Inhibitors; Humans; Maraviroc; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles; Viral Load | 2009 |
Novel drug classes: entry inhibitors [enfuvirtide, chemokine (C-C motif) receptor 5 antagonists].
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Enfuvirtide; HIV; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Peptide Fragments; Piperazines; Pyrimidines; Salvage Therapy; Triazoles; Virus Internalization | 2009 |
Novel CCR5 antagonists for the treatment of HIV infection: a review of compounds patented in 2006 - 2008.
Topics: AIDS Vaccines; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Delivery Systems; Drug Resistance, Viral; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Patents as Topic; Triazoles | 2010 |
Treatment of HIV infection with the CCR5 antagonist maraviroc.
Topics: CCR5 Receptor Antagonists; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclohexanes; Drug Resistance, Viral; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Triazoles; Viral Tropism | 2010 |
[CCR5-antagonists: contribution of a new antiretroviral class to the management of HIV infection].
Topics: Anti-Retroviral Agents; CCR5 Receptor Antagonists; Cyclohexanes; HIV; HIV Infections; Humans; Maraviroc; Triazoles; Viral Tropism | 2010 |
Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; Cyclohexanes; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Randomized Controlled Trials as Topic; Receptors, CCR5; Treatment Failure; Treatment Outcome; Triazoles; Viral Load; Viral Tropism; Young Adult | 2010 |
Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug.
Topics: Anti-HIV Agents; Antiemetics; Antineoplastic Agents; Aprepitant; CCR5 Receptor Antagonists; Cyclohexanes; Drug Approval; Drug Interactions; Glioblastoma; Humans; Maraviroc; Mitogen-Activated Protein Kinase 3; Morpholines; Neurokinin-1 Receptor Antagonists; Phosphorylation; Signal Transduction; Triazoles; United States; United States Food and Drug Administration | 2010 |
[Pharmacological profile and clinical findings of Maraviroc (Celsentri® Tablets)].
Topics: Animals; Anti-HIV Agents; CCR5 Receptor Antagonists; CD4 Antigens; Clinical Trials as Topic; Cyclohexanes; Drug Resistance, Viral; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Maraviroc; Protein Binding; Tablets; Triazoles | 2010 |
HIV-1 tropism.
Topics: Aminoquinolines; Anti-HIV Agents; Benzimidazoles; Benzylamines; Butylamines; CCR5 Receptor Antagonists; CD4 Antigens; Cyclams; Cyclohexanes; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; HIV-1; Humans; Maraviroc; Piperazines; Pyrimidines; Receptors, CCR5; Receptors, CXCR4; T-Lymphocytes; Triazoles; Viral Tropism | 2010 |
Maraviroc first-line therapy for HIV infection. Too risky.
Topics: Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Risk Factors; Triazoles | 2010 |
R5X4 HIV-1 coreceptor use in primary target cells: implications for coreceptor entry blocking strategies.
Topics: Algorithms; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Cyclohexanes; HIV-1; Human Immunodeficiency Virus Proteins; Humans; Macrophages; Maraviroc; Phenotype; Prognosis; Protein Binding; Receptors, CCR5; Receptors, CXCR4; Triazoles | 2011 |
Clinical use of CCR5 inhibitors in HIV and beyond.
Topics: Animals; Antiviral Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Disease Models, Animal; Encephalitis, Tick-Borne; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Protein Binding; Triazoles; West Nile Fever | 2011 |
Update on microbicide research and development - seeking new HIV prevention tools for women.
Topics: Adenine; Administration, Intravaginal; Adult; Africa South of the Sahara; Anti-HIV Agents; Anti-Infective Agents; Clinical Trials as Topic; Cyclohexanes; Drug Discovery; Female; HIV Infections; Humans; Male; Maraviroc; Organophosphonates; Pyridines; Pyrimidines; Tenofovir; Triazoles; Urea | 2011 |
HIV entry inhibitors: progress in development and application.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; CD4 Antigens; Cyclohexanes; Drug Resistance, Viral; Enfuvirtide; HIV Envelope Protein gp120; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Molecular Structure; Peptide Fragments; Receptors, CCR5; Receptors, Chemokine; Receptors, CXCR4; Triazoles | 2010 |
[The newest developments in anti-HIV-1 drugs].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Drug Resistance, Viral; Enfuvirtide; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Maraviroc; Molecular Structure; Peptide Fragments; Pyrrolidinones; Raltegravir Potassium; Saquinavir; Triazoles; Virus Replication; Zidovudine | 2010 |
Clinical utility of maraviroc.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Receptors, CCR5; Triazoles | 2011 |
CCR5 antagonism in HIV infection: current concepts and future opportunities.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Drug Discovery; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Receptors, CCR5; Triazoles | 2012 |
Drug safety evaluation of maraviroc for the treatment of HIV infection.
Topics: Animals; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclohexanes; Drug Monitoring; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Time Factors; Triazoles | 2012 |
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
Topics: Adenine; Adult; Amniotic Fluid; Anti-HIV Agents; Cyclohexanes; Enfuvirtide; Female; Fetal Blood; Fetus; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Maraviroc; Nevirapine; Organophosphonates; Peptide Fragments; Placenta; Pregnancy; Pregnancy Complications, Infectious; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir; Triazoles; Viral Load; Zidovudine | 2011 |
[Methods for determination of HIV tropism and their clinical use].
Topics: Algorithms; Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Europe; Genes, env; Genotype; HIV Envelope Protein gp120; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Maraviroc; Peptide Fragments; Phenotype; Practice Guidelines as Topic; Receptors, CCR5; Receptors, CXCR4; Retrospective Studies; Triazoles; Viral Tropism; Virology; Virus Internalization | 2011 |
CCR5 inhibitors: emergence, success, and challenges.
Topics: Animals; Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclohexanes; HIV Infections; Humans; Maraviroc; Receptors, CXCR4; Triazoles | 2012 |
Clinical studies with chemokine receptor-5 (CCR5)-inhibitors.
Topics: Antibodies, Monoclonal; Antiviral Agents; CCR5 Receptor Antagonists; Coinfection; Cyclohexanes; Hepatitis C, Chronic; HIV; HIV Antibodies; HIV Infections; Humans; Maraviroc; Molecular Diagnostic Techniques; Triazoles; Viral Tropism; Virology | 2012 |
The MOTIVATE trials: maraviroc therapy in antiretroviral treatment-experienced HIV-1-infected patients.
Topics: Anti-Retroviral Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Maraviroc; Randomized Controlled Trials as Topic; Triazoles; Viral Tropism | 2012 |
HIV-1 entry inhibitors: recent development and clinical use.
Topics: Antibodies, Monoclonal; Chemoprevention; Clinical Trials as Topic; Cyclohexanes; Disease Transmission, Infectious; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Organophosphates; Piperazines; Triazoles; Virus Internalization | 2013 |
Hepatoxicity of new antiretrovirals: a systematic review.
Topics: Anti-Retroviral Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Cyclohexanes; Darunavir; Heterocyclic Compounds, 3-Ring; Humans; Maraviroc; Nitriles; Oxazines; Piperazines; Pyridazines; Pyridones; Pyrimidines; Pyrrolidinones; Quinolones; Raltegravir Potassium; Rilpivirine; Sulfonamides; Triazoles | 2013 |
Modeling the allosteric modulation of CCR5 function by Maraviroc.
Topics: Allosteric Regulation; Animals; Cyclohexanes; HIV Fusion Inhibitors; Humans; Maraviroc; Models, Molecular; Protein Conformation; Receptors, CCR5; Triazoles | 2013 |
Determination of HIV tropism and its use in the clinical practice.
Topics: Biological Assay; Cyclohexanes; Genotype; HIV Fusion Inhibitors; HIV Infections; HIV-1; Host-Pathogen Interactions; Humans; Maraviroc; Molecular Typing; Phenotype; Receptors, CCR5; Receptors, CXCR4; Sensitivity and Specificity; Triazoles; Viral Tropism | 2013 |
[Use of maraviroc, the first CCR5 receptor antagonist, in HIV treatment regimens].
Topics: CCR5 Receptor Antagonists; Cyclohexanes; HIV; HIV Infections; Humans; Maraviroc; Treatment Outcome; Triazoles | 2013 |
An overview of antiretroviral pre-exposure prophylaxis of HIV infection.
Topics: Adenine; Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; Female; HIV Infections; Humans; Male; Maraviroc; Medication Adherence; Nitriles; Organophosphonates; Pre-Exposure Prophylaxis; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Triazoles | 2014 |
Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
Topics: CCR5 Receptor Antagonists; CD4 Antigens; Cyclohexanes; Disease Progression; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Receptors, CCR5; Receptors, CXCR4; Triazoles; Viral Tropism; Virus Internalization | 2015 |
Targeting CCR5 for anti-HIV research.
Topics: Anti-HIV Agents; Biological Therapy; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Drug Discovery; HIV Infections; Humans; Maraviroc; Receptors, CCR5; Triazoles | 2014 |
Pharmacological intervention at CCR1 and CCR5 as an approach for cancer: help or hindrance.
Topics: Animals; Antineoplastic Agents; Cyclohexanes; HIV Infections; Humans; Maraviroc; Molecular Structure; Neoplasms; Receptors, CCR1; Receptors, CCR5; Triazoles | 2014 |
Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applications.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Drug Discovery; HIV; HIV Infections; Humans; Maraviroc; Receptors, CCR5; Structure-Activity Relationship; Triazoles; Virus Replication | 2014 |
HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth.
Topics: Animals; Anti-HIV Agents; Cyclohexanes; Drug Design; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Maraviroc; Molecular Targeted Therapy; Receptors, CCR5; Triazoles | 2015 |
Immune reconstitution inflammatory syndrome in a patient with progressive multifocal leukoencephalopathy.
Topics: CCR5 Receptor Antagonists; CD8-Positive T-Lymphocytes; Cyclohexanes; Disease Progression; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; JC Virus; Leukoencephalopathy, Progressive Multifocal; Male; Maraviroc; Middle Aged; Treatment Outcome; Triazoles | 2015 |
Maraviroc: a review of its use in HIV infection and beyond.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Interactions; Drug Resistance, Viral; Genotype; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Mutation; Phenotype; Polypharmacy; Treatment Outcome; Triazoles | 2015 |
Off-label use of maraviroc in clinical practice.
Topics: Animals; Arthritis, Rheumatoid; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Graft vs Host Disease; Hematologic Neoplasms; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Mice; Off-Label Use; Sarcoidosis; Triazoles | 2016 |
[Companion Diagnostics for Selecting Antiretroviral Drugs against HIV-1].
Topics: Alleles; Anti-Retroviral Agents; CCR5 Receptor Antagonists; Cyclohexanes; Dideoxynucleosides; HIV Infections; HIV-1; HLA-B Antigens; Humans; Maraviroc; Pharmacogenetics; Precision Medicine; Reverse Transcriptase Inhibitors; Triazoles; Viral Tropism | 2015 |
Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis.
Topics: Anti-HIV Agents; Cyclohexanes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Male; Maraviroc; Middle Aged; Odds Ratio; Reverse Transcriptase Inhibitors; Risk; Triazoles; Viral Load | 2016 |
CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV.
Topics: Animals; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Design; HIV Infections; Humans; Imidazoles; Maraviroc; Sulfoxides; Triazoles | 2016 |
98 trial(s) available for triazoles and maraviroc
| Article | Year |
|---|---|
Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV.
Topics: Adolescent; Adult; Animals; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bile; Blood Proteins; Caco-2 Cells; CCR5 Receptor Antagonists; Cross-Over Studies; Cyclohexanes; Dogs; Double-Blind Method; Feces; Female; Humans; Intestinal Mucosa; Male; Maraviroc; Mice; Mice, Knockout; Middle Aged; Permeability; Protein Binding; Rats; Rats, Sprague-Dawley; Species Specificity; Triazoles | 2005 |
A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc.
Topics: Adult; Algorithms; Anti-HIV Agents; CCR5 Receptor Antagonists; Computer Simulation; Cyclohexanes; Dose-Response Relationship, Drug; HIV Infections; HIV-1; Humans; Male; Maraviroc; Models, Biological; Models, Statistical; Predictive Value of Tests; RNA, Viral; Triazoles; Viral Load; Virus Replication | 2005 |
A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc.
Topics: Anti-HIV Agents; Computer Simulation; Cyclohexanes; Dose-Response Relationship, Drug; Food; HIV Infections; HIV-1; Humans; Maraviroc; Monte Carlo Method; Placebos; RNA, Viral; Triazoles; Viral Load | 2006 |
Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Cell Line; Clone Cells; Cyclohexanes; Evolution, Molecular; Genes, env; Genetic Variation; HIV Envelope Protein gp160; HIV Infections; HIV-1; Humans; Maraviroc; Phylogeny; Receptors, CCR5; Receptors, CXCR4; Recombination, Genetic; Triazoles | 2006 |
Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Statistics as Topic; Triazoles | 2008 |
Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anti-HIV Agents; CCR5 Receptor Antagonists; Contraceptives, Oral; Cyclohexanes; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Ethinyl Estradiol; Female; HIV Infections; Humans; Lamivudine; Levonorgestrel; Male; Maraviroc; Midazolam; Middle Aged; Statistics as Topic; Triazoles; Zidovudine | 2008 |
Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
Topics: Adolescent; Anti-HIV Agents; Antifungal Agents; Atazanavir Sulfate; CCR5 Receptor Antagonists; Cyclohexanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Maraviroc; Middle Aged; Oligopeptides; Pyridines; Saquinavir; Statistics as Topic; Triazoles | 2008 |
Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
Topics: Adolescent; Adult; CCR5 Receptor Antagonists; Cyclohexanes; Cytochrome P-450 CYP3A; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Maraviroc; Middle Aged; Statistics as Topic; Triazoles | 2008 |
The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Organophosphonates; Receptors, CCR5; Statistics as Topic; Tenofovir; Triazoles; Trimethoprim, Sulfamethoxazole Drug Combination | 2008 |
A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects.
Topics: Administration, Oral; Adolescent; Adult; Anti-Retroviral Agents; Area Under Curve; CCR5 Receptor Antagonists; Cyclohexanes; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Receptors, CCR5; Triazoles | 2008 |
Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects.
Topics: Administration, Oral; Adolescent; Adult; Aged; Biological Availability; CCR5 Receptor Antagonists; Cyclohexanes; Double-Blind Method; Humans; Male; Maraviroc; Middle Aged; Triazoles | 2008 |
Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects.
Topics: Adolescent; Adult; Anti-Infective Agents; Aza Compounds; CCR5 Receptor Antagonists; Cyclohexanes; Electrocardiography; Epidemiologic Methods; Female; Fluoroquinolones; Heart Rate; Humans; Male; Maraviroc; Middle Aged; Models, Biological; Moxifloxacin; Quinolines; Triazoles | 2008 |
Maraviroc: integration of a new antiretroviral drug class into clinical practice.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Double-Blind Method; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Triazoles; Virology | 2008 |
Maraviroc for previously treated patients with R5 HIV-1 infection.
Topics: Adult; Aged; Anti-Retroviral Agents; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; RNA, Viral; Treatment Failure; Triazoles; Viral Load | 2008 |
Maraviroc approved for use in treatment-experienced CCR5-tropic HIV-1.
Topics: CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Double-Blind Method; Drug Approval; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Placebos; Triazoles; United States; United States Food and Drug Administration; Viral Load | 2009 |
A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.
Topics: Adult; Aged; Cyclohexanes; Double-Blind Method; Female; Genotype; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Least-Squares Analysis; Male; Maraviroc; Middle Aged; Patient Selection; Phenotype; Placebos; Triazoles; Viral Load; Young Adult | 2009 |
96-Week MERIT ES analysis shows efficacy of Celsentri=Selzentry.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Cyclopropanes; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Lamivudine; Maraviroc; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome; Triazoles; Zidovudine | 2009 |
Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment.
Topics: Adult; Aged; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Administration Schedule; Female; Humans; Liver Diseases; Male; Maraviroc; Middle Aged; Triazoles | 2009 |
Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc.
Topics: Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Cross-Over Studies; Cyclohexanes; Drug Interactions; Drug Therapy, Combination; Half-Life; Humans; Maraviroc; Quinolones; Ritonavir; Triazoles; Young Adult | 2010 |
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Antiviral Agents; Benzoxazines; CCR5 Receptor Antagonists; Cyclohexanes; Cyclopropanes; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Maraviroc; Middle Aged; Receptors, CCR5; Treatment Outcome; Triazoles; Viral Load; Viral Tropism; Young Adult; Zidovudine | 2010 |
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Cyclohexanes; Drug Administration Schedule; Drug Interactions; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Salvage Therapy; Triazoles; Young Adult | 2010 |
Hemodynamic effects of single-dose vardenafil in subjects receiving maraviroc.
Topics: Adolescent; Adult; Blood Pressure; Cross-Over Studies; Cyclohexanes; Erectile Dysfunction; HIV Fusion Inhibitors; HIV Infections; Humans; Imidazoles; Male; Maraviroc; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Single-Blind Method; Sulfones; Triazines; Triazoles; Vardenafil Dihydrochloride; Vasodilator Agents; Young Adult | 2010 |
Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice.
Topics: Antiviral Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Gene Expression Regulation, Viral; Genotype; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Prospective Studies; Salvage Therapy; Treatment Outcome; Triazoles; Viral Tropism; Virus Internalization; Virus Replication | 2010 |
Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclohexanes; Double-Blind Method; Female; Follow-Up Studies; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Triazoles | 2010 |
Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.
Topics: Adult; Albumins; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Central Nervous System Infections; Cross-Over Studies; Cyclohexanes; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Immunoglobulin G; Lopinavir; Male; Maraviroc; Middle Aged; Neopterin; Peptide Fragments; Polymerase Chain Reaction; Ritonavir; RNA, Viral; Triazoles; Viral Load; Viremia; Virus Replication | 2010 |
Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients.
Topics: Alkynes; Benzoxazines; Case-Control Studies; CD4 Lymphocyte Count; Cyclohexanes; Cyclopropanes; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Receptors, CCR5; Reverse Transcriptase Inhibitors; Triazoles; Viral Load | 2010 |
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism.
Topics: Adult; Animals; Biological Transport; Chromatography, Liquid; Cyclohexanes; Dose-Response Relationship, Drug; Female; Genetic Association Studies; Genotype; Humans; Liver-Specific Organic Anion Transporter 1; Male; Maraviroc; Mass Spectrometry; Middle Aged; Oocytes; Organic Anion Transporters; Polymorphism, Single Nucleotide; Reproducibility of Results; Substrate Specificity; Triazoles; Xenopus laevis | 2010 |
Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Salvage Therapy; Treatment Outcome; Triazoles; Viral Load | 2011 |
Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials.
Topics: Adolescent; Adult; Cyclohexanes; Darunavir; Drug Interactions; Female; Humans; Male; Maraviroc; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides; Triazoles; Young Adult | 2011 |
Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclohexanes; Cyclopropanes; Female; High-Throughput Nucleotide Sequencing; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Retrospective Studies; Treatment Failure; Treatment Outcome; Triazoles; Viral Tropism; Young Adult | 2011 |
CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study.
Topics: Adult; Anti-HIV Agents; Brain; Brain Chemistry; CCR5 Receptor Antagonists; Cerebrospinal Fluid; Cyclohexanes; Female; HIV Infections; Humans; Magnetic Resonance Spectroscopy; Male; Maraviroc; Middle Aged; Plasma; Triazoles | 2012 |
[Our experience with maraviroc treatment in HIV positive patients].
Topics: CD4 Lymphocyte Count; Cyclohexanes; Female; HIV Fusion Inhibitors; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Triazoles; Viral Load | 2011 |
Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects.
Topics: Adolescent; Adult; Anti-HIV Agents; Cross-Over Studies; Cyclohexanes; Drug Interactions; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Integrase Inhibitors; Humans; Male; Maraviroc; Middle Aged; Nitriles; Pyrazoles; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Treatment Outcome; Triazoles; Young Adult | 2012 |
Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bacteria; CCR5 Receptor Antagonists; CD8-Positive T-Lymphocytes; Chronic Disease; Cyclohexanes; Disease Reservoirs; DNA, Circular; Female; HIV Infections; HIV-1; Humans; Immunologic Memory; Lymphocyte Activation; Male; Maraviroc; Middle Aged; Plasmids; Receptors, CCR5; T-Lymphocyte Subsets; T-Lymphocytes; Triazoles; Viremia | 2011 |
T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity.
Topics: Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclohexanes; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; T-Lymphocyte Subsets; T-Lymphocytes; Treatment Outcome; Triazoles; Viral Load | 2012 |
Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Area Under Curve; Arthritis, Rheumatoid; CCR5 Receptor Antagonists; Constipation; Cyclohexanes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Maraviroc; Metabolic Clearance Rate; Methotrexate; Middle Aged; Nausea; Treatment Failure; Triazoles; Young Adult | 2012 |
HIV-1 tropism evolution after short-term maraviroc monotherapy in HIV-1-infected patients.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; CD4-Positive T-Lymphocytes; Cyclohexanes; HIV Infections; Humans; Maraviroc; Receptors, CXCR4; Triazoles; Viral Load | 2012 |
From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework.
Topics: Adenine; Anti-HIV Agents; Cyclohexanes; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Male; Maraviroc; Models, Biological; Nitriles; Organophosphonates; Oxazines; Piperazines; Pyridazines; Pyridones; Pyrimidines; RNA, Viral; Tenofovir; Triazoles | 2012 |
A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Triazoles; Viral Load; Young Adult | 2012 |
Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.
Topics: Adult; Aged; CCR5 Receptor Antagonists; Chemokine CCL3; Chemokine CCL5; Chemotaxis, Leukocyte; Cyclohexanes; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Maraviroc; Middle Aged; T-Lymphocytes; Transplantation, Homologous; Triazoles; Young Adult | 2012 |
CCR5 antagonism impacts vaccination response and immune profile in HIV-1 infection.
Topics: AIDS Vaccines; CCR5 Receptor Antagonists; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Immunity; Immunity, Cellular; Immunity, Humoral; Immunophenotyping; Male; Maraviroc; Middle Aged; Receptors, CCR5; T-Lymphocytes; Treatment Outcome; Triazoles; Vaccination | 2012 |
Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study.
Topics: Aged; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Cyclohexanes; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Prospective Studies; Triazoles; Viral Load | 2012 |
A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patients.
Topics: Adult; Aged; Algorithms; Anti-HIV Agents; Biological Assay; Biomarkers, Pharmacological; CCR5 Receptor Antagonists; Cyclohexanes; Female; Genotyping Techniques; High-Throughput Nucleotide Sequencing; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Predictive Value of Tests; Receptors, CCR5; Receptors, CXCR4; Retrospective Studies; Triazoles; Viral Tropism | 2012 |
Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Cyclohexanes; Drug Combinations; Drug Therapy, Combination; Female; Genotype; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Lamivudine; Male; Maraviroc; Middle Aged; Polymerase Chain Reaction; Retrospective Studies; Sequence Analysis, DNA; Triazoles; Viral Load; Viral Tropism; Young Adult; Zidovudine | 2012 |
Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; RNA, Viral; Tenofovir; Triazoles; Viral Load; Young Adult | 2013 |
Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; Dyslipidemias; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Hypolipidemic Agents; Intention to Treat Analysis; Male; Maraviroc; Middle Aged; Pilot Projects; Prospective Studies; Triazoles; Triglycerides; Viral Tropism | 2013 |
The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial.
Topics: Adult; CCR5 Receptor Antagonists; CD4-Positive T-Lymphocytes; Cyclohexanes; Female; Gastrointestinal Tract; Graft vs Host Disease; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Immunophenotyping; Lymphocyte Activation; Lymphoid Tissue; Male; Maraviroc; Middle Aged; Rectum; RNA, Viral; Triazoles; Viral Load | 2013 |
Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study.
Topics: Adult; Anti-HIV Agents; Brazil; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Darunavir; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Maraviroc; Middle Aged; Protease Inhibitors; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Sulfonamides; Treatment Failure; Triazoles; Viral Load; Young Adult | 2013 |
Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.
Topics: Adolescent; Adult; Aged; CCR5 Receptor Antagonists; Cyclohexanes; Female; Gene Expression; Genotype; High-Throughput Nucleotide Sequencing; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Peptide Fragments; Receptors, CCR5; Receptors, CXCR4; Treatment Failure; Triazoles; Viral Tropism | 2013 |
Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Carbamates; Cyclohexanes; Drug Administration Schedule; Drug Combinations; Drug Dosage Calculations; Drug Interactions; Furans; Humans; Male; Maraviroc; Middle Aged; Organophosphates; Ritonavir; Sulfonamides; Triazoles | 2013 |
Gut Lactobacillales are associated with higher CD4 and less microbial translocation during HIV infection.
Topics: Adult; Anti-Retroviral Agents; Bacteria; Bacterial Translocation; Biota; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclohexanes; Double-Blind Method; Drug Therapy, Combination; Gastrointestinal Tract; HIV Infections; Humans; Lactobacillales; Male; Maraviroc; Middle Aged; Placebos; Rectum; Triazoles; Young Adult | 2013 |
Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; DNA, Viral; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Treatment Outcome; Triazoles; Viral Load | 2014 |
Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Immunocompromised Host; Interleukin-7; Ki-67 Antigen; Male; Maraviroc; Middle Aged; RNA, Viral; Treatment Outcome; Triazoles; Viral Load | 2013 |
The effects of boceprevir and telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers.
Topics: Adolescent; Adult; Antiviral Agents; Cyclohexanes; Healthy Volunteers; Humans; Male; Maraviroc; Middle Aged; Oligopeptides; Proline; Triazoles; Young Adult | 2014 |
Dynamics of the HIV-1 latent reservoir after discontinuation of the intensification of antiretroviral treatment: results of two clinical trials.
Topics: Adult; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Pilot Projects; Pyrrolidinones; Raltegravir Potassium; Triazoles; Virus Latency | 2013 |
Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients.
Topics: Adult; CCR5 Receptor Antagonists; Cyclohexanes; Double-Blind Method; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Survival Analysis; Time Factors; Triazoles | 2014 |
A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; DNA, Viral; Drug Combinations; Endpoint Determination; HIV Infections; Humans; Longitudinal Studies; Male; Maraviroc; Middle Aged; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Triazoles; Viral Load; Viremia | 2014 |
Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals.
Topics: Anti-Retroviral Agents; Cyclohexanes; Cytokines; Enzyme-Linked Immunospot Assay; Flow Cytometry; HIV Infections; HIV-1; Humans; Immunity, Cellular; Maraviroc; Receptors, CCR5; Statistics, Nonparametric; T-Lymphocytes; Triazoles; Virus Internalization | 2014 |
Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Lipodystrophy; Male; Maraviroc; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Risk Factors; Treatment Failure; Triazoles; Viral Load | 2014 |
Virological response to short-course maraviroc monotherapy does not predict viral tropism in HIV-1-infected treatment-naive patients.
Topics: Adult; Anti-HIV Agents; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Pilot Projects; Treatment Outcome; Triazoles; Viral Load; Viral Tropism; Young Adult | 2014 |
Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Cell Count; Cyclohexanes; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Maraviroc; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Treatment Outcome; Triazoles | 2014 |
Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclohexanes; Cyclopropanes; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Treatment Outcome; Triazoles; Viral Load; Young Adult | 2014 |
Maintenance of virologic efficacy and decrease in levels of β2-microglobulin, soluble CD40L and soluble CD14 after switching previously treated HIV-infected patients to an NRTI-sparing dual therapy.
Topics: Adult; beta 2-Microglobulin; CD4-Positive T-Lymphocytes; CD40 Ligand; Cyclohexanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipopolysaccharide Receptors; Male; Maraviroc; Middle Aged; Reverse Transcriptase Inhibitors; Triazoles | 2014 |
Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; HIV Infections; HIV-1; Humans; Maraviroc; Mutation; Triazoles; Viral Tropism | 2015 |
Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; DNA, Viral; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Maraviroc; Prospective Studies; Ritonavir; Treatment Outcome; Triazoles; Viral Load | 2015 |
Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients.
Topics: Adult; Aged; Cyclohexanes; Drug Interactions; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Male; Maraviroc; Middle Aged; Prospective Studies; Tacrolimus; Transplantation, Homologous; Triazoles; Young Adult | 2015 |
Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study.
Topics: Anti-HIV Agents; Chromatography, Liquid; Cyclohexanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Plasma; Raltegravir Potassium; Tandem Mass Spectrometry; Triazoles | 2015 |
Dynamics of adaptive and innate immunity in patients treated during primary human immunodeficiency virus infection: results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial.
Topics: Adaptive Immunity; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Dendritic Cells; Female; HIV; HIV Infections; Humans; Immunity, Innate; Lymphocyte Subsets; Male; Maraviroc; Prospective Studies; Triazoles | 2015 |
Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial.
Topics: Administration, Intravaginal; Adolescent; Adult; Anti-Infective Agents; Area Under Curve; Cyclohexanes; Double-Blind Method; Drug Combinations; Female; Half-Life; Humans; Maraviroc; Pyrimidines; Triazoles; Young Adult | 2015 |
Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.
Topics: Adult; Anti-HIV Agents; Bone Density; Cyclohexanes; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Pelvic Bones; Tenofovir; Triazoles | 2015 |
Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women.
Topics: Adult; Anti-HIV Agents; Blood Chemical Analysis; Cyclohexanes; Europe; Female; HIV Infections; Humans; Maraviroc; Pregnancy; Pregnancy Complications, Infectious; Triazoles; United States; Young Adult | 2015 |
Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclohexanes; Double-Blind Method; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Lymphocyte Count; Male; Maraviroc; Middle Aged; Receptors, CCR5; Time Factors; Treatment Outcome; Triazoles | 2015 |
Missing CD4+ cell response in randomized clinical trials of maraviroc and dolutegravir.
Topics: Adult; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclohexanes; Data Interpretation, Statistical; Datasets as Topic; Double-Blind Method; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Male; Maraviroc; Models, Statistical; Oxazines; Piperazines; Pyridones; Triazoles; United States | 2015 |
Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial).
Topics: Anti-HIV Agents; Cyclohexanes; HIV Infections; HIV-1; Maraviroc; Raltegravir Potassium; Risk Factors; Treatment Failure; Triazoles; Viral Load | 2015 |
Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Prospective Studies; Treatment Outcome; Triazoles; Viral Load | 2015 |
Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; Chromatography, High Pressure Liquid; Cyclohexanes; Cyclopropanes; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; HIV Infections; HIV Integrase Inhibitors; Humans; Immunity, Mucosal; Lymphocyte Activation; Male; Maraviroc; Pilot Projects; Raltegravir Potassium; T-Lymphocyte Subsets; Triazoles | 2016 |
Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder.
Topics: Aged; AIDS Dementia Complex; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Cognition; Cyclohexanes; Double-Blind Method; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Pilot Projects; Prospective Studies; Treatment Outcome; Triazoles | 2016 |
Adherence and Acceptability of a Multidrug Vaginal Ring for HIV Prevention in a Phase I Study in the United States.
Topics: Adult; Anti-HIV Agents; Contraceptive Devices, Female; Cyclohexanes; Double-Blind Method; Drug Therapy, Combination; Feasibility Studies; Female; HIV Infections; Humans; Interview, Psychological; Maraviroc; Medication Adherence; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; Program Evaluation; Pyrimidines; South Africa; Text Messaging; Triazoles | 2016 |
Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 R
Topics: Adult; Comorbidity; Cyclohexanes; Female; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Male; Maraviroc; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Triazoles; Viral Load; Virus Replication | 2016 |
The effect of maraviroc on the pharmacokinetics of digoxin in healthy volunteers.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; Biological Availability; CCR5 Receptor Antagonists; Cross-Over Studies; Cyclohexanes; Digoxin; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Healthy Volunteers; Humans; Male; Maraviroc; Middle Aged; Triazoles; Young Adult | 2014 |
Differential CD4+ cell count increase and CD4+ : CD8+ ratio normalization with maraviroc compared with tenofovir.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Cyclohexanes; Darunavir; Double-Blind Method; Emtricitabine; Female; Flow Cytometry; HIV Infections; Humans; Male; Maraviroc; Placebos; Prospective Studies; Tenofovir; Treatment Outcome; Triazoles | 2016 |
Neurocognition with maraviroc compared with tenofovir in HIV.
Topics: Adult; AIDS-Related Complex; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cognition; Cyclohexanes; Double-Blind Method; Female; HIV Infections; Humans; Male; Maraviroc; Neuropsychological Tests; Placebos; Tenofovir; Treatment Outcome; Triazoles; United States | 2016 |
Pharmacodynamic correlations using fresh and cryopreserved tissue following use of vaginal rings containing dapivirine and/or maraviroc in a randomized, placebo controlled trial.
Topics: Administration, Intravaginal; Adult; Biopsy; Cervix Uteri; Contraceptive Devices, Female; Cryopreservation; Cyclohexanes; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; In Vitro Techniques; Maraviroc; Pyrimidines; Sexually Transmitted Diseases, Viral; Triazoles; United States | 2016 |
Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Maintenance Chemotherapy; Male; Maraviroc; Middle Aged; Raltegravir Potassium; Tenofovir; Treatment Outcome; Triazoles; Viral Load; Young Adult | 2016 |
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study.
Topics: Adult; Anti-HIV Agents; Cyclohexanes; Drug Administration Schedule; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Treatment Failure; Triazoles; Viral Tropism | 2016 |
Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis.
Topics: Administration, Oral; Adult; CCR5 Receptor Antagonists; Cyclohexanes; Female; Healthy Volunteers; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Intestinal Mucosa; Male; Maraviroc; Models, Biological; Pre-Exposure Prophylaxis; Randomized Controlled Trials as Topic; Rectum; Saliva; Treatment Outcome; Triazoles; Urethra; Vagina | 2016 |
Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305).
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Disease Transmission, Infectious; Double-Blind Method; HIV Infections; Homosexuality, Male; Humans; Male; Maraviroc; Middle Aged; Pre-Exposure Prophylaxis; Prospective Studies; Triazoles; Young Adult | 2017 |
A randomized controlled clinical trial on the impact of CCR5 blockade with maraviroc in early infection on T-cell dynamics.
Topics: Adult; CCR5 Receptor Antagonists; Cyclohexanes; Double-Blind Method; Female; HIV Infections; Humans; Male; Maraviroc; T-Lymphocytes; Time Factors; Triazoles | 2016 |
Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Female; Follow-Up Studies; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Nerve Tissue Proteins; RNA, Viral; Treatment Outcome; Triazoles; Viral Load | 2016 |
Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Coinfection; Cyclohexanes; Female; Hepatitis B; Hepatitis C; HIV Fusion Inhibitors; HIV Infections; Humans; Liver; Liver Function Tests; Male; Maraviroc; Middle Aged; Treatment Outcome; Triazoles; Viral Load | 2017 |
Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study.
Topics: Adult; CCR5 Receptor Antagonists; Cyclohexanes; DNA, Viral; Female; Genotype; Genotyping Techniques; HIV-1; Humans; Maintenance Chemotherapy; Male; Maraviroc; Middle Aged; Prospective Studies; Proviruses; Spain; Treatment Outcome; Triazoles; Viral Tropism | 2017 |
Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial).
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cyclohexanes; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Maraviroc; Medication Adherence; Post-Exposure Prophylaxis; Ritonavir; Triazoles; Young Adult | 2017 |
Impact of intensified antiretroviral therapy during early HIV infection on gut immunology and inflammatory blood biomarkers.
Topics: Adult; Anti-HIV Agents; Biomarkers; Canada; Cyclohexanes; Double-Blind Method; Drug Therapy, Combination; Fibrin Fibrinogen Degradation Products; Flow Cytometry; HIV Infections; Humans; Immunity, Mucosal; Inflammation; Intestinal Mucosa; Lymphocyte Activation; Male; Maraviroc; Middle Aged; Prospective Studies; Raltegravir Potassium; Th17 Cells; Treatment Outcome; Triazoles; Young Adult | 2017 |
Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study.
Topics: Adult; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; Cyclohexanes; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Maraviroc; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Triazoles; Viral Load | 2018 |
Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial.
Topics: Adolescent; Adult; Cyclohexanes; Double-Blind Method; Female; Follow-Up Studies; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Middle Aged; Patient Dropouts; Pre-Exposure Prophylaxis; Prospective Studies; Treatment Outcome; Triazoles; Young Adult | 2017 |
Tissue Pharmacologic and Virologic Determinants of Duodenal and Rectal Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution in HIV-Infected Patients Initiating Antiretroviral Therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclohexanes; Cyclopropanes; DNA, Viral; Duodenum; Female; HIV Infections; Humans; Lymphoid Tissue; Male; Maraviroc; Raltegravir Potassium; Rectum; RNA, Viral; Triazoles | 2017 |
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Ritonavir; Treatment Outcome; Triazoles; Viral Load | 2017 |
Impact of antiretroviral therapy intensification with C-C motif chemokine receptor 5 antagonist maraviroc on HIV-associated neurocognitive impairment.
Topics: Antiretroviral Therapy, Highly Active; Cyclohexanes; HIV Infections; Humans; Maraviroc; Triazoles | 2023 |
388 other study(ies) available for triazoles and maraviroc
| Article | Year |
|---|---|
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.
Topics: Anti-HIV Agents; Area Under Curve; CCR5 Receptor Antagonists; Clinical Trials, Phase II as Topic; Cyclohexanes; Dose-Response Relationship, Drug; HIV Infections; HIV-1; Humans; Maraviroc; Randomized Controlled Trials as Topic; RNA, Viral; Time Factors; Treatment Outcome; Triazoles; Viral Load | 2005 |
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
Topics: Acquired Immunodeficiency Syndrome; Animals; Anti-HIV Agents; Biological Availability; CCR5 Receptor Antagonists; Cyclohexanes; Dogs; Drug Resistance, Viral; Drug Therapy, Combination; HeLa Cells; HIV-1; Humans; Male; Maraviroc; Membrane Fusion; Rats; Rats, Sprague-Dawley; Receptors, CCR5; Triazoles | 2005 |
Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human.
Topics: Amino Acid Sequence; Animals; Base Sequence; Binding, Competitive; Cell Line; Chemokine CCL4; Cloning, Molecular; Cyclohexanes; DNA Primers; Humans; Iodine Radioisotopes; Kinetics; Macaca mulatta; Macrophage Inflammatory Proteins; Maraviroc; Molecular Sequence Data; Radioligand Assay; Receptors, CCR5; Recombinant Proteins; Sequence Homology, Amino Acid; Triazoles; Tritium | 2005 |
Organic chemistry at the interface to biology.
Topics: Awards and Prizes; Biology; CCR5 Receptor Antagonists; Chemistry, Organic; Cyclohexanes; DNA; Drug Design; Drug Evaluation, Preclinical; HIV Infections; Humans; Maraviroc; Photochemistry; Signal Transduction; Solar Energy; Triazoles | 2006 |
Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Binding, Competitive; CCR5 Receptor Antagonists; Cell Line; Cyclohexanes; Drug Synergism; HeLa Cells; HIV Antibodies; HIV Envelope Protein gp120; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV-1; Humans; Maraviroc; Membrane Fusion; Piperazines; Pyrimidines; Receptors, CCR5; Reverse Transcriptase Inhibitors; Triazoles | 2006 |
The latest in antiretroviral therapy.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Antibodies, Monoclonal; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Cyclohexanes; Darunavir; Drugs, Investigational; HIV Infections; HIV-1; Humans; Maraviroc; Nitriles; Organic Chemicals; Piperazines; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Receptors, Chemokine; Sulfonamides; Treatment Outcome; Triazoles | 2006 |
Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
Topics: Amino Acid Sequence; Amino Acid Substitution; CCR5 Receptor Antagonists; Cell Line; Cyclohexanes; Drug Resistance, Viral; Genes, env; Genetic Variation; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; In Vitro Techniques; Lymphocytes; Maraviroc; Molecular Sequence Data; Mutagenesis, Site-Directed; Peptide Fragments; Phenotype; Receptors, CXCR4; Triazoles; Virus Cultivation; Virus Replication | 2007 |
Retrovirus meeting. Hope on new AIDS drugs, but breast-feeding strategy backfires.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Botswana; Bottle Feeding; Breast Feeding; Cyclohexanes; Developing Countries; Female; Food Contamination; HIV Fusion Inhibitors; HIV Integrase Inhibitors; Humans; Infant; Infant Formula; Infectious Disease Transmission, Vertical; Maraviroc; Triazoles | 2007 |
Researchers buoyed by novel HIV drugs: will expand drug arsenal against resistant virus.
Topics: Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; Drugs, Investigational; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; Humans; Maraviroc; Organic Chemicals; Pyrrolidinones; Raltegravir Potassium; Triazoles | 2007 |
Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands.
Topics: Animals; Antibodies, Monoclonal; CCR5 Receptor Antagonists; CD4 Antigens; Chemokines, CC; Cyclohexanes; Gene Dosage; HeLa Cells; HIV-1; Humans; In Vitro Techniques; Ligands; Lymphocytes; Macaca mulatta; Maraviroc; Piperazines; Pyrazoles; Pyrimidines; Receptors, CCR5; Simian Immunodeficiency Virus; Triazoles; Valine | 2007 |
Anti-HIV agents. New drugs, new hope, old lessons.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Cyclopropanes; HIV Infections; HIV Integrase Inhibitors; Humans; Lipodystrophy; Maraviroc; Organic Chemicals; Pyrrolidinones; Raltegravir Potassium; Triazoles; Viral Load | 2007 |
New HIV drug classes on the horizon.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Cyclohexanes; Drug Resistance, Viral; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Receptors, CCR5; Receptors, CXCR4; Triazoles | 2007 |
New drugs offer options.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Anti-HIV Agents; Clinical Trials as Topic; Cyclohexanes; Humans; Maraviroc; Organic Chemicals; Pyrrolidinones; Raltegravir Potassium; Triazoles | 2007 |
Identifying safety concerns from genetic data: lessons from the development of CCR5 inhibitors.
Topics: Arthritis, Rheumatoid; CCR5 Receptor Antagonists; Cyclohexanes; Drug Design; Genotype; Hepatitis C; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Meta-Analysis as Topic; Multiple Sclerosis; Mutation; Pharmacogenetics; Receptors, CCR5; Research Design; Risk Assessment; Risk Factors; Triazoles | 2007 |
Pivotal moments in HIV treatment: the 14th CROI.
Topics: Anti-Retroviral Agents; Clinical Trials as Topic; Congresses as Topic; Cyclohexanes; HIV Fusion Inhibitors; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Maraviroc; Multicenter Studies as Topic; Organic Chemicals; Pyrimidinones; Pyrrolidinones; Raltegravir Potassium; Treatment Outcome; Triazoles; United States | 2007 |
Advances in HIV therapeutics: the 14th CROI.
Topics: Acyclovir; Anti-HIV Agents; Circumcision, Male; Cyclohexanes; Dideoxynucleosides; Drug Interactions; Female; Hepatitis C; HIV Fusion Inhibitors; HIV Infections; Humans; Male; Maraviroc; Multicenter Studies as Topic; Nitriles; Organic Chemicals; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Triazoles | 2007 |
More data on maraviroc in treatment-experienced patients.
Topics: Cyclohexanes; Drugs, Investigational; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Treatment Outcome; Triazoles | 2007 |
FDA panel backs HIV drug.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Drug Approval; HIV Infections; Humans; Maraviroc; Triazoles; United States; United States Food and Drug Administration | 2007 |
Translational research: application to HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Animals; Anti-Retroviral Agents; CCR5 Receptor Antagonists; Child; Cyclohexanes; Drug Resistance, Viral; HIV-1; Humans; Maraviroc; Receptors, CCR5; Research; Triazoles | 2007 |
Report from the XVI International HIV Drug Resistance Workshop.
Topics: Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; Humans; Lopinavir; Maraviroc; Nitriles; Piperazines; Pyridazines; Pyrimidines; Pyrimidinones; Triazoles | 2007 |
First medication in new class of ARTs poised to be available for salvage therapy. Tropism testing helps determine best patients for drug.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; HIV Infections; Humans; Maraviroc; Salvage Therapy; Triazoles; Tropism; Viral Load | 2007 |
Novel HIV treatment approved.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Drug Approval; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Triazoles | 2007 |
FDA approves drug for resistant HIV.
Topics: Cyclohexanes; Drug Approval; HIV Fusion Inhibitors; Humans; Maraviroc; Triazoles; United States; United States Food and Drug Administration | 2007 |
FDA approves maraviroc tablets.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Drug Approval; HIV Infections; Humans; Maraviroc; Tablets; Triazoles; United States; United States Food and Drug Administration | 2007 |
Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor.
Topics: Amides; Amino Acid Sequence; Amino Acid Substitution; Animals; Binding, Competitive; Calcium; CCR5 Receptor Antagonists; Cell Line; Cell Membrane; Chemokine CCL3; Chemokine CCL4; Chemokine CCL5; Cyclic N-Oxides; Cyclohexanes; HIV Fusion Inhibitors; Humans; Macaca mulatta; Maraviroc; Mice; Molecular Sequence Data; Oximes; Piperidines; Precursor Cells, B-Lymphoid; Pyridines; Quaternary Ammonium Compounds; Radioligand Assay; Receptors, CCR5; Sequence Homology, Amino Acid; Species Specificity; Transfection; Triazoles | 2007 |
Changes in HIV-1 tropism: clinical and prognostic consequences.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; HIV Infections; HIV-1; Humans; Maraviroc; Prognosis; Receptors, CCR5; Receptors, CXCR4; Triazoles | 2007 |
Maraviroc reduces viral load in naive patients at 48 weeks.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclohexanes; Cyclopropanes; HIV Infections; HIV-1; Humans; Maraviroc; Triazoles; Viral Load | 2007 |
Maraviroc approved in the European Union.
Topics: Anti-HIV Agents; Controlled Clinical Trials as Topic; Cyclohexanes; Drug Approval; European Union; HIV Infections; Humans; Maraviroc; Triazoles | 2007 |
Asymmetric allylboration of acyl imines catalyzed by chiral diols.
Topics: Allyl Compounds; Anti-HIV Agents; Boranes; Boronic Acids; Cyclohexanes; Imines; Magnetic Resonance Spectroscopy; Maraviroc; Naphthols; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Infrared; Stereoisomerism; Triazoles | 2007 |
Post-exposure prophylaxis with a maraviroc-containing regimen after occupational exposure to a multi-resistant HIV-infected source person.
Topics: Adult; Anti-HIV Agents; Cyclohexanes; Drug Resistance, Multiple, Viral; Health Personnel; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Patient-to-Professional; Male; Maraviroc; Middle Aged; Needlestick Injuries; Occupational Exposure; Triazoles | 2008 |
Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.
Topics: Amides; Amino Acid Sequence; Animals; Anti-HIV Agents; Benzoates; Binding Sites; CCR5 Receptor Antagonists; CHO Cells; Cricetinae; Cricetulus; Cyclohexanes; Diketopiperazines; HIV Fusion Inhibitors; HIV-1; Humans; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; Maraviroc; Membrane Fusion; Models, Molecular; Molecular Sequence Data; Molecular Structure; Mutagenesis, Site-Directed; Piperazines; Piperidines; Protein Structure, Secondary; Protein Structure, Tertiary; Pyrimidines; Quaternary Ammonium Compounds; Radioligand Assay; Receptors, CCR5; Sequence Homology, Amino Acid; Spiro Compounds; Static Electricity; Transfection; Triazoles | 2008 |
Two new drugs for HIV infection.
Topics: Administration, Oral; CCR5 Receptor Antagonists; Cyclohexanes; Drug Administration Schedule; Drug Costs; Drug Interactions; Drug Resistance, Viral; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Maraviroc; Organic Chemicals; Pyrrolidinones; Raltegravir Potassium; Treatment Outcome; Triazoles | 2008 |
A review of the clinical pharmacology of maraviroc. Introduction.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Maraviroc; Triazoles | 2008 |
A receptor theory-based semimechanistic PD model for the CCR5 noncompetitive antagonist maraviroc.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Computer Simulation; Cyclohexanes; HIV Infections; Humans; Maraviroc; Models, Biological; Models, Statistical; Triazoles; Viral Load | 2008 |
FDA approval: maraviroc.
Topics: Anti-HIV Agents; Cyclohexanes; Drug Approval; Drug Costs; Maraviroc; Triazoles; United States; United States Food and Drug Administration | 2007 |
Report from the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Maraviroc in treatment-experienced and treatment-naive patients.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; HIV Infections; Humans; Maraviroc; Treatment Outcome; Triazoles | 2007 |
FDA notifications. Maraviroc approved as a CCR5 co-receptor antagonist.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Drug Approval; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Triazoles; United States; United States Food and Drug Administration; Viral Load | 2007 |
[New drugs for HIV infection].
Topics: Anti-HIV Agents; Contraindications; Cyclohexanes; Darunavir; Drug Monitoring; HIV Infections; Humans; Maraviroc; Nitriles; Organic Chemicals; Patient Education as Topic; Patient Selection; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Triazoles | 2008 |
[CCR5 antagonists: a new class of antiretrovirals].
Topics: Benzoates; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Diketopiperazines; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Piperazines; Pyrimidines; Spiro Compounds; Triazoles | 2008 |
[Clinical pharmacokinetic of maraviroc].
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Drug Interactions; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Triazoles | 2008 |
[Maraviroc: clinical trials results].
Topics: Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Cyclohexanes; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Triazoles | 2008 |
New drugs08, part 2.
Topics: Acromegaly; Adult; Anti-Bacterial Agents; Anti-HIV Agents; Antineoplastic Agents; Biopterins; Carbapenems; Child; Child, Preschool; Cyclohexanes; Doripenem; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Epothilones; Humans; Infant; Maraviroc; Peptides, Cyclic; Pharmaceutical Preparations; Phenylketonurias; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Sirolimus; Somatostatin; Triazoles | 2008 |
Maraviroc: in vitro assessment of drug-drug interaction potential.
Topics: Area Under Curve; Atazanavir Sulfate; Cyclohexanes; Cytochrome P-450 CYP3A; Drug Interactions; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ketoconazole; Liver; Male; Maraviroc; Microsomes, Liver; Oligopeptides; Predictive Value of Tests; Pyridines; Ritonavir; Saquinavir; Triazoles | 2008 |
Anti-HIV agents. Is PF-232798 a possible successor to maraviroc?
Topics: Azabicyclo Compounds; CD4 Lymphocyte Count; Cyclohexanes; HIV Fusion Inhibitors; HIV Infections; Humans; Imidazoles; Maraviroc; Piperidines; Triazoles; Tropanes; Viral Load | 2008 |
Overcoming hERG affinity in the discovery of maraviroc; a CCR5 antagonist for the treatment of HIV.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Evaluation, Preclinical; Ether-A-Go-Go Potassium Channels; Humans; Maraviroc; Receptors, CCR5; Triazoles | 2008 |
An in-depth look at the challenges of prescribing maraviroc.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Dose-Response Relationship, Drug; Drug Interactions; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Triazoles | 2008 |
Discovery of a novel CCR5 antagonist lead compound through fragment assembly.
Topics: Anti-HIV Agents; Butanones; Calcium Signaling; CCR5 Receptor Antagonists; Cyclohexanes; Drug Design; Humans; Maraviroc; Structure-Activity Relationship; Triazoles | 2008 |
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
Topics: Adult; Aged; Anti-Retroviral Agents; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Double-Blind Method; Drug Therapy, Combination; Enfuvirtide; Ethnicity; Female; Genotype; Hepatitis B; Hepatitis C; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Odds Ratio; Peptide Fragments; Receptors, CCR5; RNA, Viral; Transaminases; Treatment Outcome; Triazoles; Viral Load | 2008 |
A new class of anti-HIV therapy and new challenges.
Topics: Anti-Retroviral Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Resistance, Viral; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Triazoles | 2008 |
Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Drug Resistance, Viral; Genotype; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV-1; Humans; Maraviroc; Mutation; Triazoles | 2008 |
Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT).
Topics: Animals; Brain; Cyclohexanes; Drug Evaluation, Preclinical; Feasibility Studies; HIV; HIV Fusion Inhibitors; Intestinal Mucosa; Lymphoid Tissue; Male; Maraviroc; Rats; Tissue Distribution; Triazoles | 2008 |
[Pretreated HIV patients profit from Maraviroc. Oral HIV fusion inhibitor opens new therapy chances].
Topics: Administration, Oral; Cyclohexanes; Drug Resistance, Viral; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Randomized Controlled Trials as Topic; Triazoles; Viral Load | 2008 |
New insights into missed endpoint trial.
Topics: CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Endpoint Determination; HIV Infections; HIV-1; Humans; Maraviroc; Patient Selection; Receptors, CXCR4; Triazoles | 2008 |
Antiretroviral treatment update from the 17th International AIDS Conference.
Topics: Anti-HIV Agents; Cardiovascular Diseases; CCR5 Receptor Antagonists; Cyclohexanes; HIV Infections; HIV Integrase Inhibitors; Humans; Maraviroc; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Triazoles | 2008 |
[Introduction. A brief history of AIDS].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; Cyclohexanes; Drug Design; History, 20th Century; History, 21st Century; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Receptors, CCR5; Triazoles | 2008 |
A note of caution on yellow fever vaccination during maraviroc treatment: a hypothesis on a potential dangerous interaction.
Topics: Anti-HIV Agents; Cyclohexanes; Drug Interactions; Humans; Maraviroc; Mutation; Receptors, CCR5; Triazoles; Yellow Fever Vaccine | 2009 |
Report from the 2008 joint ICAAC/IDSA meeting. Maraviroc vs. efavirenz: a reanalysis of MERIT.
Topics: Alkynes; Benzoxazines; CCR5 Receptor Antagonists; Cyclohexanes; Cyclopropanes; HIV Infections; Humans; Maraviroc; Reverse Transcriptase Inhibitors; Triazoles | 2008 |
Simultaneous determination of maraviroc and raltegravir in human plasma by HPLC-UV.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Cyclohexanes; Drug Monitoring; Humans; Maraviroc; Pyrrolidinones; Raltegravir Potassium; Triazoles; Ultraviolet Rays | 2009 |
Maraviroc and CD4+ cell count recovery in patients with virologic suppression and blunted CD4+ cell response.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; Drug Interactions; HIV Infections; HIV-1; Humans; Maraviroc; Triazoles; Viral Load | 2009 |
Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients.
Topics: Anti-HIV Agents; Cyclohexanes; HIV Infections; HIV-1; Humans; Maraviroc; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles | 2009 |
Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing.
Topics: Cyclohexanes; DNA, Viral; Drug Resistance, Viral; Evolution, Molecular; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Phenotype; Phylogeny; Receptors, CXCR4; Sequence Alignment; Sequence Analysis, DNA; Triazoles | 2009 |
CCR5 pharmacology methodologies and associated applications.
Topics: Animals; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Discovery; HIV Infections; Humans; Maraviroc; Receptors, CCR5; Triazoles | 2009 |
Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women.
Topics: Adolescent; Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; Cervix Uteri; Cyclohexanes; Female; HIV Infections; HIV Seronegativity; HIV-1; Humans; Maraviroc; Middle Aged; Protein Binding; Triazoles; Vagina; Young Adult | 2009 |
Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery.
Topics: Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; Drug Evaluation; Endotoxins; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Retrospective Studies; RNA, Viral; Treatment Outcome; Triazoles | 2009 |
Concurrent use of statins does not influence efficacy of maraviroc in Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients 1 and 2 trials.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Drug Interactions; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Maraviroc; Treatment Outcome; Triazoles | 2009 |
Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Cyclohexanes; Female; HIV; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Receptors, HIV; Triazoles; Viral Load; Young Adult | 2009 |
Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4.
Topics: Adaptation, Biological; Animals; Anti-HIV Agents; Antibodies, Monoclonal; CCR5 Receptor Antagonists; CD4 Antigens; Cell Line; Cyclohexanes; HIV Envelope Protein gp120; HIV-1; Humans; Maraviroc; Mutation; Receptors, CCR5; Recombinant Proteins; Triazoles | 2009 |
Optimizing care for patients on maraviroc salvage therapy.
Topics: Adult; Cyclohexanes; Drug Interactions; Drug Therapy, Combination; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Middle Aged; Salvage Therapy; Triazoles | 2009 |
Maraviroc modelling strategy: use of early phase 1 data to support a semi-mechanistic population pharmacokinetic model.
Topics: Administration, Oral; Anti-HIV Agents; Clinical Trials, Phase I as Topic; Cyclohexanes; Dose-Response Relationship, Drug; Female; HIV Infections; Humans; Injections, Intravenous; Male; Maraviroc; Metabolic Clearance Rate; Models, Biological; Models, Statistical; Triazoles | 2009 |
[New antiretroviral drug classes in HIV therapy].
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Maraviroc; Piperazines; Pyrimidines; Pyrrolidinones; Quinolones; Raltegravir Potassium; Succinates; Triazoles; Triterpenes; Viral Load | 2009 |
[Immunorecovery after prolonged HIV-related immunosuppression: opportunities of the new antiretroviral classes].
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclohexanes; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Immunocompetence; Interleukin-2; Male; Maraviroc; Middle Aged; Reverse Transcriptase Inhibitors; Sulfonamides; T-Lymphocyte Subsets; Triazoles; Viral Load | 2009 |
Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients.
Topics: Adult; CCR5 Receptor Antagonists; Cyclohexanes; HIV Fusion Inhibitors; HIV Infections; Humans; Male; Maraviroc; Mass Spectrometry; Middle Aged; Pilot Projects; Triazoles | 2009 |
Is maraviroc beneficial in paradoxical progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome management?
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Cyclohexanes; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Immune Reconstitution Inflammatory Syndrome; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Maraviroc; Triazoles | 2009 |
Maraviroc and raltegravir.
Topics: Anti-HIV Agents; Cyclohexanes; Humans; Maraviroc; Pyrrolidinones; Raltegravir Potassium; Triazoles | 2009 |
Satisfactory cross-cultural validity of the ACTG symptom distress module in HIV-1-infected antiretroviral-naive patients.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cultural Competency; Cyclohexanes; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Language; Male; Maraviroc; Middle Aged; Multicenter Studies as Topic; Psychometrics; Randomized Controlled Trials as Topic; Reproducibility of Results; Stress, Psychological; Surveys and Questionnaires; Triazoles; Zidovudine | 2009 |
FDA advisory committee approves Selzentry.
Topics: Advisory Committees; CCR5 Receptor Antagonists; Cyclohexanes; Drug Approval; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Receptors, CCR5; Triazoles; United States; United States Food and Drug Administration | 2009 |
CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2.
Topics: CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Clinical Trials as Topic; Cyclohexanes; Drug Resistance, Viral; HIV Fusion Inhibitors; Humans; Maraviroc; Opportunistic Infections; T-Lymphocytes; Time Factors; Treatment Outcome; Triazoles | 2010 |
A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients.
Topics: CCR5 Receptor Antagonists; Chromatography, High Pressure Liquid; Cyclohexanes; Drug Monitoring; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Reproducibility of Results; Triazoles | 2010 |
Different selection patterns of resistance and cross-resistance to HIV-1 agents targeting CCR5.
Topics: Amides; Anti-HIV Agents; CCR5 Receptor Antagonists; Cell Line; Cells, Cultured; Cyclohexanes; Drug Resistance, Viral; HIV Envelope Protein gp120; HIV-1; Humans; Inhibitory Concentration 50; Leukocytes, Mononuclear; Maraviroc; Microbial Sensitivity Tests; Quaternary Ammonium Compounds; Triazoles | 2010 |
Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir.
Topics: Adult; Area Under Curve; Chromatography, Liquid; Cyclohexanes; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV Seronegativity; Humans; Male; Maraviroc; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Tandem Mass Spectrometry; Triazoles | 2010 |
Evaluation of a 3-amino-8-azabicyclo[3.2.1]octane replacement in the CCR5 antagonist maraviroc.
Topics: Anti-HIV Agents; Azabicyclo Compounds; CCR5 Receptor Antagonists; Cell Line, Tumor; Cyclohexanes; HIV Fusion Inhibitors; Humans; Maraviroc; Models, Chemical; Receptors, CCR5; Triazoles | 2010 |
Maraviroc for treatment-naive patients with HIV-1 infection: is the glass half empty or half full?
Topics: Antiviral Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Maraviroc; Triazoles | 2010 |
Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cyclohexanes; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Maraviroc; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Salvage Therapy; Triazoles; Viral Load | 2010 |
Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc.
Topics: Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; Genotype; HIV Infections; HIV-2; Humans; Maraviroc; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Treatment Outcome; Triazoles | 2010 |
Using density functional theory to rationalise the mass spectral fragmentation of maraviroc and its metabolites.
Topics: Chromatography, High Pressure Liquid; Computer Simulation; Cyclohexanes; Drug Stability; HIV Fusion Inhibitors; Maraviroc; Models, Chemical; Molecular Structure; Tandem Mass Spectrometry; Thermodynamics; Triazoles | 2010 |
Are the proposed env mutations actually associated with resistance to maraviroc?
Topics: Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; env Gene Products, Human Immunodeficiency Virus; HIV Infections; HIV-1; Humans; Maraviroc; Mutation, Missense; Triazoles | 2010 |
Characterization of a SHIV162P3 variant evolved in an infected rhesus macaque with persistent plasma viremia.
Topics: Amino Acid Substitution; Animals; Anti-HIV Agents; Antibodies, Neutralizing; CD4 Lymphocyte Count; Cyclohexanes; Gene Products, env; HIV Antibodies; Macaca mulatta; Male; Maraviroc; Mutation, Missense; Plasma; Sequence Analysis, DNA; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Triazoles; Viremia | 2010 |
Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.
Topics: Analysis of Variance; Anti-HIV Agents; Chromatography, High Pressure Liquid; Cyclohexanes; Drug Stability; Maraviroc; Nitriles; Pyridazines; Pyrimidines; Reproducibility of Results; Rilpivirine; Sensitivity and Specificity; Tandem Mass Spectrometry; Triazoles | 2010 |
Effects of CC chemokine receptor 5 (CCR5) inhibitors on the dynamics of CCR5 and CC-chemokine-CCR5 interactions.
Topics: Animals; Anti-HIV Agents; Bacterial Proteins; Benzoates; CCR5 Receptor Antagonists; Cell Line; Chemokine CCL5; Chemokines, CC; CHO Cells; Cricetinae; Cricetulus; Cyclohexanes; Diketopiperazines; Fluorescence Recovery After Photobleaching; HIV Fusion Inhibitors; Humans; Luminescent Proteins; Maraviroc; Piperazines; Receptors, CCR5; Spiro Compounds; Triazoles | 2010 |
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.
Topics: Adult; CCR5 Receptor Antagonists; Cyclohexanes; Female; Genotype; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Male; Maraviroc; Middle Aged; Molecular Sequence Data; Phenotype; Receptors, CCR5; Receptors, HIV; Sensitivity and Specificity; Sequence Analysis, DNA; Treatment Outcome; Triazoles; Tropism | 2010 |
Shift in phenotypic susceptibility suggests a competition mechanism in a case of acquired resistance to maraviroc.
Topics: Adult; Cyclohexanes; Drug Resistance, Viral; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Phenotype; Triazoles | 2010 |
An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes.
Topics: Animals; CCR5 Receptor Antagonists; Cells, Cultured; Cyclohexanes; Dogs; env Gene Products, Human Immunodeficiency Virus; HIV Fusion Inhibitors; HIV-1; Humans; Macrophages; Maraviroc; Molecular Biology; Protein Conformation; Receptors, CCR5; Triazoles; Virus Internalization | 2010 |
Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms.
Topics: Adult; Anti-HIV Agents; Central Nervous System Diseases; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Triazoles | 2010 |
Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor.
Topics: Administration, Intravaginal; Animals; Anti-HIV Agents; Cyclohexanes; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Macaca mulatta; Maraviroc; Receptors, CCR5; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Treatment Outcome; Triazoles; Vaginal Diseases; Virus Internalization; Virus Replication | 2010 |
Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; Female; Hepatitis C, Chronic; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Maraviroc; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Retrospective Studies; Spain; Time; Triazoles; Viral Load | 2010 |
Downregulation of leukocyte migration after treatment with CCR5 antagonist maraviroc.
Topics: Anti-HIV Agents; Cell Migration Assays, Leukocyte; Cell Movement; Cyclohexanes; Down-Regulation; Humans; Immunologic Factors; Leukocytes; Maraviroc; Triazoles | 2010 |
Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques.
Topics: Animals; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cyclohexanes; Female; Infectious Disease Transmission, Vertical; Macaca mulatta; Maraviroc; Pregnancy; Receptors, CCR5; Triazoles | 2010 |
A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5.
Topics: Base Sequence; Binding Sites; CCR5 Receptor Antagonists; Cell Line; Cohort Studies; Cyclohexanes; DNA Primers; Drug Resistance, Viral; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; In Vitro Techniques; Maraviroc; Models, Biological; Mutant Proteins; Mutation; Peptide Fragments; Protein Structure, Tertiary; Receptors, CCR5; Triazoles | 2010 |
Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Chromatography, Liquid; Cyclohexanes; Didanosine; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Organophosphonates; Polymerase Chain Reaction; Tandem Mass Spectrometry; Tenofovir; Triazoles; Viral Load | 2010 |
Analysis of co-receptor usage of circulating viral and proviral HIV genome quasispecies by ultra-deep pyrosequencing in patients who are candidates for CCR5 antagonist treatment.
Topics: Adult; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; Cyclohexanes; Female; Genome, Viral; HIV; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Receptors, CCR5; Receptors, HIV; Sequence Analysis, DNA; Sequence Analysis, RNA; Triazoles; Viral Load | 2011 |
Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies.
Topics: Adult; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclohexanes; Female; Genotype; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Male; Maraviroc; Receptors, HIV; RNA, Viral; Sequence Analysis, DNA; Triazoles; Viral Load; Viral Tropism | 2010 |
C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitors.
Topics: Amides; Antibodies, Monoclonal; CCR5 Receptor Antagonists; Cyclohexanes; env Gene Products, Human Immunodeficiency Virus; HIV Fusion Inhibitors; HIV-1; Humans; Maraviroc; Protein Binding; Pyrazoles; Quaternary Ammonium Compounds; Receptors, CCR5; Receptors, HIV; Triazoles; Valine; Virus Internalization | 2010 |
Development and application of a simple LC-MS method for the determination of plasma maraviroc concentrations.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Chemical Analysis; CCR5 Receptor Antagonists; Chromatography, Liquid; Cyclohexanes; Drug Monitoring; HIV Infections; HIV-1; Humans; Male; Maraviroc; Mass Spectrometry; Triazoles | 2010 |
Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.
Topics: Amides; Amino Acid Sequence; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Resistance, Viral; Evolution, Molecular; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Maraviroc; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Peptide Fragments; Piperazines; Pyrimidines; Quaternary Ammonium Compounds; Receptors, CCR5; Triazoles | 2010 |
Hepatic safety and tolerability in the maraviroc clinical development program.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; HIV Infections; HIV-1; Humans; Maraviroc; Triazoles | 2010 |
Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients.
Topics: Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; HIV Envelope Protein gp120; HIV Infections; HIV Seropositivity; HIV-1; Humans; Maraviroc; Mutation; Peptide Fragments; Receptors, CCR5; Sequence Analysis, DNA; Triazoles; Viral Tropism | 2010 |
TROCAI (tropism coreceptor assay information): a new phenotypic tropism test and its correlation with Trofile enhanced sensitivity and genotypic approaches.
Topics: Adult; Anti-HIV Agents; Cyclohexanes; Female; HIV; HIV Infections; Humans; Male; Maraviroc; Microbial Sensitivity Tests; Middle Aged; Triazoles; Viral Tropism; Virus Cultivation | 2010 |
Maraviroc does not affect humoral response to the pandemic influenza A-H1N1v 2009 adjuvanted vaccine in HIV-1-infected patients.
Topics: Adult; Aged; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclohexanes; Disease Outbreaks; Female; HIV Infections; HIV-1; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Maraviroc; Middle Aged; Triazoles | 2010 |
Evaluation of primary resistance to HIV entry inhibitors among brazilian patients failing reverse transcriptase/protease inhibitors treatment reveal high prevalence of maraviroc resistance-related mutations.
Topics: Adult; Ambulatory Care Facilities; Anti-HIV Agents; Brazil; Cyclohexanes; DNA, Viral; Drug Resistance, Viral; Enfuvirtide; env Gene Products, Human Immunodeficiency Virus; Female; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Male; Maraviroc; Middle Aged; Molecular Sequence Data; Mutation, Missense; Peptide Fragments; Piperazines; Prevalence; Proviruses; Sequence Analysis, DNA; Treatment Failure; Triazoles | 2010 |
An LC-MS-MS method for quantitative determination of maraviroc (UK-427,857) in human plasma, urine and cerebrospinal fluid.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Cyclohexanes; Humans; Maraviroc; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Triazoles | 2010 |
The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects.
Topics: Algorithms; Computer Simulation; Cyclohexanes; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Models, Statistical; Research Design; Software; Triazoles; Viral Load | 2011 |
Cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals in Mexico.
Topics: Computer Simulation; Cost-Benefit Analysis; Cyclohexanes; Female; HIV Fusion Inhibitors; HIV Infections; Humans; Male; Maraviroc; Mexico; Middle Aged; Models, Biological; Quality-Adjusted Life Years; Triazoles | 2010 |
New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection.
Topics: Allosteric Regulation; Chemokine CCL3; Cyclohexanes; Guanosine Triphosphate; HEK293 Cells; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Ligands; Maraviroc; Protein Binding; Receptors, CCR5; Triazoles | 2011 |
An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
Topics: Animals; Anti-HIV Agents; Azabicyclo Compounds; CCR5 Receptor Antagonists; Cell Line; Cricetinae; Cyclohexanes; Dogs; Drug Resistance, Viral; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; HIV-1; Humans; Imidazoles; Leukocytes, Mononuclear; Maraviroc; Models, Molecular; Protein Binding; Rats; Stereoisomerism; Structure-Activity Relationship; Triazoles; Tropanes | 2011 |
Discordance rates between Trofile test and short-term virological response to maraviroc.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Treatment Outcome; Triazoles; Viral Tropism; Young Adult | 2011 |
Direct measurement of thermal stability of expressed CCR5 and stabilization by small molecule ligands.
Topics: Antibodies, Monoclonal; Crystallography, X-Ray; Cyclohexanes; Fluorescein; HEK293 Cells; Humans; Immunoblotting; Ligands; Lipid Bilayers; Maraviroc; Niacinamide; Piperazines; Protein Binding; Protein Folding; Protein Stability; Pyrimidines; Receptors, CCR5; Solubility; Thermodynamics; Triazoles | 2011 |
The evolutionary analysis of emerging low frequency HIV-1 CXCR4 using variants through time--an ultra-deep approach.
Topics: Algorithms; Computational Biology; Cyclohexanes; Genetic Variation; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Receptors, CXCR4; Sequence Alignment; Sequence Analysis, RNA; Software; Triazoles; Viral Tropism | 2010 |
Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment.
Topics: Cyclohexanes; Genotype; HIV Infections; HIV-1; Humans; Maraviroc; Phenotype; Receptors, CCR5; Receptors, CXCR4; Triazoles; Viral Tropism | 2011 |
Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model.
Topics: Administration, Oral; Animals; Anti-HIV Agents; Cyclohexanes; Disease Models, Animal; Female; Flow Cytometry; HIV Infections; HIV-1; Humans; Maraviroc; Mice; Mice, Transgenic; Post-Exposure Prophylaxis; Pyrrolidinones; Raltegravir Potassium; Triazoles; Vagina | 2010 |
CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells.
Topics: Anti-HIV Agents; Antibodies; CCR5 Receptor Antagonists; Cells, Cultured; Cyclohexanes; Drug Resistance, Viral; HIV-1; Humans; Leukocytes, Mononuclear; Maraviroc; Microbial Sensitivity Tests; Receptors, CCR5; Triazoles; Virus Internalization | 2011 |
It's official...but not infallible.
Topics: Cyclohexanes; Drug Approval; Europe; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Off-Label Use; Triazoles; United States | 2010 |
Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Cyclohexanes; env Gene Products, Human Immunodeficiency Virus; Genotype; High-Throughput Nucleotide Sequencing; HIV Infections; HIV-1; Humans; Maraviroc; Receptors, CCR5; Receptors, HIV; Retrospective Studies; RNA, Viral; Triazoles; Viral Tropism; Virology; Virus Attachment | 2011 |
CCR5 blockade in combination with cyclosporine increased cardiac graft survival and generated alternatively activated macrophages in primates.
Topics: Animals; Binding, Competitive; CCR5 Receptor Antagonists; Cell Differentiation; Cells, Cultured; Coculture Techniques; Cyclohexanes; Cyclosporine; Drug Therapy, Combination; Graft Survival; Heart Transplantation; Lymphocyte Culture Test, Mixed; Macaca mulatta; Macrophage Activation; Macrophages; Male; Maraviroc; PPAR gamma; Protein Binding; Receptors, CCR5; Triazoles; Up-Regulation | 2011 |
Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system.
Topics: Adult; Aged; Anti-HIV Agents; CCR5 Receptor Antagonists; Cost-Benefit Analysis; Cyclohexanes; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Markov Chains; Middle Aged; Models, Economic; National Health Programs; Quality-Adjusted Life Years; Spain; Triazoles; Young Adult | 2010 |
HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism.
Topics: Amino Acid Sequence; Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; HIV Envelope Protein gp120; HIV-1; Humans; Macrophages; Maraviroc; Models, Molecular; Molecular Sequence Data; Mutant Proteins; Protein Binding; Receptors, CCR5; Triazoles; Viral Tropism | 2011 |
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
Topics: Anti-HIV Agents; Cell Line; Cyclohexanes; High-Throughput Nucleotide Sequencing; HIV Envelope Protein gp120; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Maraviroc; Molecular Sequence Data; Receptors, Virus; Triazoles; Viral Tropism; Virus Attachment; Virus Replication | 2011 |
Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
Topics: Animals; Anti-HIV Agents; Benzeneacetamides; CCR5 Receptor Antagonists; Cell Line; Chemokine CCL5; Chemokines; Chemotaxis; Cricetinae; Cyclohexanes; DNA Replication; Drug Resistance, Multiple, Viral; HEK293 Cells; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Macrophages; Maraviroc; Protein Binding; Receptors, CCR5; Receptors, CXCR4; Sulfonamides; Triazoles; Virus Replication | 2011 |
Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.
Topics: Anti-HIV Agents; Cell Line; Cyclohexanes; Genotype; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Treatment Outcome; Triazoles; Viral Tropism | 2011 |
Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro.
Topics: Animals; Anti-Retroviral Agents; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Cell Survival; Cyclohexanes; Dogs; Gene Expression Profiling; Maraviroc; Piperazines; Pyrimidines; Pyrrolidinones; Quinolones; Raltegravir Potassium; Triazoles | 2011 |
A combination of polymorphic mutations in V3 loop of HIV-1 gp120 can confer noncompetitive resistance to maraviroc.
Topics: Amino Acid Sequence; Anti-HIV Agents; Cell Line; Cyclohexanes; Drug Resistance, Viral; HIV Envelope Protein gp120; HIV-1; Humans; Maraviroc; Mutation; Polymorphism, Genetic; Triazoles; Virus Internalization | 2011 |
Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Cyclohexanes; Drug Administration Schedule; Humans; Male; Maraviroc; Rectum; Saliva; Semen; Triazoles; Young Adult | 2011 |
Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Maraviroc; Receptors, CCR5; Triazoles | 2011 |
Mutations in gp41 are correlated with coreceptor tropism but do not improve prediction methods substantially.
Topics: Algorithms; Amino Acid Sequence; Anti-HIV Agents; Cyclohexanes; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Maraviroc; Molecular Sequence Data; Mutation; Predictive Value of Tests; Receptors, CCR5; Receptors, CXCR4; Reverse Transcriptase Inhibitors; Treatment Outcome; Triazoles; Tropism | 2011 |
Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Cyclohexanes; Drug Resistance, Viral; Genotype; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Logistic Models; Maraviroc; Microbial Sensitivity Tests; Phenotype; Predictive Value of Tests; RNA, Viral; T-Lymphocytes; Treatment Outcome; Triazoles; Viral Load | 2011 |
Maraviroc intensification for suboptimal CD4⁺ T cell response in a perinatally HIV-infected adolescent.
Topics: Adolescent; CD4-Positive T-Lymphocytes; Cyclohexanes; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Male; Maraviroc; Pregnancy; Pregnancy Complications, Infectious; Triazoles | 2011 |
[CCR5 antagonist Maraviroc: effective and well tolerated. "A very promising substance"].
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Therapy, Combination; Genotype; HIV Infections; HIV-1; Humans; Maraviroc; Medication Adherence; Triazoles | 2011 |
[Utilizing the potential of maraviroc early. "Clear in second line therapy" (interview by Dr. Felicitas Zorn)].
Topics: Anti-HIV Agents; Cyclohexanes; Drug Therapy, Combination; Early Diagnosis; Genotype; HIV Infections; HIV-1; Humans; Maraviroc; Triazoles | 2011 |
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Salvage Therapy; Triazoles | 2011 |
Estimating the threshold surface density of Gp120-CCR5 complexes necessary for HIV-1 envelope-mediated cell-cell fusion.
Topics: CCR5 Receptor Antagonists; Clinical Trials, Phase III as Topic; Cloning, Molecular; Cyclohexanes; Down-Regulation; HIV Envelope Protein gp120; HIV-1; Humans; Maraviroc; Models, Biological; Piperazines; Protein Binding; Pyrimidines; Receptors, CCR5; Reproducibility of Results; Sirolimus; Triazoles; Virus Internalization | 2011 |
A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice.
Topics: Animals; Anti-Infective Agents, Local; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Chemistry, Pharmaceutical; Cyclohexanes; Disease Models, Animal; DNA-Binding Proteins; Female; Gels; HIV Infections; HIV-1; Homeodomain Proteins; Humans; Maraviroc; Mice; Placebos; Triazoles; Vagina | 2011 |
Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors.
Topics: Anti-HIV Agents; Antibodies, Monoclonal; CCR5 Receptor Antagonists; CD4-Positive T-Lymphocytes; Cell Line; Cell Membrane; Cyclohexanes; Drug Resistance, Viral; Epitopes; Flow Cytometry; HEK293 Cells; HIV Envelope Protein gp120; HIV Envelope Protein gp41; HIV-1; Humans; Maraviroc; Membrane Microdomains; Microscopy, Fluorescence; Piperazines; Pyrimidines; Receptors, CCR5; Triazoles; Viral Fusion Proteins; Virus Internalization | 2011 |
Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use.
Topics: Amino Acid Sequence; CCR5 Receptor Antagonists; Chemokines, CC; Cyclohexanes; Directed Molecular Evolution; Drug Resistance, Viral; HIV Envelope Protein gp160; HIV-1; Humans; Maraviroc; Molecular Sequence Data; Receptors, CCR5; Receptors, CXCR4; Triazoles; Virus Replication | 2011 |
Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5).
Topics: Allosteric Regulation; Amino Acid Sequence; Cell Membrane; Crystallography, X-Ray; Cyclohexanes; Humans; Maraviroc; Models, Biological; Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Receptors, CCR5; Small Molecule Libraries; Triazoles; User-Computer Interface | 2011 |
Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C.
Topics: Adenine; Algal Proteins; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; Cyclohexanes; Drug Synergism; Enfuvirtide; Genotype; HIV Envelope Protein gp41; HIV-1; Humans; Lectins; Leukocytes, Mononuclear; Maraviroc; Microbial Sensitivity Tests; Organophosphonates; Peptide Fragments; Plant Lectins; Tenofovir; Triazoles | 2011 |
Virological response after short-term CCR5 antagonist exposure in HIV-infected patients: frequency of subjects with virological response and associated factors.
Topics: Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cell Line; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Receptors, CXCR4; RNA, Viral; Triazoles; Viral Load | 2011 |
Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in South Africa.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclohexanes; Drug Resistance, Viral; Female; HIV Seropositivity; HIV-1; Humans; Logistic Models; Male; Maraviroc; Medication Adherence; Multivariate Analysis; Phylogeny; Predictive Value of Tests; Receptors, CXCR4; Receptors, HIV; Sensitivity and Specificity; South Africa; Treatment Failure; Triazoles | 2012 |
Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc.
Topics: Administration, Intravaginal; Animals; Cyclohexanes; Delayed-Action Preparations; Female; Gels; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Macaca mulatta; Maraviroc; Silicone Elastomers; Triazoles; Vagina; Vaginal Creams, Foams, and Jellies | 2011 |
Susceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitors.
Topics: Antibodies, Monoclonal; Cyclohexanes; Genetic Predisposition to Disease; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV-2; Humans; Ligands; Maraviroc; Receptors, CCR5; Receptors, CXCR4; Triazoles; Virus Replication | 2012 |
Maraviroc concentrations in seminal plasma in HIV-infected patients.
Topics: Adult; Anti-Retroviral Agents; CCR5 Receptor Antagonists; Chromatography, Liquid; Cyclohexanes; HIV Infections; HIV-1; Humans; Male; Maraviroc; Mass Spectrometry; Middle Aged; Semen; Triazoles | 2010 |
In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells.
Topics: CCR5 Receptor Antagonists; Chemokine CCL2; Chemokine CCL4; Chemokine CCL5; Chemotaxis; Chemotaxis, Leukocyte; Cyclohexanes; Dendritic Cells; HIV Fusion Inhibitors; HIV Infections; Humans; Macrophages; Maraviroc; Monocytes; N-Formylmethionine Leucyl-Phenylalanine; Receptors, CCR5; Triazoles | 2011 |
Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120.
Topics: Animals; Blotting, Western; CCR5 Receptor Antagonists; Cell Survival; Cells, Cultured; Cyclohexanes; Cytokines; Dinoprostone; DNA Primers; HIV Envelope Protein gp120; HIV Infections; Inflammation; Interferon-gamma; Macrophage Activation; Maraviroc; Microglia; Nitric Oxide; Rats; Real-Time Polymerase Chain Reaction; RNA, Messenger; Triazoles | 2012 |
Rescue of HIV-1 long-time archived X4 strains to escape maraviroc.
Topics: Antiretroviral Therapy, Highly Active; Base Sequence; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Genotype; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Maraviroc; Microbial Sensitivity Tests; Molecular Sequence Data; Phylogeny; Receptors, CCR5; Receptors, CXCR4; Sequence Alignment; Treatment Failure; Triazoles; Viral Load; Viral Tropism | 2011 |
HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry.
Topics: CCR5 Receptor Antagonists; Cell Line; Cyclohexanes; Drug Resistance, Viral; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Protein Binding; Receptors, CCR5; Triazoles; Virus Internalization | 2011 |
In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Cells, Cultured; Cyclohexanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; HIV-2; Humans; Inhibitory Concentration 50; Leukocytes, Mononuclear; Lymphocyte Activation; Male; Maraviroc; Models, Biological; Phytohemagglutinins; Receptors, CCR5; Receptors, CXCR4; Species Specificity; Triazoles; Virus Replication | 2012 |
Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods.
Topics: Adult; Algorithms; CCR5 Receptor Antagonists; Chromatography, High Pressure Liquid; Cyclohexanes; Female; Genotype; High-Throughput Nucleotide Sequencing; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Molecular Typing; Receptors, CCR5; RNA, Viral; Tandem Mass Spectrometry; Treatment Outcome; Triazoles; Viral Load; Viral Tropism | 2012 |
SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses.
Topics: Administration, Intravaginal; Animals; Cell Line; Cyclohexanes; Drug Resistance, Viral; Entropy; Female; Genome, Viral; Humans; Macaca mulatta; Maraviroc; Membrane Glycoproteins; Models, Genetic; Molecular Sequence Data; Mutation; Reproducibility of Results; Simian Immunodeficiency Virus; Triazoles; Vaginal Creams, Foams, and Jellies; Viral Envelope Proteins; Viral Load; Viral Proteins | 2011 |
Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg.
Topics: Adult; Anti-HIV Agents; Cyclohexanes; Darunavir; Drug Interactions; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Retrospective Studies; Ritonavir; Sulfonamides; Triazoles | 2012 |
In vitro downregulation of matrix metalloproteinase-9 in rat glial cells by CCR5 antagonist maraviroc: therapeutic implication for HIV brain infection.
Topics: Animals; Astrocytes; Brain; CCR5 Receptor Antagonists; Cell Death; Cell Shape; Cell Survival; Cells, Cultured; Cyclohexanes; Down-Regulation; Gene Expression Regulation, Enzymologic; HIV Infections; Humans; Lipopolysaccharides; Maraviroc; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Neuroglia; Rats; Receptors, CCR5; RNA, Messenger; Tetradecanoylphorbol Acetate; Triazoles | 2011 |
Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival.
Topics: Aminopyridines; Animals; CCR5 Receptor Antagonists; Clinical Trials, Phase II as Topic; Cyclohexanes; Drug Evaluation; HIV Infections; Humans; Maraviroc; Morpholines; Neuralgia; Pharmaceutical Preparations; Pharmacokinetics; Receptors, Dopamine D3; Sexual Dysfunction, Physiological; Triazoles | 2012 |
Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists.
Topics: Amino Acid Sequence; Amino Acid Substitution; Anti-HIV Agents; Antibodies, Blocking; Antibodies, Monoclonal; CCR5 Receptor Antagonists; Cyclohexanes; Drug Resistance, Viral; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Piperazines; Pyrimidines; Receptors, CCR5; Triazoles | 2012 |
Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Cyclohexanes; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Maraviroc; Matrix Metalloproteinase 2; Middle Aged; Pilot Projects; Prospective Studies; RNA, Viral; Serum; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta; Triazoles | 2012 |
Responses to switching to maraviroc-based antiretroviral therapy in treated patients with suppressed plasma HIV-1-RNA load.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Ki-1 Antigen; Lymphocyte Activation; Male; Maraviroc; Middle Aged; Plasma; RNA, Viral; Treatment Outcome; Triazoles; Viral Load; Viral Tropism | 2012 |
Baseline susceptibility of primary HIV-2 to entry inhibitors.
Topics: Amides; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; HIV-2; Humans; Inhibitory Concentration 50; Male; Maraviroc; Microbial Sensitivity Tests; Peptide Fragments; Quaternary Ammonium Compounds; Triazoles | 2012 |
Antiviral effect of maraviroc in semen: a case report.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cyclohexanes; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Semen; Sperm Count; Triazoles; Viral Load | 2012 |
Novel agents for the treatment of HIV-2 infection.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV-2; Humans; Male; Maraviroc; Peptide Fragments; Triazoles | 2012 |
Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration.
Topics: Adult; CCR5 Receptor Antagonists; Chromatography, Reverse-Phase; Cross-Sectional Studies; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Male; Maraviroc; Middle Aged; RNA, Viral; Tandem Mass Spectrometry; Triazoles | 2012 |
Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques.
Topics: Administration, Intravaginal; Animals; Anti-HIV Agents; Biopsy; CCR5 Receptor Antagonists; Chromatography, High Pressure Liquid; Contraceptive Devices, Female; Cyclohexanes; Delayed-Action Preparations; Female; HIV Infections; HIV-1; Humans; Longitudinal Studies; Macaca mulatta; Maraviroc; Medroxyprogesterone Acetate; Pyrazoles; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tissue Distribution; Triazoles; Vagina; Valine; Virus Internalization | 2012 |
Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy.
Topics: Adult; Anti-HIV Agents; Cyclohexanes; DNA, Viral; Evolution, Molecular; Female; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Proviruses; Selection, Genetic; Triazoles; Viral Tropism | 2012 |
Impaired maraviroc and raltegravir clearance in a human immunodeficiency virus-infected patient with end-stage liver disease and renal impairment: a management dilemma.
Topics: Adult; Cyclohexanes; Disease Management; End Stage Liver Disease; Fatal Outcome; HIV Infections; Humans; Male; Maraviroc; Metabolic Clearance Rate; Pyrrolidinones; Raltegravir Potassium; Renal Insufficiency; Triazoles | 2012 |
V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc.
Topics: Amino Acid Sequence; CCR5 Receptor Antagonists; Cyclohexanes; Drug Resistance, Viral; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV-1; Maraviroc; Models, Molecular; Molecular Sequence Data; Peptide Fragments; Piperazines; Protein Conformation; Pyrimidines; Triazoles | 2012 |
CCR5 antagonist TD-0680 uses a novel mechanism for enhanced potency against HIV-1 entry, cell-mediated infection, and a resistant variant.
Topics: Amides; Anti-HIV Agents; Binding Sites; CCR5 Receptor Antagonists; Cell Line; Cyclohexanes; HIV Infections; HIV-1; Humans; Maraviroc; Protein Structure, Secondary; Quaternary Ammonium Compounds; Receptors, CCR5; Sulfonamides; Triazoles; Tropanes; Virus Internalization; Virus Replication | 2012 |
Genetically encoded photo-cross-linkers map the binding site of an allosteric drug on a G protein-coupled receptor.
Topics: Allosteric Site; CCR5 Receptor Antagonists; Cross-Linking Reagents; Cyclohexanes; HEK293 Cells; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Models, Molecular; Mutagenesis, Site-Directed; Mutation; Receptors, CCR5; Triazoles; Ultraviolet Rays; Virus Internalization | 2012 |
[Features and the method of application of a CCR5 antagonist, a new integrase inhibitor].
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; HIV Integrase Inhibitors; Humans; Maraviroc; Pyrrolidinones; Raltegravir Potassium; Triazoles | 2009 |
Structural insights from binding poses of CCR2 and CCR5 with clinically important antagonists: a combined in silico study.
Topics: Amino Acid Sequence; Benzamides; Binding Sites; Cyclohexanes; Glutamic Acid; Humans; Maraviroc; Models, Molecular; Molecular Dynamics Simulation; Molecular Sequence Data; Molecular Structure; Protein Binding; Protein Structure, Tertiary; Pyrrolidines; Receptors, CCR2; Receptors, CCR5; Sequence Homology, Amino Acid; Triazoles | 2012 |
Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission.
Topics: Administration, Intravaginal; AIDS Vaccines; Animals; Anti-Infective Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Macaca mulatta; Maraviroc; RNA, Viral; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Treatment Outcome; Triazoles; Viral Load | 2012 |
Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Benzylamines; Cell Line; Cyclams; Cyclohexanes; Cyclopropanes; DNA, Viral; Drug Resistance, Viral; Enfuvirtide; Heterocyclic Compounds; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Maraviroc; Peptide Fragments; Pyrrolidinones; Raltegravir Potassium; Receptors, CCR5; Receptors, CXCR4; RNA, Viral; Triazoles; Viral Load; Virus Internalization | 2012 |
CCR5 antagonist blocks metastasis of basal breast cancer cells.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; CCR5 Receptor Antagonists; Chemokine CCL5; Cyclohexanes; Female; Gene Expression Regulation, Neoplastic; Humans; Maraviroc; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplasms, Basal Cell; Piperazines; Pyrimidines; Receptors, CCR5; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Immune recovery and T cell subset analysis during effective treatment with maraviroc.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Antigens; Cyclohexanes; Female; HIV Infections; Humans; Immunophenotyping; Male; Maraviroc; Middle Aged; Receptors, CCR5; Receptors, CXCR4; T-Lymphocyte Subsets; Treatment Outcome; Triazoles | 2012 |
Levels of soluble endothelial protein C receptor are associated with CD4+ changes in Maraviroc-treated HIV-infected patients.
Topics: Adult; Aged; Antigens, CD; Biomarkers; Blood Coagulation; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Endothelial Protein C Receptor; Endothelium, Vascular; Female; Follow-Up Studies; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Receptors, Cell Surface; Triazoles | 2012 |
Long-term maraviroc use as salvage therapy in HIV-2 infection.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Cyclohexanes; Drug Monitoring; HIV Infections; HIV-2; Humans; Maraviroc; Salvage Therapy; Treatment Outcome; Triazoles | 2012 |
A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model.
Topics: Adenine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Darunavir; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Flow Cytometry; Fluorescent Antibody Technique; Macaca mulatta; Maraviroc; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Simian Acquired Immunodeficiency Syndrome; Sulfonamides; T-Lymphocyte Subsets; Tenofovir; Triazoles; Viral Load; Viremia | 2012 |
Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens.
Topics: Anti-HIV Agents; Blood Glucose; Cyclohexanes; Darunavir; Fasting; Glucose Tolerance Test; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Insulin; Insulin Resistance; Maraviroc; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Treatment Outcome; Triazoles; Viral Load | 2012 |
Patients on a combined antiretroviral therapy after maraviroc clinical test show no immunovirological impairment.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Cyclohexanes; Female; Follow-Up Studies; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Treatment Outcome; Triazoles; Viral Load; Viral Tropism; Young Adult | 2012 |
Pharmacokinetic interaction between maraviroc and etravirine in HIV-infected patients receiving regimens containing both drugs and no ritonavir-boosted protease inhibitor.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Drug Interactions; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Multicenter Studies as Topic; Nitriles; Plasma; Pyridazines; Pyrimidines; Ritonavir; Triazoles | 2012 |
High prevalence of X4/DM-tropic variants in children and adolescents infected with HIV-1 by vertical transmission.
Topics: Adolescent; Anti-HIV Agents; CCR5 Receptor Antagonists; Child; Cross-Sectional Studies; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Male; Maraviroc; Prevalence; Receptors, HIV; Salvage Therapy; Triazoles; Viral Tropism | 2012 |
An expanded model of HIV cell entry phenotype based on multi-parameter single-cell data.
Topics: Amino Acid Sequence; Benzylamines; CCR5 Receptor Antagonists; Computational Biology; Cyclams; Cyclohexanes; Genetic Vectors; HEK293 Cells; Heterocyclic Compounds; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Models, Biological; Molecular Sequence Data; Multivariate Analysis; Phenotype; Receptors, CCR5; Receptors, CXCR4; Transfection; Triazoles; Virus Internalization | 2012 |
Stochastic model of in-vivo X4 emergence during HIV infection: implications for the CCR5 inhibitor maraviroc.
Topics: CCR5 Receptor Antagonists; CD4-Positive T-Lymphocytes; Cyclohexanes; HIV Infections; Humans; Maraviroc; Models, Theoretical; Triazoles | 2012 |
Maraviroc observational study: the impact of expanded resistance testing and clinical considerations for antiretroviral regimen selection in treatment-experienced patients.
Topics: Adult; Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Male; Maraviroc; Microbial Sensitivity Tests; Salvage Therapy; Treatment Failure; Triazoles | 2013 |
Cytochrome P450 3A5 plays a prominent role in the oxidative metabolism of the anti-human immunodeficiency virus drug maraviroc.
Topics: Alleles; Amino Acid Sequence; Animals; Chlorocebus aethiops; Chromatography, High Pressure Liquid; COS Cells; Cyclohexanes; Cytochrome P-450 CYP3A; HIV Fusion Inhibitors; Humans; Hydroxylation; Male; Maraviroc; Mass Spectrometry; Metabolic Detoxication, Phase I; Microsomes, Liver; Molecular Sequence Data; Mutation; Triazoles | 2012 |
Effect of maraviroc on HIV disease progression-related biomarkers.
Topics: Adult; Antiretroviral Therapy, Highly Active; Biomarkers; CCR5 Receptor Antagonists; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclohexanes; Disease Progression; Female; Fibrin Fibrinogen Degradation Products; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Lipopolysaccharide Receptors; Lymphocyte Activation; Lymphocyte Count; Male; Maraviroc; Middle Aged; Receptors, CCR5; RNA, Viral; Triazoles; Viral Load | 2012 |
Chemokine receptor blockade in graft-versus-host disease.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Graft vs Host Disease; Humans; Immunologic Factors; Maraviroc; Stem Cell Transplantation; Treatment Outcome; Triazoles | 2012 |
The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression.
Topics: Adult; Anti-Retroviral Agents; Bacterial Translocation; CD4-CD8 Ratio; Clinical Trials, Phase II as Topic; Cross-Sectional Studies; Cyclohexanes; Female; HIV Infections; Host-Pathogen Interactions; Humans; Lymphocyte Activation; Male; Maraviroc; Middle Aged; Multivariate Analysis; Pyrrolidinones; Raltegravir Potassium; Risk Factors; Statistics, Nonparametric; T-Lymphocytes; Triazoles; Viral Load | 2013 |
Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brazil; CD4 Lymphocyte Count; Cyclohexanes; Drug Resistance, Viral; Enfuvirtide; Follow-Up Studies; Genotyping Techniques; HIV Envelope Protein gp41; HIV Infections; HIV Integrase; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Maraviroc; Mutation; Peptide Fragments; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Salvage Therapy; Treatment Outcome; Triazoles; Viral Load; Virus Replication | 2012 |
Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques.
Topics: Administration, Intravaginal; Animals; Body Fluids; Cyclohexanes; Female; HIV Fusion Inhibitors; Macaca mulatta; Maraviroc; Plasma; Simian Acquired Immunodeficiency Syndrome; Time Factors; Triazoles; Vagina; Vaginal Creams, Foams, and Jellies | 2013 |
HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120.
Topics: Anti-HIV Agents; Cyclohexanes; DNA Mutational Analysis; Drug Resistance, Viral; HIV Envelope Protein gp120; HIV-1; Humans; Maraviroc; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation, Missense; Sequence Analysis, DNA; Serial Passage; Triazoles; Virus Cultivation | 2013 |
In vitro effects of the CCR5 inhibitor maraviroc on human T cell function.
Topics: Anti-HIV Agents; Antigens, CD; Cell Movement; Cell Proliferation; Cells, Cultured; Cyclohexanes; HLA-DR Antigens; Humans; Immunosuppressive Agents; Leukocytes, Mononuclear; Lymphocyte Activation; Maraviroc; Receptors, CCR5; Triazoles | 2013 |
HIV-1 dynamics and coreceptor usage in Maraviroc-treated patients with ongoing replication.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Drug Resistance, Viral; Evolution, Molecular; Genotype; High-Throughput Nucleotide Sequencing; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Peptide Fragments; Receptors, CCR5; Receptors, CXCR4; Selection, Genetic; Sequence Analysis, RNA; Triazoles; Viral Tropism | 2013 |
Pharmacokinetic interaction of maraviroc with tacrolimus in a patient coinfected with HIV and hepatitis B virus following hepatic transplant due to hepatocellular carcinoma.
Topics: Anti-HIV Agents; Carcinoma, Hepatocellular; Cyclohexanes; Drug Interactions; Hepatitis B; HIV Infections; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Maraviroc; Middle Aged; Plasma; Tacrolimus; Treatment Outcome; Triazoles | 2013 |
A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action.
Topics: Calorimetry, Differential Scanning; CCR5 Receptor Antagonists; Contraceptive Devices, Female; Cyclohexanes; Delayed-Action Preparations; Drug Combinations; Drug Delivery Systems; Drug Stability; Drug Storage; HIV Infections; HIV Reverse Transcriptase; Hot Temperature; Maraviroc; Mechanical Phenomena; Pyrimidines; Reverse Transcriptase Inhibitors; Silicone Elastomers; Solubility; Triazoles | 2013 |
Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.
Topics: CCR5 Receptor Antagonists; CD4-Positive T-Lymphocytes; Cell Line; Cyclohexanes; env Gene Products, Human Immunodeficiency Virus; HEK293 Cells; HIV Infections; HIV-1; Humans; Maraviroc; Receptors, CCR5; Triazoles; Virus Attachment; Virus Internalization | 2013 |
Impact of antiretroviral pressure on selection of primary human immunodeficiency virus type 1 envelope sequences in vitro.
Topics: Amino Acid Sequence; Anti-HIV Agents; Base Sequence; Cyclohexanes; DNA, Viral; Genetic Variation; Genotype; Glycosylation; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Lamivudine; Maraviroc; Molecular Sequence Data; Phylogeny; Pyrrolidinones; Raltegravir Potassium; Receptors, CCR5; Receptors, CXCR4; Saquinavir; Sequence Analysis, DNA; Triazoles; Viral Tropism | 2013 |
Placental transfer of maraviroc in an ex vivo human cotyledon perfusion model and influence of ABC transporter expression.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Chromatography, Liquid; Cyclohexanes; Diffusion Chambers, Culture; Female; Fetus; Gene Expression; HIV Fusion Inhibitors; Humans; Kinetics; Maraviroc; Maternal-Fetal Exchange; Models, Biological; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organ Culture Techniques; Perfusion; Placenta; Pregnancy; Tandem Mass Spectrometry; Triazoles | 2013 |
Long-term suppressive combined antiretroviral treatment does not normalize the serum level of soluble CD14.
Topics: Adult; Aged; Anti-Retroviral Agents; Case-Control Studies; CD4 Lymphocyte Count; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Lipopolysaccharide Receptors; Longitudinal Studies; Male; Maraviroc; Middle Aged; RNA, Viral; Solubility; Time Factors; Treatment Outcome; Triazoles; Viral Load | 2013 |
Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; CCR5 Receptor Antagonists; Cell Proliferation; Cyclohexanes; Humans; Liver Cirrhosis; MAP Kinase Signaling System; Maraviroc; Mice; Neoplasms, Experimental; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Receptors, CCR5; Triazoles | 2013 |
Pharmacokinetics of maraviroc, raltegravir, darunavir, and etravirine in the semen of HIV-infected men.
Topics: Anti-HIV Agents; Area Under Curve; Cyclohexanes; Darunavir; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Nitriles; Prospective Studies; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Semen; Sulfonamides; Triazoles | 2013 |
Impact of antiretroviral therapy duration and intensification on isolated shedding of HIV-1 RNA in semen.
Topics: Amino Acid Sequence; Anti-Retroviral Agents; Base Sequence; Case-Control Studies; Cyclohexanes; HIV Infections; HIV-1; Humans; Incidence; Male; Maraviroc; Molecular Sequence Data; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Semen; Sequence Analysis, RNA; Sexual Behavior; Time Factors; Treatment Outcome; Triazoles; Viral Load; Viremia; Virus Shedding | 2013 |
Maraviroc reduces cytokine expression and secretion in human adipose cells without altering adipogenic differentiation.
Topics: Adipocytes; Adipogenesis; Adipokines; Biomarkers; Cells, Cultured; Cyclohexanes; Cytokines; DNA, Mitochondrial; Gene Expression Regulation; Humans; Inflammation; Inflammation Mediators; Lipopolysaccharides; Maraviroc; Mitochondria; RNA, Messenger; Triazoles | 2013 |
Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.
Topics: Adult; Antiretroviral Therapy, Highly Active; Area Under Curve; CD4 Lymphocyte Count; Cyclohexanes; Darunavir; Drug Therapy, Combination; Female; Half-Life; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Male; Maraviroc; Middle Aged; Prospective Studies; Ritonavir; RNA, Viral; Sulfonamides; Triazoles | 2013 |
Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicides.
Topics: Adenine; Animals; Antibodies, Monoclonal; Antibodies, Neutralizing; Antiviral Agents; Chromatography, Affinity; Cyclohexanes; Drug Combinations; Drug Synergism; Genetic Vectors; HIV Antibodies; HIV Envelope Protein gp120; HIV-1; Humans; Immunoglobulin G; Maraviroc; Neutralization Tests; Nicotiana; Organophosphonates; Plant Lectins; Recombinant Proteins; Tenofovir; Tobamovirus; Triazoles | 2013 |
Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing.
Topics: Cyclohexanes; DNA, Viral; Genotype; High-Throughput Nucleotide Sequencing; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Kaplan-Meier Estimate; Leukocytes, Mononuclear; Maraviroc; Treatment Outcome; Triazoles; Viral Tropism | 2013 |
Use of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; CD4-Positive T-Lymphocytes; Cell Line; Cyclohexanes; Drug Resistance, Viral; env Gene Products, Human Immunodeficiency Virus; GTP-Binding Proteins; HEK293 Cells; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Pertussis Toxin; Piperazines; Pyrimidines; Receptors, CCR5; Transfection; Triazoles | 2013 |
Sensitive cell-based assay for determination of human immunodeficiency virus type 1 coreceptor tropism.
Topics: Anti-HIV Agents; Cell Fusion; Cell Line; Cyclohexanes; env Gene Products, Human Immunodeficiency Virus; Genome, Viral; Genotype; HEK293 Cells; HIV Infections; HIV-1; Humans; Maraviroc; Pilot Projects; Receptors, CCR5; Receptors, CXCR4; Receptors, HIV; RNA, Viral; Saccharomyces cerevisiae Proteins; Sensitivity and Specificity; Triazoles; Viral Tropism | 2013 |
Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients.
Topics: Adult; Anti-HIV Agents; Cyclohexanes; Drug Therapy, Combination; HIV Infections; Humans; Lopinavir; Male; Maraviroc; Plasma; Ritonavir; Time Factors; Triazoles | 2013 |
Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc.
Topics: Animals; Anti-HIV Agents; CCR5 Receptor Antagonists; Cell Line; Chemokine CCL5; Cyclohexanes; Down-Regulation; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Macaca; Maraviroc; Microbial Sensitivity Tests; Receptors, CCR5; Triazoles; Virus Internalization; Virus Replication | 2013 |
Transplacental passage of etravirine and maraviroc in a multidrug-experienced HIV-infected woman failing on darunavir-based HAART in late pregnancy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Darunavir; Female; HIV Infections; Humans; Infant; Infant, Newborn; Maraviroc; Nitriles; Pregnancy; Pregnancy Complications, Infectious; Pyridazines; Pyrimidines; RNA, Viral; Sulfonamides; Treatment Failure; Triazoles; Viral Load | 2013 |
Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc Switch collaborative study.
Topics: Anti-HIV Agents; Clinical Laboratory Techniques; Cyclohexanes; DNA, Viral; HIV Infections; HIV-1; Humans; Laboratory Proficiency Testing; Maraviroc; Proviruses; Triazoles; Viral Tropism | 2013 |
Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.
Topics: Adult; Aged; CCR5 Receptor Antagonists; Cyclohexanes; Drug Resistance, Viral; Drug Substitution; Female; Follow-Up Studies; Genotype; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Prevalence; Receptors, CCR5; Sequence Analysis, DNA; Treatment Outcome; Triazoles; Viral Load; Viral Tropism; Virus Replication; Young Adult | 2013 |
The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets.
Topics: CCR5 Receptor Antagonists; CD4-Positive T-Lymphocytes; Cell Line; Cyclohexanes; Drug Resistance, Viral; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV-1; Humans; Macrophages; Maraviroc; T-Lymphocyte Subsets; Triazoles | 2013 |
A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations.
Topics: Anti-HIV Agents; Cyclohexanes; Genetic Variation; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Maraviroc; Molecular Sequence Data; Mutation, Missense; Sequence Analysis, DNA; Treatment Failure; Triazoles; Virus Internalization | 2013 |
Synergistic activity of carbosilane dendrimers in combination with maraviroc against HIV in vitro.
Topics: Anti-HIV Agents; Cyclohexanes; Dendrimers; Drug Synergism; HeLa Cells; HIV-1; Humans; Maraviroc; Microbial Sensitivity Tests; Silanes; Triazoles | 2013 |
Profile of HIV type 1 coreceptor tropism among Kenyan patients from 2009 to 2010.
Topics: Adolescent; Adult; Aged; CCR5 Receptor Antagonists; Child; Child, Preschool; Cyclohexanes; Female; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Kenya; Male; Maraviroc; Middle Aged; Molecular Sequence Data; Receptors, CCR5; Receptors, CXCR4; Sequence Analysis, DNA; Triazoles; Viral Tropism; Young Adult | 2013 |
Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice.
Topics: Animals; Anti-Retroviral Agents; Apolipoproteins E; Atherosclerosis; CCR5 Receptor Antagonists; Cell Movement; Chemokine CCL2; Chemokine CCL5; Cyclohexanes; Disease Models, Animal; Intercellular Adhesion Molecule-1; Interleukin-17; Macrophages; Male; Maraviroc; Mice; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Ritonavir; Treatment Outcome; Triazoles; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2013 |
Oral administration of the CCR5 inhibitor, maraviroc, blocks HIV ex vivo infection of Langerhans cells within the epithelium.
Topics: Administration, Oral; Adult; CCR5 Receptor Antagonists; Chromatography, Liquid; Coculture Techniques; Cyclohexanes; Drug Administration Schedule; Epithelium; HIV Fusion Inhibitors; HIV Infections; Humans; Langerhans Cells; Male; Maraviroc; Mass Spectrometry; Receptors, CCR5; Time Factors; Triazoles; Young Adult | 2013 |
HIV-1 tropism determination using a phenotypic Env recombinant viral assay highlights overestimation of CXCR4-usage by genotypic prediction algorithms for CRF01_AE and CRF02_AG [corrected].
Topics: Algorithms; Cyclohexanes; Genotype; HIV Envelope Protein gp120; HIV-1; Humans; Luciferases; Maraviroc; Phenotype; Receptors, CXCR4; Triazoles; Viral Tropism; Virus Internalization | 2013 |
Maraviroc treatment in non-R5-HIV-1-infected patients results in the selection of extreme CXCR4-using variants with limited effect on the total viral setpoint.
Topics: Anti-HIV Agents; Cohort Studies; Cyclohexanes; High-Throughput Nucleotide Sequencing; HIV Infections; HIV-1; Humans; Longitudinal Studies; Maraviroc; Receptors, CCR5; Receptors, CXCR4; Receptors, HIV; Selection, Genetic; Triazoles; Viral Tropism | 2013 |
Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues.
Topics: Animals; Anti-Retroviral Agents; Chemoprevention; Cyclohexanes; Female; Intestinal Mucosa; Macaca; Male; Maraviroc; Plasma; Rectum; Simian Acquired Immunodeficiency Syndrome; Treatment Failure; Triazoles | 2013 |
A novel bivalent HIV-1 entry inhibitor reveals fundamental differences in CCR5-μ-opioid receptor interactions between human astroglia and microglia.
Topics: Astrocytes; Cells, Cultured; Cyclohexanes; Genes, Reporter; HIV Fusion Inhibitors; HIV-1; Humans; Luciferases; Maraviroc; Microglia; Naltrexone; Receptors, CCR5; Receptors, Opioid; Triazoles; Virus Internalization | 2013 |
Identifying chemicals with potential therapy of HIV based on protein-protein and protein-chemical interaction network.
Topics: 1-Deoxynojirimycin; Algorithms; Anti-HIV Agents; CCR5 Receptor Antagonists; Computer Simulation; Cyclohexanes; Databases, Chemical; Didanosine; Drug Design; Drug Discovery; HIV Infections; HIV-1; Host-Pathogen Interactions; Humans; Maraviroc; Models, Molecular; Protein Interaction Mapping; Protein Interaction Maps; Receptors, CCR5; Triazoles | 2013 |
Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.
Topics: Anti-HIV Agents; Antibodies, Monoclonal; CCR5 Receptor Antagonists; CD4 Antigens; Cyclohexanes; Drug Resistance, Viral; Enfuvirtide; HEK293 Cells; HIV Envelope Protein gp120; HIV Envelope Protein gp41; HIV-1; Humans; Maraviroc; Organophosphates; Peptide Fragments; Piperazines; Prodrugs; Receptors, CCR5; Receptors, CXCR4; Receptors, Virus; Triazoles; Virus Internalization | 2013 |
Preventing graft-versus-host disease: transplanters glimpse hope beyond immunosuppressants.
Topics: Acute Disease; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Chronic Disease; Clinical Trials as Topic; Cyclohexanes; Cyclophosphamide; Cyclosporine; Evidence-Based Medicine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Immunosuppressive Agents; Maraviroc; Methotrexate; Pentostatin; Peripheral Blood Stem Cell Transplantation; Pyrazines; Quality of Life; Tacrolimus; Triazoles; Vorinostat | 2013 |
Primary resistance of CCR5-tropic HIV-1 to maraviroc cannot be predicted by the V3 sequence.
Topics: Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; France; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Maraviroc; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation, Missense; Sequence Analysis, DNA; Triazoles | 2013 |
Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cyclohexanes; Darunavir; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Maraviroc; Pilot Projects; Ritonavir; RNA Stability; RNA, Viral; Sulfonamides; Treatment Outcome; Triazoles; Viral Load | 2013 |
Analysis of primary resistance mutations to HIV-1 entry inhibitors in therapy naive subtype C HIV-1 infected mother-infant pairs from Zambia.
Topics: Adult; Amino Acid Sequence; Cloning, Molecular; Cyclohexanes; Drug Resistance, Viral; env Gene Products, Human Immunodeficiency Virus; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Male; Maraviroc; Molecular Sequence Data; Mutation, Missense; Piperazines; Pregnancy; Pyrimidines; Sequence Analysis, DNA; Triazoles; Young Adult; Zambia | 2013 |
A validated stability-indicating UPLC method for the determination of impurities in Maraviroc.
Topics: Chromatography, High Pressure Liquid; Cyclohexanes; Drug Contamination; Drug Stability; Limit of Detection; Linear Models; Maraviroc; Oxidation-Reduction; Reproducibility of Results; Triazoles | 2014 |
Structure and dynamics of the gp120 V3 loop that confers noncompetitive resistance in R5 HIV-1(JR-FL) to maraviroc.
Topics: Amino Acid Motifs; Amino Acid Sequence; Amino Acid Substitution; Cyclohexanes; Drug Resistance, Viral; HeLa Cells; HIV Core Protein p24; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV-1; Humans; Maraviroc; Molecular Dynamics Simulation; Molecular Sequence Data; Mutagenesis, Site-Directed; Protein Structure, Tertiary; Triazoles; Virus Replication | 2013 |
CCR5 and FPR1 mediate neutrophil recruitment in endotoxin-induced lung injury.
Topics: Acute Lung Injury; Animals; CCR5 Receptor Antagonists; Cell Movement; Cells, Cultured; Cyclohexanes; Cyclosporine; Humans; Lipopolysaccharides; Lung; Male; Maraviroc; Mice; Mice, Inbred C57BL; Mice, Knockout; Neutrophils; Receptors, CCR2; Receptors, CCR5; Receptors, Formyl Peptide; Triazoles | 2014 |
[Ophthalmological alterations at the initial diagnosis of HIV infection].
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Cyclohexanes; Deoxycytidine; Drug Therapy, Combination; Early Diagnosis; Emtricitabine; Eye Infections, Viral; HIV Infections; Humans; Lopinavir; Male; Maraviroc; Organophosphonates; Retinal Diseases; Syndrome; Tenofovir; Treatment Outcome; Triazoles; Zidovudine | 2014 |
Dissimilarities in the metabolism of antiretroviral drugs used in HIV pre-exposure prophylaxis in colon and vagina tissues.
Topics: Adult; Anti-HIV Agents; Chemoprevention; Colon; Cyclohexanes; Cytochrome P-450 Enzyme System; Female; Glucuronosyltransferase; HIV Infections; Humans; Isoenzymes; Male; Maraviroc; Mucous Membrane; Organ Specificity; Pyrimidines; Triazoles; Vagina; Young Adult | 2013 |
Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice: role of different tropism testing results and of concomitant treatments.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Peptide Fragments; Retrospective Studies; RNA, Viral; Survival; Triazoles; Viral Load; Viral Tropism | 2014 |
Validation of a fast method for quantitative analysis of elvitegravir, raltegravir, maraviroc, etravirine, tenofovir, boceprevir and 10 other antiretroviral agents in human plasma samples with a new UPLC-MS/MS technology.
Topics: Adenine; Anti-Retroviral Agents; Chromatography, High Pressure Liquid; Cyclohexanes; Humans; Maraviroc; Mass Spectrometry; Nitriles; Organophosphonates; Proline; Pyridazines; Pyrimidines; Pyrrolidinones; Quinolones; Raltegravir Potassium; Tandem Mass Spectrometry; Tenofovir; Time Factors; Triazoles | 2013 |
A reduced grade of liver fibro-steatosis after raltegravir, maraviroc and fosamprenavir in an HIV/HCV co-infected patient with chronic hepatitis, cardiomyopathy, intolerance to nelfinavir and a marked increase of serum creatine phosphokinase levels probab
Topics: Adult; Carbamates; Cardiomyopathies; Chemical and Drug Induced Liver Injury; Creatine Kinase; Cyclohexanes; Drug Substitution; Drug Therapy, Combination; Fatty Liver; Furans; Hepatitis C, Chronic; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Liver Cirrhosis; Male; Maraviroc; Organophosphates; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Triazoles | 2012 |
Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex.
Topics: Binding Sites; Cyclohexanes; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV-1; Humans; Ligands; Maraviroc; Protein Conformation; Receptors, CCR5; Receptors, CXCR4; Triazoles; Virus Internalization | 2013 |
Structural biology. A new bundle of prospects for blocking HIV-1 entry.
Topics: Cyclohexanes; HIV Fusion Inhibitors; HIV-1; Humans; Maraviroc; Receptors, CCR5; Triazoles; Virus Internalization | 2013 |
Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques: reduced replicating and latent SIV in the brain.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Brain; CCR5 Receptor Antagonists; Chemokine CCL2; Cyclohexanes; Enzyme-Linked Immunosorbent Assay; Immunohistochemistry; Macaca mulatta; Maraviroc; Plasma; Real-Time Polymerase Chain Reaction; Receptors, Cell Surface; RNA, Viral; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Triazoles; Tumor Necrosis Factor-alpha; Viral Load | 2013 |
HIV-1 coreceptor tropism in India: increasing proportion of X4-tropism in subtype C strains over two decades.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Child, Preschool; Cyclohexanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; India; Male; Maraviroc; Middle Aged; Polymorphism, Genetic; Receptors, HIV; Triazoles; Viral Tropism; Young Adult | 2014 |
Maraviroc attenuates trauma-hemorrhage-induced hepatic injury through PPAR gamma-dependent pathway in rats.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Cyclohexanes; Dose-Response Relationship, Drug; Gene Expression Regulation; Hemorrhage; Intercellular Adhesion Molecule-1; Interleukin-6; Liver; Male; Maraviroc; Peroxidase; PPAR gamma; Rats; Rats, Sprague-Dawley; Triazoles | 2013 |
Oral CCR5 inhibitors to prevent HIV transmission: the new "morning-before pill"?
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Epithelium; HIV Fusion Inhibitors; HIV Infections; Humans; Langerhans Cells; Male; Maraviroc; Receptors, CCR5; Triazoles | 2013 |
Frequency and predictors of HIV-1 co-receptor switch in treatment naive patients.
Topics: Anti-Retroviral Agents; CCR5 Receptor Antagonists; Cyclohexanes; Genotype; HIV-1; Humans; Maraviroc; Phylogeny; Receptors, CCR5; Receptors, CXCR4; Triazoles | 2013 |
The CCL5/CCR5 axis contributes to the perineural invasion of human salivary adenoid cystic carcinoma.
Topics: Carcinoma, Adenoid Cystic; CCR5 Receptor Antagonists; Cell Line, Tumor; Cell Movement; Chemokine CCL5; Cyclohexanes; Humans; Maraviroc; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Peripheral Nerves; Receptors, CCR5; Salivary Gland Neoplasms; Triazoles | 2014 |
Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection.
Topics: Cyclohexanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Mutation, Missense; Pyrrolidinones; Raltegravir Potassium; Treatment Failure; Triazoles; Viral Load | 2014 |
Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome.
Topics: Adult; Antibodies, Monoclonal, Humanized; CCR5 Receptor Antagonists; Cyclohexanes; Female; Humans; Immune Reconstitution Inflammatory Syndrome; Immunocompromised Host; JC Virus; Leukoencephalopathy, Progressive Multifocal; Maraviroc; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Receptors, CCR5; Triazoles; Viral Load | 2014 |
Innate immunity cell activation in virologically suppressed HIV-infected maraviroc-treated patients.
Topics: Adult; Anti-Retroviral Agents; Antigens, CD; Biomarkers; Case-Control Studies; Cross-Sectional Studies; Cyclohexanes; Female; HIV Infections; HLA Antigens; Humans; Killer Cells, Natural; Male; Maraviroc; Middle Aged; Monocytes; Treatment Outcome; Triazoles | 2014 |
A validated HPLC-MS method for quantification of the CCR5 inhibitor maraviroc in HIV+ human plasma.
Topics: Calibration; CCR5 Receptor Antagonists; Chromatography, High Pressure Liquid; Cyclohexanes; HIV Infections; Humans; Limit of Detection; Maraviroc; Mass Spectrometry; Receptors, CCR5; Reference Standards; Sensitivity and Specificity; Triazoles | 2014 |
Development and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma.
Topics: Calibration; CCR5 Receptor Antagonists; Chromatography, High Pressure Liquid; Cyclohexanes; HIV Fusion Inhibitors; Humans; Maraviroc; Reference Standards; Reproducibility of Results; Tandem Mass Spectrometry; Triazoles | 2014 |
Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting.
Topics: Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Male; Maraviroc; Middle Aged; Retrospective Studies; Ritonavir; RNA, Viral; Sulfonamides; Triazoles | 2014 |
Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides.
Topics: Administration, Intravaginal; Anti-Infective Agents, Local; Anti-Retroviral Agents; Cellulose; Cyclohexanes; Delayed-Action Preparations; Female; Gels; HIV Infections; HIV-1; Humans; Hydrophobic and Hydrophilic Interactions; Maraviroc; Silicone Elastomers; Triazoles; Vagina; Vaginal Creams, Foams, and Jellies | 2014 |
A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands.
Topics: Allosteric Regulation; Binding Sites; CCR5 Receptor Antagonists; Cyclohexanes; Dose-Response Relationship, Drug; Humans; Kinetics; Ligands; Maraviroc; Receptors, CCR5; Structure-Activity Relationship; Time Factors; Triazoles | 2014 |
Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD).
Topics: Animals; Cyclohexanes; Disease Models, Animal; Fatty Liver; Histocytochemistry; Liver; Liver Function Tests; Male; Maraviroc; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Triazoles | 2014 |
Maraviroc reduces the regulatory T-cell frequency in antiretroviral-naive HIV-infected subjects.
Topics: Adult; CD4 Lymphocyte Count; Cyclohexanes; Dose-Response Relationship, Drug; Female; Flow Cytometry; HIV Fusion Inhibitors; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Receptors, CCR5; Retrospective Studies; T-Lymphocytes, Regulatory; Triazoles | 2014 |
Reactivation of hepatitis B virus infection associated with maraviroc use in an HIV-infected patient.
Topics: Aged; Anti-HIV Agents; Cyclohexanes; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Male; Maraviroc; Triazoles; Virus Activation | 2014 |
CCR5 inhibition prevents cardiac dysfunction in the SIV/macaque model of HIV.
Topics: Animals; CCR5 Receptor Antagonists; Cyclohexanes; Diastole; Disease Models, Animal; Echocardiography, Doppler; Heart Ventricles; HIV Fusion Inhibitors; Ligands; Macaca mulatta; Maraviroc; Myocytes, Cardiac; Receptors, CCR5; Signal Transduction; Simian Acquired Immunodeficiency Syndrome; Triazoles; Ventricular Dysfunction; Ventricular Function; Viral Load | 2014 |
Potential anti-inflammatory effects of maraviroc in HIV-positive patients: a pilot study of inflammation, endothelial dysfunction, and coagulation markers.
Topics: Adult; Anti-Inflammatory Agents; Biomarkers; Case-Control Studies; CCR5 Receptor Antagonists; Cyclohexanes; Cytokines; Female; HIV Fusion Inhibitors; HIV Infections; Humans; Inflammation; Male; Maraviroc; Middle Aged; Pilot Projects; Thrombophilia; Triazoles | 2014 |
Integrated computational tools for identification of CCR5 antagonists as potential HIV-1 entry inhibitors: homology modeling, virtual screening, molecular dynamics simulations and 3D QSAR analysis.
Topics: Amino Acid Sequence; CCR5 Receptor Antagonists; Cyclohexanes; Drug Design; Drug Discovery; High-Throughput Screening Assays; HIV Fusion Inhibitors; HIV-1; Humans; Hydrophobic and Hydrophilic Interactions; Maraviroc; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Sequence Data; Principal Component Analysis; Protein Binding; Quantitative Structure-Activity Relationship; Receptors, CCR5; Small Molecule Libraries; Thermodynamics; Triazoles; User-Computer Interface; Virus Internalization | 2014 |
Molecular recognition of CCR5 by an HIV-1 gp120 V3 loop.
Topics: Amino Acid Motifs; Cyclohexanes; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV-1; Humans; Hydrogen Bonding; Maraviroc; Molecular Dynamics Simulation; Protein Binding; Protein Interaction Domains and Motifs; Protein Structure, Secondary; Receptors, CCR5; Receptors, CXCR4; Thermodynamics; Triazoles | 2014 |
Maraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+ T cell recovery and gene expression.
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cell Proliferation; Cyclohexanes; Female; Gene Expression; Gene Expression Profiling; HIV Infections; Humans; Male; Maraviroc; Microarray Analysis; Middle Aged; Treatment Outcome; Triazoles; Tumor Necrosis Factor-alpha; Viremia | 2014 |
HIV-2 viral tropism influences CD4+ T cell count regardless of viral load.
Topics: Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclohexanes; Female; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-2; Humans; Male; Maraviroc; Middle Aged; Peptide Fragments; RNA, Viral; Spain; Triazoles; Viral Load; Viral Tropism; Viremia | 2014 |
Impact of maraviroc-resistant and low-CCR5-adapted mutations induced by in vitro passage on sensitivity to anti-envelope neutralizing antibodies.
Topics: Anti-HIV Agents; Antibodies, Neutralizing; Cyclohexanes; Drug Resistance, Viral; env Gene Products, Human Immunodeficiency Virus; HIV Antibodies; HIV-1; Humans; Maraviroc; Molecular Sequence Data; Mutant Proteins; Mutation, Missense; Sequence Analysis, DNA; Serial Passage; Triazoles | 2014 |
Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Cyclohexanes; HIV Infections; Humans; Lopinavir; Male; Maraviroc; Middle Aged; Plasma; Ritonavir; Semen; Triazoles | 2014 |
Extravirologic modulation of immune response by an NRTI-sparing antiretroviral regimen including darunavir and maraviroc.
Topics: Anti-HIV Agents; Apoptosis; Cells, Cultured; Cyclohexanes; Darunavir; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Maraviroc; Neutrophils; Sulfonamides; Triazoles | 2014 |
Exposure to entry inhibitors alters HIV infectiousness and sensitivity to broadly neutralizing monoclonal antibodies.
Topics: Antibodies, Monoclonal; Cell Line; Cyclohexanes; Drug Synergism; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Maraviroc; Neutralization Tests; Regression Analysis; Triazoles; Virus Replication | 2014 |
Electrospun solid dispersions of Maraviroc for rapid intravaginal preexposure prophylaxis of HIV.
Topics: Administration, Intravaginal; Anti-HIV Agents; Anti-Infective Agents, Local; Cell Line; Cell Survival; Cyclohexanes; Electrochemical Techniques; Excipients; Female; HIV Infections; Humans; Kinetics; Maraviroc; Nanofibers; Polyethylene Glycols; Polysorbates; Povidone; Suspensions; Triazoles; Vaginal Creams, Foams, and Jellies; Wettability; Wetting Agents | 2014 |
Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy.
Topics: Adult; Alkynes; Area Under Curve; Benzoxazines; Cyclohexanes; Cyclopropanes; Drug Administration Schedule; Drug Substitution; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Reverse Transcriptase Inhibitors; Treatment Outcome; Triazoles; Viral Load | 2015 |
Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclohexanes; Cyclopropanes; Dideoxynucleosides; Feasibility Studies; Female; Humans; Male; Maraviroc; Middle Aged; Organophosphonates; Ritonavir; Tenofovir; Triazoles | 2014 |
CCR5 as a treatment target in pulmonary arterial hypertension.
Topics: Animals; CCR5 Receptor Antagonists; Cell Proliferation; Cells, Cultured; Cyclohexanes; Disease Models, Animal; Familial Primary Pulmonary Hypertension; HIV Fusion Inhibitors; HIV Infections; Humans; Hypertension, Pulmonary; Hypoxia; Macaca mulatta; Macrophages; Male; Maraviroc; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Smooth, Vascular; Pulmonary Artery; Receptors, CCR5; Simian Acquired Immunodeficiency Syndrome; Triazoles | 2014 |
Dual quantification of dapivirine and maraviroc in cervicovaginal secretions from ophthalmic tear strips and polyester-based swabs via liquid chromatographic-tandem mass spectrometric (LC-MS/MS) analysis.
Topics: Antiviral Agents; Calibration; Cervix Uteri; Chromatography, Liquid; Cyclohexanes; Female; Humans; Maraviroc; Polyesters; Pyrimidines; Reagent Strips; Tandem Mass Spectrometry; Triazoles; Vagina | 2014 |
HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.
Topics: Adenine; Animals; Anti-HIV Agents; Cyclohexanes; Disease Models, Animal; Female; HIV Infections; HIV-1; Humans; Maraviroc; Mice; Mucous Membrane; Organophosphonates; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Tenofovir; Triazoles; Virus Internalization | 2014 |
CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.
Topics: Adolescent; Adult; Aged; Area Under Curve; Base Sequence; Cyclohexanes; Cytochrome P-450 CYP3A; DNA Primers; Healthy Volunteers; Heterozygote; HIV Fusion Inhibitors; Homozygote; Humans; Maraviroc; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Triazoles; Young Adult | 2014 |
The utility of genotypic tropism testing in clinical practice.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; DNA, Viral; Drug Prescriptions; Female; Genotype; HIV Infections; HIV-1; Humans; London; Male; Maraviroc; Medical Audit; Practice Patterns, Physicians'; Retrospective Studies; RNA, Viral; Sequence Analysis, DNA; Triazoles; Viral Tropism | 2015 |
Ligand- and mutation-induced conformational selection in the CCR5 chemokine G protein-coupled receptor.
Topics: Binding Sites; Crystallography, X-Ray; Cyclohexanes; Humans; Ligands; Maraviroc; Models, Molecular; Mutant Proteins; Mutation; Protein Structure, Secondary; Receptors, CCR5; Structural Homology, Protein; Thermodynamics; Triazoles | 2014 |
Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasis.
Topics: Aminosalicylic Acids; Animals; Antibodies, Neutralizing; Benzenesulfonates; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CCL5; Culture Media, Conditioned; Cyclohexanes; Female; Gene Expression; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Interleukin-6; Lung; Lymph Nodes; Lymphatic Metastasis; Lymphatic Vessels; Maraviroc; MCF-7 Cells; Mice; Mice, Nude; Neoplasm Transplantation; STAT3 Transcription Factor; Transplantation, Heterologous; Triazoles; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A | 2014 |
Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associa
Topics: Acquired Immunodeficiency Syndrome; Aged; AIDS Dementia Complex; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cognition; Cyclohexanes; Disease Management; Female; Gene Expression; GPI-Linked Proteins; HIV-1; Humans; Leukocyte Count; Male; Maraviroc; Middle Aged; Monocytes; Neuropsychological Tests; Receptors, CCR5; Receptors, IgG; Triazoles; Viral Load | 2014 |
Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-Retroviral Agents; Benzoxazines; Clinical Trials as Topic; Computer Simulation; Cyclohexanes; Cyclopropanes; Dose-Response Relationship, Drug; Female; HIV Fusion Inhibitors; Humans; In Vitro Techniques; Male; Maraviroc; Middle Aged; Models, Biological; Nevirapine; Reverse Transcriptase Inhibitors; Triazoles; Young Adult | 2015 |
HIV-2 X4 tropism is associated with lower CD4+ cell count in treatment-experienced patients.
Topics: CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Disease Progression; Drug Resistance, Viral; Genotype; HIV Infections; HIV-2; Humans; Maraviroc; Prevalence; Receptors, CCR5; Retrospective Studies; Triazoles; Viral Load; Viral Tropism | 2014 |
Synergistic combinations of the CCR5 inhibitor VCH-286 with other classes of HIV-1 inhibitors.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Cyclohexanes; Drug Antagonism; Drug Combinations; Drug Synergism; Gene Expression; HIV-1; Humans; Leukocytes, Mononuclear; Maraviroc; Microbial Sensitivity Tests; Piperazines; Pyrimidines; Receptors, CCR5; Reverse Transcriptase Inhibitors; Spiro Compounds; Triazoles; Tropanes; Virus Replication | 2014 |
Complexity and dynamics of HIV-1 chemokine receptor usage in a multidrug-resistant adolescent.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemokine CCL5; Cyclohexanes; Darunavir; Drug Resistance, Multiple, Viral; Heterocyclic Compounds, 3-Ring; HIV Envelope Protein gp120; HIV Reverse Transcriptase; HIV-1; Humans; Maraviroc; Oxazines; Peptide Fragments; Phylogeny; Piperazines; Pyridones; Receptors, CCR5; Receptors, CXCR4; Ritonavir; Sulfonamides; Triazoles; Viral Load; Viral Tropism | 2014 |
Computational study on the interaction between CCR5 and HIV-1 entry inhibitor maraviroc: insight from accelerated molecular dynamics simulation and free energy calculation.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; HIV Infections; HIV-1; Humans; Hydrogen Bonding; Maraviroc; Models, Molecular; Molecular Dynamics Simulation; Protein Conformation; Receptors, CCR5; Thermodynamics; Triazoles | 2014 |
Treatment. Maraviroc dosing not effective in half of blacks.
Topics: Black People; Cyclohexanes; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Triazoles | 2014 |
The effects of CCR5 inhibition on regulatory T-cell recruitment to colorectal cancer.
Topics: Animals; Antineoplastic Agents; CCR5 Receptor Antagonists; Cell Line, Tumor; Cell Proliferation; Chemokine CCL4; Chemotaxis, Leukocyte; Colorectal Neoplasms; Cyclohexanes; Drug Screening Assays, Antitumor; Female; Humans; Maraviroc; Melanoma, Experimental; Mice, Inbred BALB C; Neoplasm Transplantation; Receptors, CCR5; T-Lymphocytes, Regulatory; Triazoles | 2015 |
Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response.
Topics: Adult; Aged; Anti-Retroviral Agents; Cyclohexanes; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; RNA, Viral; Treatment Outcome; Triazoles; Viral Load; Young Adult | 2015 |
Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc.
Topics: CD4 Antigens; Cell Line; Cyclohexanes; HIV Antibodies; HIV Envelope Protein gp120; HIV-1; Humans; Immunoglobulin G; Maraviroc; Microscopy, Confocal; Protein Binding; Receptors, CCR5; Recombinant Fusion Proteins; Single-Chain Antibodies; Triazoles; Virus Internalization | 2014 |
Models for predicting effective HIV chemoprevention in women.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Cell Culture Techniques; Cell Survival; Chemoprevention; Chromatography, Liquid; Cyclohexanes; Disease Transmission, Infectious; Dose-Response Relationship, Drug; Female; HIV Infections; Humans; Maraviroc; Middle Aged; Organ Culture Techniques; Organophosphonates; Tandem Mass Spectrometry; Tenofovir; Triazoles; Vagina; Viral Load; Young Adult | 2015 |
Multiplex detection of functional G protein-coupled receptors harboring site-specifically modified unnatural amino acids.
Topics: Amino Acids; Azides; Cyclohexanes; Epitopes; Fluorescent Dyes; HEK293 Cells; Humans; Immunoassay; Maraviroc; Models, Molecular; Mutagenesis, Site-Directed; Mutation; Phenylalanine; Receptors, CCR5; Triazoles | 2015 |
Prophylaxis of acute graft-versus-host disease by CCR5 blockade combined with cyclosporine A in a murine model.
Topics: Animals; CCR5 Receptor Antagonists; Cyclohexanes; Cyclosporine; Cytokines; Disease Models, Animal; Drug Synergism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Immunosuppressive Agents; Intestines; Liver; Male; Maraviroc; Mice, Inbred BALB C; Mice, Inbred C57BL; Receptors, CCR5; Receptors, CCR7; Receptors, CXCR3; Triazoles | 2015 |
Therapeutic use of CCR5 antagonists is supported by strong expression of CCR5 on CD8(+) T cells in progressive multifocal leukoencephalopathy-associated immune reconstitution inflammatory syndrome.
Topics: Anti-Retroviral Agents; CCR5 Receptor Antagonists; CD8-Positive T-Lymphocytes; Cyclohexanes; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Leukoencephalopathy, Progressive Multifocal; Maraviroc; Microscopy, Confocal; Receptors, CCR5; Triazoles | 2015 |
High CCR5 expression in natalizumab-associated progressive multifocal leukoencephalopathy immune reconstitution inflammatory syndrome supports treatment with the CCR5 inhibitor maraviroc.
Topics: B-Lymphocytes; CCR5 Receptor Antagonists; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclohexanes; Humans; Immune Reconstitution Inflammatory Syndrome; Leukoencephalopathy, Progressive Multifocal; Maraviroc; Multiple Sclerosis; Natalizumab; Receptors, CCR5; Triazoles | 2015 |
Antiretroviral blood levels in HIV/HCV-coinfected patients with cirrhosis after liver transplant: a report of three cases.
Topics: Anti-Retroviral Agents; Coinfection; Cyclohexanes; Darunavir; Drug Monitoring; Female; Hepatitis C; HIV Infections; Humans; Liver Cirrhosis; Liver Transplantation; Male; Maraviroc; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Triazoles | 2015 |
Virological failure of patients on maraviroc-based antiretroviral therapy.
Topics: Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Retrospective Studies; Treatment Failure; Triazoles; Viral Load; Viral Tropism | 2015 |
Reliable genotypic tropism tests for the major HIV-1 subtypes.
Topics: Algorithms; Amino Acid Sequence; CCR5 Receptor Antagonists; Computational Biology; Cyclohexanes; Genotype; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Maraviroc; Mutation; Peptide Fragments; Phenotype; Receptors, CCR5; Triazoles; Viral Tropism | 2015 |
Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremia.
Topics: Anti-HIV Agents; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclohexanes; Female; HIV Infections; Humans; Lymphocyte Activation; Male; Maraviroc; Middle Aged; Monocytes; Raltegravir Potassium; RNA, Viral; Treatment Outcome; Triazoles; Viral Load; Viremia | 2015 |
Structural biology. Structural basis for chemokine recognition and activation of a viral G protein-coupled receptor.
Topics: CCR5 Receptor Antagonists; Chemokine CX3CL1; Crystallography, X-Ray; Cyclohexanes; Humans; Ligands; Maraviroc; Piperidines; Protein Binding; Protein Structure, Secondary; Protein Structure, Tertiary; Receptors, Chemokine; Receptors, CXCR4; Triazoles; Viral Proteins | 2015 |
A prospective evaluation of maraviroc administration in patients with advanced HIV disease and multiple comorbidities: focus on efficacy and tolerability issues.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Comorbidity; Cyclohexanes; Female; Follow-Up Studies; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Prospective Studies; Treatment Outcome; Triazoles; Viral Load | 2015 |
CCR5 blockage by maraviroc induces cytotoxic and apoptotic effects in colorectal cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Cyclohexanes; G1 Phase; Humans; Maraviroc; Receptors, CCR5; RNA, Messenger; Signal Transduction; Triazoles | 2015 |
Triple combination of carbosilane dendrimers, tenofovir and maraviroc as potential microbicide to prevent HIV-1 sexual transmission.
Topics: Adenine; Animals; Anti-HIV Agents; Anti-Infective Agents; Antiviral Agents; Cell Survival; Cyclohexanes; Dendrimers; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Maraviroc; Mice; Mice, Inbred BALB C; Mucous Membrane; Organophosphonates; Silanes; Software; Tenofovir; Triazoles; Vagina | 2015 |
Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
Topics: 3T3 Cells; Animals; Antiviral Agents; Benzylamines; Cell Death; Cell Line; Cyclams; Cyclohexanes; Flow Cytometry; Heterocyclic Compounds; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Membrane Fusion; Mice; Receptors, CCR5; Receptors, CXCR4; Triazoles; Virus Internalization; Virus Replication | 2015 |
The integration of solid-form informatics into solid-form selection.
Topics: Analgesics; Chemistry, Pharmaceutical; Crizotinib; Crystallization; Cyclohexanes; Databases, Factual; Drug Stability; Humans; Hydrogen Bonding; Informatics; Maraviroc; Molecular Conformation; Pharmaceutical Preparations; Pyrazoles; Pyridines; Technology, Pharmaceutical; Triazoles | 2015 |
Preclinical discovery and development of maraviroc for the treatment of HIV.
Topics: Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Maraviroc; Triazoles | 2015 |
Development of maraviroc, a CCR5 antagonist for treatment of HIV, using a novel tropism assay.
Topics: Anti-HIV Agents; Biological Assay; Clinical Trials as Topic; Cyclohexanes; Drug Design; Drug Evaluation, Preclinical; HIV Infections; HIV-1; Humans; Maraviroc; Receptors, CCR5; Triazoles; Viral Tropism | 2015 |
Ineffective central nervous system HIV suppression of once-a-day maraviroc and ritonavir-boosted darunavir dual therapy: four case reports.
Topics: Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Darunavir; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Maraviroc; Middle Aged; Nervous System; Ritonavir; RNA, Viral; Treatment Outcome; Triazoles; Viral Load | 2016 |
Parameters Influencing Baseline HIV-1 Genotypic Tropism Testing Related to Clinical Outcome in Patients on Maraviroc.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cyclohexanes; Female; Genes, Viral; Genetic Association Studies; Genotype; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Treatment Outcome; Triazoles; Viral Tropism; Young Adult | 2015 |
Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Retrospective Studies; RNA, Viral; Salvage Therapy; Treatment Outcome; Triazoles; Viral Load | 2015 |
Experimental design of complement component 5a-induced acute lung injury (C5a-ALI): a role of CC-chemokine receptor type 5 during immune activation by anaphylatoxin.
Topics: Acute Lung Injury; Animals; CCR5 Receptor Antagonists; Complement Activation; Complement C3a; Complement C5a, des-Arginine; Cyclohexanes; Leukocytes; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Maraviroc; Mice; Mice, Knockout; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pulmonary Alveoli; Receptor, Anaphylatoxin C5a; Receptors, CCR5; Triazoles | 2015 |
Clinical and immunologic effects of maraviroc in progressive multifocal leukoencephalopathy.
Topics: Aged; CCR5 Receptor Antagonists; CD4-Positive T-Lymphocytes; Cyclohexanes; Female; Humans; Leukoencephalopathy, Progressive Multifocal; Male; Maraviroc; Middle Aged; Treatment Outcome; Triazoles | 2015 |
The efficacy and safety of maraviroc addition to a stable antiretroviral regimen in subjects with suppressed plasma HIV-RNA is not influenced by age.
Topics: Adult; Age Factors; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; Cyclohexanes; HIV; HIV Infections; Humans; Maraviroc; Middle Aged; Multivariate Analysis; Retrospective Studies; RNA, Viral; Treatment Outcome; Triazoles; Viral Load | 2015 |
HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc.
Topics: Adult; Algorithms; Antiretroviral Therapy, Highly Active; Area Under Curve; Cyclohexanes; Female; High-Throughput Nucleotide Sequencing; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Peptide Fragments; RNA, Viral; ROC Curve; Sequence Analysis, RNA; Software; Triazoles; Viral Tropism | 2015 |
Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir.
Topics: Administration, Topical; Animals; Anti-HIV Agents; Cross-Over Studies; Cyclohexanes; Disease Models, Animal; Disease Transmission, Infectious; Gels; Macaca; Maraviroc; Placebos; Simian Acquired Immunodeficiency Syndrome; Tenofovir; Treatment Outcome; Triazoles | 2015 |
Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 Prevention.
Topics: Administration, Topical; Anti-HIV Agents; Cell Survival; Cervix Uteri; Colon; Cyclohexanes; Drug Combinations; Drug Liberation; Female; Gels; HIV Fusion Inhibitors; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; In Vitro Techniques; Maraviroc; Mucous Membrane; Pyrimidines; Rectum; Rheology; Triazoles | 2015 |
A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.
Topics: Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; HIV Envelope Protein gp120; HIV-1; Humans; Maraviroc; Mutant Proteins; Mutation, Missense; Protein Binding; Receptors, CCR5; Receptors, HIV; Triazoles; Virus Internalization; Virus Replication | 2015 |
Maraviroc Clinical Test (MCT) as an alternative tool to decide CCR5-antagonists prescription in naïve HIV-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; Cyclohexanes; Female; Genotype; Genotyping Techniques; HIV; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Retrospective Studies; RNA, Viral; Time Factors; Treatment Outcome; Triazoles; Viral Load; Viral Tropism; Young Adult | 2015 |
Impact of the Maraviroc-Resistant Mutation M434I in the C4 Region of HIV-1 gp120 on Sensitivity to Antibody-Mediated Neutralization.
Topics: Antibodies, Monoclonal; Antibodies, Neutralizing; Antibodies, Viral; CD4-Positive T-Lymphocytes; Cell Line; Cyclohexanes; Drug Resistance, Viral; Gene Expression; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Immune Sera; Immunoglobulin G; Maraviroc; Mutation; Neutralization Tests; Receptors, CCR5; Triazoles | 2016 |
Beneficial properties of maraviroc on neuropathic pain development and opioid effectiveness in rats.
Topics: Analgesics, Opioid; Animals; Astrocytes; Buprenorphine; CCR5 Receptor Antagonists; Cells, Cultured; Chronic Disease; Cyclohexanes; Cytokines; Disease Models, Animal; Drug Synergism; Ganglia, Spinal; Hyperalgesia; Lipopolysaccharides; Male; Maraviroc; Microglia; Morphine; Neuralgia; Rats, Wistar; Sciatic Nerve; Spinal Cord; Triazoles | 2016 |
Maraviroc modifies gut microbiota composition in a mouse model of obesity: a plausible therapeutic option to prevent metabolic disorders in HIV-infected patients.
Topics: Animals; Bacterial Translocation; Bacteroidetes; CCR5 Receptor Antagonists; Cecum; Cyclohexanes; Diet, High-Fat; Drug Evaluation, Preclinical; Firmicutes; HIV Fusion Inhibitors; HIV Infections; Humans; Insulin Resistance; Male; Maraviroc; Metabolic Diseases; Mice; Mice, Inbred C57BL; Microbiota; Non-alcoholic Fatty Liver Disease; Obesity; Proteobacteria; Random Allocation; Species Specificity; Triazoles; Weight Gain | 2015 |
Metastasis Suppressors Regulate the Tumor Microenvironment by Blocking Recruitment of Prometastatic Tumor-Associated Macrophages.
Topics: Animals; Cell Line, Tumor; Chemokine CCL5; Chemokines; Chemotaxis; Cyclohexanes; Disease-Free Survival; Female; Gene Expression Profiling; Gene Knockdown Techniques; Heterografts; HMGA2 Protein; Humans; Macrophages; Mammary Neoplasms, Experimental; Maraviroc; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neoplasm Metastasis; Neoplasm Proteins; Phosphatidylethanolamine Binding Protein; Receptors, CCR5; RNA, Messenger; RNA, Neoplasm; Sequence Analysis, RNA; Triazoles; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2015 |
Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Cells, Cultured; Coculture Techniques; Cyclohexanes; HIV Infections; HIV-2; Humans; Imidazoles; Leukocytes, Mononuclear; Maraviroc; Phenotype; Phytohemagglutinins; Receptors, CCR2; Receptors, CCR5; Sulfoxides; Triazoles; Virus Replication | 2015 |
Investigation of Inhibition Mechanism of Chemokine Receptor CCR5 by Micro-second Molecular Dynamics Simulations.
Topics: Algorithms; Cluster Analysis; Cyclohexanes; Humans; Hydrogen Bonding; Ligands; Maraviroc; Molecular Dynamics Simulation; Principal Component Analysis; Protein Structure, Secondary; Protein Structure, Tertiary; Receptors, CCR5; Time Factors; Triazoles; Virus Internalization | 2015 |
Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.
Topics: Amino Acid Sequence; Base Sequence; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Drug Resistance, Viral; Glycosylation; HIV Envelope Protein gp120; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Molecular Sequence Data; Protein Structure, Tertiary; Receptors, CCR5; Receptors, CXCR4; Sequence Alignment; Sequence Analysis, RNA; Signal Transduction; Treatment Failure; Triazoles; Virus Internalization; Virus Replication | 2015 |
Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Cell Line; Cyclohexanes; Drug Synergism; Flow Cytometry; HIV Infections; HIV-1; Humans; Immunoglobulin G; Maraviroc; Receptors, CCR5; Receptors, CXCR4; Recombinant Fusion Proteins; Triazoles; Virus Internalization | 2016 |
Role of Semen on Vaginal HIV-1 Transmission and Maraviroc Protection.
Topics: Administration, Intravaginal; Animals; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cyclohexanes; Disease Models, Animal; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Mice; Mice, Transgenic; Semen; Triazoles; Vagina; Viral Load | 2015 |
Mucosal Topical Microbicide Candidates Exert Influence on the Subsequent SIV Infection and Survival by Regulating SIV-Specific T-Cell Immune Responses.
Topics: Administration, Rectal; Animals; Anti-Infective Agents, Local; CD4-Positive T-Lymphocytes; Cyclohexanes; Disease Progression; Gene Expression Profiling; Humans; Immunity, Cellular; Macaca mulatta; Maraviroc; Mucous Membrane; Oligonucleotide Array Sequence Analysis; Peptides; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Survival Rate; Tenofovir; Triazoles; Viral Load | 2016 |
Antiretroviral drugs do not interfere with bryostatin-mediated HIV-1 latency reversal.
Topics: Adult; Anti-Retroviral Agents; Bryostatins; CD4-Positive T-Lymphocytes; Cells, Cultured; Cyclohexanes; Drug Interactions; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV-1; Humans; Male; Maraviroc; Middle Aged; Triazoles; Virus Latency | 2015 |
Reduced Baseline Sensitivity to Maraviroc Inhibition Among R5 HIV-1 Isolates From Individuals With Severe Immunodeficiency.
Topics: Acquired Immunodeficiency Syndrome; CCR5 Receptor Antagonists; Cyclohexanes; Drug Resistance, Viral; env Gene Products, Human Immunodeficiency Virus; HIV-1; Humans; Maraviroc; Mutation; Triazoles | 2016 |
Differences in the variability of cerebral proton magnetic resonance spectroscopy (1H-MRS) measurements within three HIV-infected cohorts.
Topics: Adult; Antiretroviral Therapy, Highly Active; Aspartic Acid; Basal Ganglia; Brain; Brain Chemistry; Cohort Studies; Creatine; Cyclohexanes; Female; Hepatitis C; HIV Fusion Inhibitors; HIV Infections; Humans; Inositol; Magnetic Resonance Imaging; Male; Maraviroc; Middle Aged; Proton Magnetic Resonance Spectroscopy; Protons; Triazoles; Young Adult | 2015 |
Single oral dose of maraviroc does not prevent ex-vivo HIV infection of rectal mucosa in HIV-1 negative human volunteers.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Biopsy; Cyclohexanes; Healthy Volunteers; HIV Infections; HIV-1; Humans; Intestinal Mucosa; Maraviroc; Models, Biological; Organoids; Treatment Failure; Triazoles | 2015 |
Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Off-Label Use; Retrospective Studies; Salvage Therapy; Treatment Outcome; Triazoles; Viral Load; Young Adult | 2015 |
Involvement of CCL3/CCR5 Signaling in Dorsal Root Ganglion in Remifentanil-induced Hyperalgesia in Rats.
Topics: Analgesics, Opioid; Animals; CCR5 Receptor Antagonists; Chemokine CCL3; Cyclohexanes; Disease Models, Animal; Ganglia, Spinal; Hot Temperature; Hyperalgesia; Male; Maraviroc; Piperidines; Rats, Sprague-Dawley; Receptors, CCR5; Remifentanil; RNA, Messenger; Touch; Triazoles | 2016 |
Clinical outcome of maraviroc-containing therapy in heavily pre-treated HIV-1-infected patients.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cyclohexanes; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Retrospective Studies; Treatment Outcome; Triazoles; Viral Load; Viral Tropism; Young Adult | 2016 |
Position-specific automated processing of V3 env ultra-deep pyrosequencing data for predicting HIV-1 tropism.
Topics: Amino Acid Sequence; Cyclohexanes; Genotype; High-Throughput Nucleotide Sequencing; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Host-Pathogen Interactions; Humans; Maraviroc; Molecular Sequence Data; Peptide Fragments; Phenotype; Point Mutation; Receptors, CCR5; Receptors, CXCR4; Reproducibility of Results; Triazoles; Viral Tropism | 2015 |
Antiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activation.
Topics: Adult; Antiretroviral Therapy, Highly Active; Biomarkers; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Lymphocyte Activation; Macrophages; Male; Maraviroc; Middle Aged; Monocytes; Triazoles; Viral Load | 2016 |
CCL5 derived from platelets increases megakaryocyte proplatelet formation.
Topics: Animals; Blood Platelets; Chemokine CCL5; Cyclohexanes; Humans; Maraviroc; Megakaryocytes; Mice; Receptors, CCR5; Signal Transduction; Triazoles | 2016 |
Is there a role for maraviroc to treat HIV-associated central nervous system white matter disease?
Topics: Anti-HIV Agents; Cyclohexanes; HIV Infections; Humans; Infant; Infant, Newborn; Leukoencephalopathies; Male; Maraviroc; Treatment Outcome; Triazoles | 2016 |
Short Communication: Limited Anti-HIV-1 Activity of Maraviroc in Mucosal Tissues.
Topics: Anti-HIV Agents; Cells, Cultured; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Maraviroc; Models, Biological; Mucous Membrane; Organ Culture Techniques; Treatment Outcome; Triazoles | 2016 |
Durability and Effectiveness of Maraviroc-Containing Regimens in HIV-1-Infected Individuals with Virological Failure in Routine Clinical Practice.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cyclohexanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Treatment Outcome; Triazoles; Viral Load | 2015 |
No selection of CXCR4-using variants in cell reservoirs of dual-mixed HIV-infected patients on suppressive maraviroc therapy.
Topics: Anti-HIV Agents; Cyclohexanes; Genotype; High-Throughput Nucleotide Sequencing; HIV; HIV Infections; Humans; Leukocytes, Mononuclear; Maraviroc; Selection, Genetic; Triazoles; Viral Tropism | 2016 |
A Rapid Screening Assay Identifies Monotherapy with Interferon-ß and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola Virus.
Topics: Antiviral Agents; CCR5 Receptor Antagonists; Cyclohexanes; Ebolavirus; Humans; Interferon-beta; Maraviroc; Nucleosides; Toremifene; Triazoles; Virus Replication | 2016 |
Maraviroc contributes to the restoration of the homeostasis of regulatory T-cell subsets in antiretroviral-naive HIV-infected subjects.
Topics: CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Forkhead Transcription Factors; HIV Infections; Homeostasis; Humans; Immunophenotyping; Leukocyte Common Antigens; Longitudinal Studies; Maraviroc; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Triazoles | 2016 |
Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates.
Topics: Anti-HIV Agents; Cells, Cultured; Chemoprevention; Cyclohexanes; Disease Transmission, Infectious; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Maraviroc; Models, Biological; Organ Culture Techniques; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Triazoles | 2016 |
Biophysical characterization of small molecule antiviral-loaded nanolipogels for HIV-1 chemoprophylaxis and topical mucosal application.
Topics: Administration, Topical; Animals; Anti-HIV Agents; Biophysical Phenomena; Body Fluids; Cell Line; Cell Survival; Chemoprevention; Cryoelectron Microscopy; Cyclohexanes; Detergents; Drug Liberation; Female; HIV-1; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate; Lipid Bilayers; Liposomes; Maraviroc; Mice, Inbred C57BL; Mucous Membrane; Nanoparticles; Small Molecule Libraries; Tenofovir; Triazoles | 2016 |
A comparison of two post-processing analysis methods to quantify cerebral metabolites measured via proton magnetic resonance spectroscopy in HIV disease.
Topics: Biomarkers; Brain; Brain Diseases; CCR5 Receptor Antagonists; Cyclohexanes; HIV Infections; Humans; Maraviroc; Proton Magnetic Resonance Spectroscopy; Triazoles | 2016 |
Immune Responses to HIV.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Cytomegalovirus; Hepacivirus; HIV Antibodies; HIV Infections; HIV-1; Humans; Maraviroc; Receptors, CCR5; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Triazoles | 2016 |
Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design.
Topics: Adult; Anti-HIV Agents; Biomarkers; Body Fluids; Cervix Uteri; Clinical Trials as Topic; Cyclohexanes; Emtricitabine; Female; Healthy Volunteers; Humans; Maraviroc; Raltegravir Potassium; Rectum; Tenofovir; Triazoles; Vagina | 2016 |
HIV-1 adaptation to low levels of CCR5 results in V3 and V2 loop changes that increase envelope pathogenicity, CCR5 affinity and decrease susceptibility to Maraviroc.
Topics: Adaptation, Physiological; Anti-HIV Agents; Cell Line; Cyclohexanes; Drug Resistance, Viral; HeLa Cells; HIV Envelope Protein gp120; HIV-1; Humans; Inverted Repeat Sequences; Maraviroc; Models, Molecular; Protein Conformation; Receptors, CCR5; T-Lymphocytes; Triazoles; Virulence; Virus Replication | 2016 |
Reduced Frequencies and Activation of Regulatory T Cells After the Treatment of HIV-1-Infected Individuals with the CCR5 Antagonist Maraviroc Are Associated with a Reduction in Viral Loads Rather Than a Direct Effect of the Drug on Regulatory T Cells.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Receptors, CCR5; T-Lymphocytes, Regulatory; Triazoles; Viral Load; Virus Replication | 2016 |
Coaxially electrospun fiber-based microbicides facilitate broadly tunable release of maraviroc.
Topics: Anti-HIV Agents; Anti-Infective Agents; Cell Line; Cell Survival; Cellulose; Cyclohexanes; Drug Carriers; Drug Liberation; Humans; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Maraviroc; Microscopy, Electron, Scanning; Photoelectron Spectroscopy; Povidone; Surface Properties; Triazoles | 2016 |
Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model.
Topics: Administration, Intravaginal; Animals; Anti-HIV Agents; Contraceptive Devices, Female; Cyclohexanes; Delayed-Action Preparations; Drug Combinations; Female; HIV Infections; Humans; Maraviroc; Models, Animal; Primary Prevention; Sheep; Tenofovir; Triazoles; Vagina | 2016 |
Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients.
Topics: Adenocarcinoma; Apoptosis; Chemokine CCL5; Chemokines; Chemotaxis; Clinical Trials, Phase I as Topic; Clodronic Acid; Colorectal Neoplasms; Cyclohexanes; Humans; Interferon-alpha; Liver Neoplasms; Lung Neoplasms; Lymphocytes, Tumor-Infiltrating; Macrophages; Maraviroc; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Proteins; NG-Nitroarginine Methyl Ester; Phenylurea Compounds; Pilot Projects; Pyridines; Receptors, CCR5; STAT3 Transcription Factor; Survival Analysis; Triazoles; Tumor Cells, Cultured; Tumor Microenvironment | 2016 |
Maraviroc reduces neuropathic pain through polarization of microglia and astroglia - Evidence from in vivo and in vitro studies.
Topics: Animals; Astrocytes; CCR5 Receptor Antagonists; Cyclohexanes; Inflammation Mediators; Male; Maraviroc; Microglia; Neuralgia; Pain Measurement; Rats; Rats, Wistar; Triazoles | 2016 |
Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients.
Topics: Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Treatment Outcome; Triazoles; Viral Load | 2016 |
Simultaneous measurement of etravirine, maraviroc and raltegravir in pigtail macaque plasma, vaginal secretions and vaginal tissue using a LC-MS/MS assay.
Topics: Animals; Anti-HIV Agents; Bodily Secretions; Chromatography, Liquid; Cyclohexanes; Female; Limit of Detection; Linear Models; Macaca nemestrina; Maraviroc; Nitriles; Pyridazines; Pyrimidines; Raltegravir Potassium; Reproducibility of Results; Tandem Mass Spectrometry; Triazoles; Vagina | 2016 |
Blockade of the chemokine receptor, CCR5, reduces the growth of orthotopically injected colon cancer cells via limiting cancer-associated fibroblast accumulation.
Topics: Animals; CCR5 Receptor Antagonists; Cell Line, Tumor; Colonic Neoplasms; Cyclohexanes; Female; Fibroblasts; Humans; Male; Maraviroc; Mice; Mice, Inbred BALB C; NIH 3T3 Cells; Receptors, CCR5; Triazoles | 2016 |
Maraviroc Reduces Arterial Stiffness in PI-Treated HIV-infected Patients.
Topics: Atherosclerosis; Carotid Intima-Media Thickness; Case-Control Studies; Cyclohexanes; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Male; Maraviroc; Risk Factors; Treatment Outcome; Triazoles; Vascular Stiffness | 2016 |
Prevention. Raltegravir, maraviroc show promise as PrEP drugs in studies.
Topics: Cyclohexanes; HIV Infections; Humans; Maraviroc; Raltegravir Potassium; Triazoles | 2016 |
CCR5 blockade combined with cyclosporine A attenuates liver GVHD by impairing T cells function.
Topics: Animals; CCR5 Receptor Antagonists; Cyclohexanes; Cyclosporine; Cytokines; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Immunosuppressive Agents; Liver; Male; Maraviroc; Mice, Inbred BALB C; Mice, Inbred C57BL; Receptors, CCR5; T-Lymphocytes; Triazoles | 2016 |
Validation of the HIV Tropism Test TROCAI Using the Virological Response to a Short-Term Maraviroc Monotherapy Exposure.
Topics: Cyclohexanes; HIV; HIV Fusion Inhibitors; Humans; Inhibitory Concentration 50; Maraviroc; Triazoles; Viral Tropism; Virology | 2016 |
Highly specific blockade of CCR5 inhibits leukocyte trafficking and reduces mucosal inflammation in murine colitis.
Topics: Animals; CD11b Antigen; CD4-Positive T-Lymphocytes; Chemokine CCL5; Chemokines; Colitis; Colon; Cyclohexanes; Dextran Sulfate; Disease Models, Animal; Homeodomain Proteins; Inflammation; Intestinal Mucosa; Leukocytes; Maraviroc; Mice; Mice, Inbred C57BL; Mice, Knockout; Th17 Cells; Triazoles; Trinitrobenzenesulfonic Acid; Up-Regulation | 2016 |
A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses.
Topics: Acute Disease; Child; Child, Preschool; Cyclohexanes; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Maraviroc; Premedication; Prospective Studies; Receptors, CCR5; Transplantation Conditioning; Treatment Outcome; Triazoles; Viscera | 2016 |
Maraviroc-Mediated Lung Protection following Trauma-Hemorrhagic Shock.
Topics: Anilides; Animals; Cyclohexanes; Lung Injury; Male; Maraviroc; Rats; Rats, Sprague-Dawley; Shock, Hemorrhagic; Triazoles; Wounds and Injuries | 2016 |
Development and validation of a liquid chromatographic-tandem mass spectrometric method for the multiplexed quantification of etravirine, maraviroc, raltegravir, and rilpivirine in human plasma and tissue.
Topics: Chromatography, Liquid; Cyclohexanes; Humans; Maraviroc; Nitriles; Pyridazines; Pyrimidines; Raltegravir Potassium; Reproducibility of Results; Rilpivirine; Tandem Mass Spectrometry; Triazoles | 2016 |
Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization.
Topics: Anti-HIV Agents; Cyclohexanes; Dimerization; Dose-Response Relationship, Drug; HIV Infections; HIV-1; Humans; Ligands; Maraviroc; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Naltrexone; Receptors, CCR5; Receptors, Opioid, mu; Structure-Activity Relationship; Triazoles | 2016 |
Maraviroc ameliorates the increased adipose tissue macrophage recruitment induced by a high-fat diet in a mouse model of obesity.
Topics: Adipose Tissue; Animals; Anti-HIV Agents; CCR5 Receptor Antagonists; Chemokine CCL2; Cyclohexanes; Cytokines; Diet, High-Fat; Disease Models, Animal; Gene Expression Regulation; Humans; Insulin Resistance; Macrophages; Male; MAP Kinase Kinase 4; Maraviroc; Mice; Mice, Inbred C57BL; Obesity; Triazoles; Weight Gain | 2017 |
Addition of maraviroc to antiretroviral therapy decreased interferon-γ mRNA in the CD4+ T cells of patients with suboptimal CD4+ T-cell recovery.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Interferon-gamma; Leukocytes, Mononuclear; Male; Maraviroc; Middle Aged; RNA, Messenger; RNA, Viral; Triazoles; Viral Load | 2017 |
Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.
Topics: Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; CD4 Antigens; Cyclohexanes; HEK293 Cells; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Maraviroc; Mutagenesis; Peptide Fragments; Receptors, CCR5; Triazoles; Virus Internalization | 2016 |
Cancer cell CCL5 mediates bone marrow independent angiogenesis in breast cancer.
Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; CCR5 Receptor Antagonists; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CCL5; Culture Media, Conditioned; Cyclohexanes; Endothelial Cells; Female; Humans; Maraviroc; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Neoplasm Grading; Neoplasm Invasiveness; Neovascularization, Pathologic; Paracrine Communication; Proto-Oncogene Proteins c-akt; Receptors, CCR5; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; Triazoles; Tumor Burden; Tumor Microenvironment | 2016 |
Short Communication: Lack of Effect of Maraviroc Intensification on Blood and Gut Reservoir.
Topics: Blood; CCR5 Receptor Antagonists; Cyclohexanes; Gastrointestinal Tract; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Pilot Projects; Prospective Studies; Treatment Outcome; Triazoles | 2017 |
Off-licence use of once-daily maraviroc in children and adolescents with perinatally acquired HIV-1 infection.
Topics: Adolescent; CCR5 Receptor Antagonists; Child; Cyclohexanes; Female; HIV Infections; Humans; Male; Maraviroc; Off-Label Use; Retrospective Studies; Treatment Outcome; Triazoles | 2017 |
Effects of Therapy with Maraviroc on the Carotid Intima Media Thickness in HIV-1/HCV Co-infected Patients.
Topics: Biomarkers; Carotid Intima-Media Thickness; CCR5 Receptor Antagonists; Coinfection; Cyclohexanes; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Liver Cirrhosis; Male; Maraviroc; Middle Aged; Pilot Projects; Polymerase Chain Reaction; Prospective Studies; Triazoles; Ultrasonography, Doppler, Color | 2017 |
Strategic use of dual regimens of boosted protease inhibitors plus maraviroc in poorly adherent subjects in view of long-acting drugs: A retrospective study.
Topics: Adult; Cyclohexanes; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; Humans; Male; Maraviroc; Medication Adherence; Middle Aged; Protease Inhibitors; Retrospective Studies; Triazoles; Young Adult | 2017 |
In vitro-ex vivo correlations between a cell-laden hydrogel and mucosal tissue for screening composite delivery systems.
Topics: Animals; Chemistry, Pharmaceutical; Cyclohexanes; Delayed-Action Preparations; Drug Delivery Systems; Female; Hydrogel, Polyethylene Glycol Dimethacrylate; Lactic Acid; Macaca nemestrina; Maraviroc; Methacrylates; Mucous Membrane; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Primates; Pyrimidines; Tenofovir; Triazoles; Vagina | 2016 |
Chemokine receptor CCR5 and CXCR4 might influence virus replication during IBDV infection.
Topics: Animals; Benzylamines; Bursa of Fabricius; CCR5 Receptor Antagonists; Cell Movement; Chickens; Cyclams; Cyclohexanes; Cytokines; Heterocyclic Compounds; Infectious bursal disease virus; Interferon-gamma; Interleukin-2; Interleukin-6; Interleukin-8; Maraviroc; Poultry Diseases; Real-Time Polymerase Chain Reaction; Receptors, CCR5; Receptors, Chemokine; Receptors, CXCR4; RNA, Messenger; T-Lymphocytes; Transcription, Genetic; Transforming Growth Factor beta; Triazoles; Viral Structural Proteins; Virus Replication | 2017 |
Repurposing a Bacterial Immune System to Discover Antiviral Targets.
Topics: Antiviral Agents; Cell Line; Clustered Regularly Interspaced Short Palindromic Repeats; Cyclohexanes; Gene Knockout Techniques; HIV Infections; HIV-1; Humans; Immune System; Maraviroc; RNA, Viral; T-Lymphocytes; Triazoles; Viral Proteins; Virion; Virus Replication | 2017 |
Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?
Topics: Adult; Brain; Cyclohexanes; Female; Humans; Immune Reconstitution Inflammatory Syndrome; Immunologic Factors; Leukoencephalopathy, Progressive Multifocal; Longitudinal Studies; Male; Maraviroc; Middle Aged; Multiple Sclerosis; Natalizumab; Treatment Failure; Triazoles; Viral Fusion Protein Inhibitors | 2017 |
Structure of CC Chemokine Receptor 5 with a Potent Chemokine Antagonist Reveals Mechanisms of Chemokine Recognition and Molecular Mimicry by HIV.
Topics: Animals; CCR5 Receptor Antagonists; Chemokine CCL5; Cloning, Molecular; Crystallography, X-Ray; Cyclohexanes; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Models, Molecular; Molecular Mimicry; Protein Binding; Protein Conformation; Receptors, CCR5; Sf9 Cells; Spodoptera; Structure-Activity Relationship; Triazoles; Virus Internalization | 2017 |
Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists.
Topics: Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cell Line; Cyclohexanes; Drug Resistance, Viral; Female; HEK293 Cells; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Receptors, CCR5; Treatment Failure; Triazoles; Virus Internalization | 2017 |
Central nervous system-penetrating antiretrovirals impair energetic reserve in striatal nerve terminals.
Topics: Adenosine Triphosphate; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cerebral Cortex; Corpus Striatum; Cyclohexanes; Cyclopropanes; Darunavir; Dideoxynucleosides; Dose-Response Relationship, Drug; Emtricitabine; Lopinavir; Male; Maraviroc; Mitochondria; Neurons; Nevirapine; Oxidative Phosphorylation; Permeability; Presynaptic Terminals; Raltegravir Potassium; Rats; Rats, Long-Evans; Triazoles; Zidovudine | 2017 |
Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.
Topics: Adult; Anti-HIV Agents; Body Fluids; Cervix Uteri; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Prospective Studies; Raltegravir Potassium; Rilpivirine; Semen; Triazoles; Vagina; Viral Load | 2017 |
HIV-1 subtype CRF01_AE and B differ in utilization of low levels of CCR5, Maraviroc susceptibility and potential N-glycosylation sites.
Topics: Cell Line; Cloning, Molecular; Cyclohexanes; env Gene Products, Human Immunodeficiency Virus; Gene Expression Regulation, Viral; Glycosylation; HIV-1; Humans; Maraviroc; Models, Molecular; Protein Conformation; Receptors, CCR5; Triazoles; Virus Replication | 2017 |
Maraviroc improves hepatic triglyceride content but not inflammation in a murine nonalcoholic fatty liver disease model induced by a chronic exposure to high-fat diet.
Topics: Animals; CCR5 Receptor Antagonists; Cyclohexanes; Diet, High-Fat; Disease Models, Animal; Insulin Resistance; Lipogenesis; Liver; Male; Maraviroc; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; PPAR gamma; Sterol Regulatory Element Binding Protein 1; Triazoles; Triglycerides | 2018 |
Unique Phenotypic Characteristics of Recently Transmitted HIV-1 Subtype C Envelope Glycoprotein gp120: Use of CXCR6 Coreceptor by Transmitted Founder Viruses.
Topics: Adult; Anti-HIV Agents; Antibodies, Monoclonal; Antibodies, Neutralizing; Antibodies, Viral; CCR5 Receptor Antagonists; Cell Line; Cyclohexanes; HEK293 Cells; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Infant; Maraviroc; Receptors, CXCR6; Triazoles; Virus Replication | 2018 |
Structure-based identification of novel scaffolds as potential HIV-1 entry inhibitors involving CCR5.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Receptors, CCR5; Receptors, Chemokine; Triazoles | 2022 |
Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.
Topics: Animals; Anti-HIV Agents; Biological Availability; CCR5 Receptor Antagonists; Cyclohexanes; HIV Infections; HIV-1; Maraviroc; Rats; Rats, Sprague-Dawley; Receptors, CCR5; Triazoles; Tropanes | 2022 |